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SUMMARY 
Transposons are DNA segments that autonomously move within and between genomes 
across the tree of life. Tc1/mariners in particular have frequently crossed species 
boundaries in nature and provide powerful broad-host-range genetic vectors. Among them, 
the Sleeping Beauty (SB) transposon inserts DNA in vertebrate genomes with 
extraordinarily high efficiency, making it a prime genetic tool with applications expanding 
to gene therapy clinical trials. Nevertheless, the molecular principles of SB’s distinctive 
activity remain elusive, greatly hampering its further development.  
 
In the first part of this thesis, I investigated the molecular mechanisms of the SB transposon 
in comparison to Human mariner 1 (Hsmar1), a representative transposon of the same 
superfamily. Using biochemical and biophysical techniques together with fluorescence-
based assays, I have characterized the initial steps of SB and Hsmar1 transposition and 
shown that the two transposons assemble their molecular machineries (or transpososomes) 
differently. By combining crystallographic data and SAXS-based modelling, I visualized 
the structural basis of these differences and explained how transpososome assembly is 
coupled to catalysis in the Hsmar1 transposon. Moreover, the data demonstrated that the 
unique assembly pathway of SB largely contributes to its exceptional efficiency and that it 
can be chemically modulated to control insertion rates in living cells. I have further 
reconstituted in vitro the ordered series of events comprising SB transposition, including 
transposon end binding, cleavage, and integration, and dissected previously unrevealed 
molecular features of the process. 
In the second part of my work, building on these mechanistic insights, I developed a novel 
SB transposase variant (hsSB) by employing a structure-based protein design approach.  
Using hsSB allowed for establishing a new genome engineering method based on the 
direct delivery of recombinant SB protein to cells. We showed that this new method, 
named SBprotAct, provides safer and more controlled genome modification of several cell 
types (including stem cells and human T cells), as compared to the state-of-art technology.  
 
This work sheds first light on the molecular determinants of SB transposition and its hyper-
activity, providing a unique resource for the rational design of improved genome 
engineering platforms for research and medicine. 
 
  vi 
ZUSAMMENFASSUNG 
Transposons sind mobile genetische Elemente, die sich selbständig innerhalb des Genoms, 
sowie zwischen den Genomen verschiedener Spezies bewegen. Insbesondere Tc1/mariners 
haben häufig Speziesgrenzen in der Natur überschritten und stellen deshalb leistungsfähige 
genetische Vektoren für einen breiten Wirtsbereich dar. Sleeping Beauty (SB) Transposon 
übertragt DNS in die Genome von Vertebraten mit außergewöhnlich hoher Effizienz. 
Diese Eigenschaft macht SB immer häufiger zu einem genetischen Werkzeug in klinischen 
Studien zur Gentherapie. Die molekularen Prinzipien von SB’s ausgeprägter Aktivität sind 
weitgehend unbekannt, was eine weiter Entwicklung stark beeinträchtigt.  
 
Im ersten Teil dieser Arbeit habe ich die molekularen Mechanismen des SB Transposons 
mit Human mariner 1 (Hsmar1), einem repräsentativen Transposon aus der selben 
Superfamilie, verglichen. Ich habe die anfänglichen Schritte der Transposition von SB und 
Hsmar1 mittels biochemischer und biophysikalischer Techniken, sowie 
fluoreszenzbasierten Untersuchungen, charakterisiert. Dies zeigte dass die beiden 
Transposons ihre molekularen Maschinen (Transpososomes) auf unterschiedliche Weise 
zusammenfügen. Durch die Verbindung von kristallografischen Daten und SAXS-
basiertem Modellierungen zeige ich die strukturelle Grundlage dieser Unterschiede und 
erkläre wie das Zusammenfügen des Transpososomes von Hsmar1 mit der Katalyse 
gekoppelt ist. Des Weiteren zeigen diese Daten, dass der einzigartige 
Assemblierungsprozess von SB zu dessen außergewöhnlich hoher Effizienz beiträgt. Diese 
Erkenntnis wiederum eröffnet die Möglichkeit Insertionsraten in lebenden Zellen chemisch 
zu kontrollieren. Außerdem habe ich die geordnete Reihenfolge der Ereignisse der SB 
Transposition, einschließlich Bindung, Ausschneiden und Integration des Transposons in 
vitro rekonstruiert und untersuchte bislang unbekannte molekulare Eigenschaften des 
Prozesses.  
Im  zweiten Teil meiner Arbeit, die auf diesen mechanistischen Erkenntnissen aufbaut, 
habe ich mittels strukturbasiertem Protein Design eine neuartige SB Transposase Variante 
(hsSB) entwickelt.  Die Verwendung von hsSB erlaubte die Entwicklung einer neuen 
Methode zur Genomveränderung, basierend auf dem direkten Einschleusen von 
rekombinantem SB Protein in Zellen. Verglichen mit anderen modernsten Technologien 
erlaubt diese neue Methode, die wir SBprotAct getauft haben, eine sicherere und 
kontrolliertere Modifikation von Genomen verschiedenster Zelltypen, einschließlich 
Stammzellen und humaner T-Zellen.  
 
Diese Arbeit gibt zum ersten mal Aufschluss über die molekularen Faktoren der SB 
Transposition und seiner Hyperaktivität und bietet eine einzigartige Quelle für das 
rationale Design von verbesserten Genom-Modifikationsplattformen für Wissenschaft und 
Medizin. 
      vii 
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1 GENERAL INTRODUCTION 
                                                                            ‘They thought I was crazy, absolutely mad.’ 
                                                                                                                B. McClintock, 1944 
 
 
This chapter introduces transposable elements, with focus on DNA transposons, and their 
impacts on evolution and genetic engineering. This introduction highlights the motivation 
of the research carried out in my PhD project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Jumping” genes: an overview 
 2 
Genomes of all organisms have the capacity to undergo DNA rearrangements, which can 
result in modification of their genetic pool and modulation of their gene expression. 
Among the factors responsible for these recombination events, transposable elements (TEs, 
also known as transposons) have been found in all genomes sequenced to date and 
generally occupy a large fraction of them (Craig, 2002). Notably, they make up about half 
of the genome content in humans and represent even up to the ~85% of sequences in some 
plant genomes (Lander et al., 2001; Lee et al., 2014).  
1.1  “Jumping” genes: an overview 
 
TEs are defined as discrete DNA segments with the distinctive ability to autonomously 
“jump” from one location to another in a host genome without any requirement for 
sequence homology.  
They were discovered in the late 1940s (even before the molecular structure of the DNA 
was revealed) by Barbara McClintock (McClintock, 1950), who was studying mutable 
genetic loci in maize. The mutations she observed were the consequences of movement of 
DNA transposons known as Ac (for “Activator”) and Ds (for “Dissociation”), Ac being the 
autonomous element regulating Ds. McClintock's work was revolutionary since it 
suggested that an organism's genome is not a stationary entity, but rather is subject to 
dynamic alterations (or mobile). This principle was met with heavy criticism from the 
scientific community until McClintock was finally awarded the Nobel Prize in 1983 in 
recognition of her contributions to the field of genetics and epigenetics.  
 
Nowadays, scientists are well aware of the extraordinary number of transposons existing in 
nature. As new transposons were discovered and the related molecular mechanisms were 
elucidated, several classification systems were proposed (Jurka et al., 2005; Piegu et al., 
2015; Wicker et al., 2007). One of the most common and still valid classifications is based 
on the TEs’ general mechanism of transfer, according to which they are categorized into 
two classes (Figure 1-1): 
- Class I elements, generally referred to as retroelements, retrotransposons or RNA 
transposons, which move by reverse transcription of an RNA intermediate; 
- Class II elements, or DNA transposons, which move only via DNA-mediated 
mechanisms (Craig, 2002). 
Chapter 1: General introduction 
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Retrotransposons follow a so-called copy-and-paste mechanism for their mobilization, 
while most DNA transposons move through a cut-and-paste pathway.  
This work focuses on TEs belonging to Class II, or DNA transposons. DNA transposons 
are further subclassified into different families based on the general transposon architecture 
and on the nature of their associated proteins. 
 
 
Figure 1-1: Transposons move within genomes mainly by two distinct mechanisms: 1. the copy-and-paste 
pathway, typical of RNA transposons, which involves single-stranded RNA intermediates and 2. the cut-and-
paste mechanism, followed by most DNA transposons, which exclusively relies on DNA intermediates. If the 
integration site is located in a gene (represented in purple), insertion of the transposon (in orange, flanked by 
transposon’s termini in grey) results in interruption of the gene’s DNA sequence. 
All complete or “autonomous” DNA transposons consist of at least one open reading frame 
(ORF) encoding the transposase protein, an enzyme needed for autonomous mobility 
(transposition), flanked by two inverted repeat (IR) sequences at the transposon termini 
(Figure 1-2). These components are an indispensable requirement for transposition: the 
transposase binds to specific DNA sequences within the IRs and catalyses the complete 
excision of the transposon from the donor locus and its integration to a different target 
locus in the host genome. Of note, “non-autonomous” transposons also exist, which 
accumulated inactivating mutations in their transposase-encoding ORF and thus “borrow” 
the transposition machinery from their active mates for their mobility (as the Ds element 
found by McClintock).  
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Figure 1-2: Schematic representation of the general cut-and-paste DNA transposition mechanism. Individual 
transposase molecules are represented as purple ovals. They initially bind to specific inverted repeat (IR) 
sequences at the transposon ends, they then perform cleavage at these sites to liberate the transposon from its 
donor locus (excision) and finally promote transposon insertion into a new locus (integration) upon capture 
of a target DNA. Donor DNA is shown in blue; target DNA is in red. 
Transposases represent the most abundant genes known in nature (Aziz et al., 2010) and 
contain a high variety of protein sequences. This generates an extraordinary diversity of 
transposases’ structures and transposition mechanisms, which are mostly unexplored 
(Dyda et al., 2012; Hickman et al., 2016). Therefore, biochemical and structural 
investigation of transposons and their associated transposases represents a thrilling and 
fast-evolving research field. 
1.2 Biological impacts of DNA transposons 
 
Due to their ability to carry and modify genes (Figure 1-1), TEs are prominent 
evolutionary forces that act in genome remodelling and antibiotic resistance spreading in 
prokaryotes (Alekshun et al., 2007) and contribute to the emergence of new biological 
Chapter 1: General introduction 
     5 
Word	T
emplat
e	by	Fr
iedman
	&	Mor
gan	20
14 
functions (S. Huang et al., 2016; Sinzelle et al., 2009) and gene-regulatory networks 
(Chuong et al., 2017; Imbeault et al., 2017) in eukaryotes.  
 
Eukaryotic DNA transposons are active in plants and lower-order animals (C. R. Huang et 
al., 2012). Interestingly, they have established a special relationship with some unicellular 
eukaryotic organisms, ciliates, where transposon-derived proteins have been domesticated 
to carry out programmed genome rearrangements required for sexual reproduction (Baudry 
et al., 2009; Cheng et al., 2010; Nowacki et al., 2009). In higher organisms (except bats) 
activity of DNA transposons is often severely down-regulated or disabled through 
mutations. In mammals, for example, the vast majority of DNA transposons are non-
autonomous and in some genomes, such as the human genome, almost none of the ca. 
300,000 DNA transposons have a functional transposase gene (Feschotte et al., 2007). 
Thus, higher-order organisms genomes are riddled by remnants of once active elements 
and, for this reason, transposons have been for a long time dismissed as “junk” DNA. 
However, an overwhelming body of evidence highlights that DNA transposons can 
introduce genomic changes that have beneficial or detrimental functional consequences in 
their hosts, including in higher-order animals (Chenais et al., 2012; Feschotte et al., 2007).  
 
The beneficial roles of DNA transposons are obvious for exaptation, meaning the 
repurposing of transposon-derived DNA sequences or proteins to execute a different task 
other than transposition. In fact DNA transposons have been proven to provide cis-
regulatory elements and thus contribute to the evolution of regulatory networks (Imbeault 
et al., 2017). For instance, in the peppered moth a polymorphic carbonaria TE insertion 
within an intron of the cortex gene enhances its expression levels, underlying the adaptive 
cryptic coloration of moths emerged during the industrial revolution (Van't Hof et al., 
2016). Regarding transposon-derived proteins, the RAG1 and RAG2 (recombination 
activating genes) proteins of the vertebrate V(D)J recombination system have arisen from 
an ancient RAG transposon (S. Huang et al., 2016). Moreover, the once functional 
transposase protein of the Human mariner 1 (Hsmar1) transposon makes up the C-terminal 
domain of the SETMAR [Suppressor of variegation 3-9, Enhancer-of-zeste, Trithorax 
(SET) domain and Mariner transposase] fusion protein, a DNA repair factor involved in 
the non-homologous end joining (NHEJ) pathway in humans (Goodwin et al., 2010). 
Notably, transposases have been also an important source of DNA binding and chromatin-
associated domains (Feschotte, 2008).  
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Apart from beneficial outcomes, the DNA breaking activity and mobility of DNA 
transposons present also a danger for their hosts as these can scramble and dramatically 
disrupt the host genomes. For these reasons, the activity and retention of DNA transposons 
are finely modulated by a combination of intrinsic (host- or self-mediated) and extrinsic 
(environmental, ecological) factors over evolutionary time (Feschotte et al., 2007) to 
minimize detrimental effects. Perhaps, it is more correct to say that an arms race is 
established between host organisms and transposons, which can eventually escape existing 
repression mechanisms. Recently, a piggyBac transposable element derived 5 (PGBD5) 
gene was found in humans, which encodes an active transposase expressed in the majority 
of childhood solid tumours, including lethal rhabdoid tumours (Henssen et al., 2015). This 
discovery provides the first example of a DNA transposon with autonomous (even if 
conditional) activity in the human genome and which can exhibit oncogenic consequences. 
1.3 Technological impacts of DNA transposons 
 
DNA transposons are natural gene delivery vehicles capable of efficient genomic insertion. 
They exhibit important features that make them particularly attractive as genetic vectors. 
Due to specificity of donor sites, DNA transposons are mobilized very precisely and only 
single transposon copies are cut-and-pasted at a time. This ensures that single copies of 
desired transgenes are inserted with absolute fidelity. Differently to viruses that often have 
highly immunogenic protein coats, transposons are mostly DNA-based vectors and hence 
avoid immune defence mechanisms evolved by the cells against viral proteins. DNA 
transposons are generally not restricted by the size of the transgene to be delivered (Zayed 
et al., 2004), in contrast to viral vectors in which DNA packaging capacity is fairly 
limiting. 
 
Due to these intrinsic properties, the mobile nature of DNA transposons has been 
successfully exploited to provide efficient insertional mutagens or sensors in functional 
genomics (de la Rosa et al., 2017; Dupuy et al., 2006; Ruf et al., 2011) as well as artificial 
gene carriers in transgenesis (Miskey et al., 2005; Skipper et al., 2013) and even in gene 
therapy applications (Kebriaei et al., 2016). One recent and exciting application is the high 
resolution mapping of nucleosome positions using transposon integrations into accessible 
chromatin followed by sequencing [called ATAC-seq method; (Buenrostro et al., 2013; 
Chen et al., 2016)].  
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In their applications, the mobility of DNA transposons is experimentally controlled by 
separating the two functional components of the transposon: the IR sequences are placed to 
flank a gene of interest, and the transposase protein is conditionally supplied in trans to 
drive the transposition reaction. In principle, any sequence between the IRs can be 
mobilized by the transposase and can be stably integrated into the genome in a regulated 
and highly efficient manner (Ammar et al., 2012). 
 
The most widely applied transposons are piggyBac (PB), and Tc1/mariners. PB was 
discovered as an active mobile element in the cabbage moth Trichoplusia ni (Cary et al., 
1989) and is used as a versatile tool in various genetic modification experiments (Woodard 
et al., 2015). Recent reports have shown that the PB transposon vector can be mobilized by 
the human transposase-derived PGBD5 protein (Henssen et al., 2015; Henssen et al., 2017; 
Ivics, 2016), raising major concerns about the use of PB in human applications. 
Tc1/mariner elements are preferred systems for the development of transposon-based 
genetic tools, because of their unique evolutionary, mechanistic and structural 
characteristics. These TEs have frequently crossed species boundaries in nature and 
provide very powerful gene delivery vehicles in a broad range of hosts (Grabundzija et al., 
2010; Plasterk et al., 1999). Their transposition is not-host restricted, probably because it 
requires minimal transposon- and host-encoded machineries, if any. Tc1/mariners are 
generally not limited by the size of the transgene to be delivered (Zayed et al., 2004) and 
have no preference for integration into genes or regulatory units (Sultana et al., 2017). In 
addition, no human proteins have been identified that could remobilize genomically 
integrated Tc1/mariner transposon vectors to date.  
 
Among Tc1/mariners, the Sleeping Beauty (SB) transposon (Ivics et al., 1997) is 
exceptionally efficient in inserting into vertebrate genomes (Dupuy et al., 2006), making it 
a prime genetic tool with applications spanning from transgenesis (Ammar et al., 2012), 
forward mutagenesis screening (de la Rosa et al., 2017; Dupuy et al., 2006; Ruf et al., 
2011) to even cancer immunotherapy trials in humans (Kebriaei et al., 2016; Singh et al., 
2015). However, the mechanistic principles underlying SB’s transposition and distinctive 
performance have remained elusive, greatly hampering the rational design and further 
improvement of this transposon as genetic tool in research and medicine.    
Aims of this study 
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1.4 Aims of this study 
 
Nowadays, mobility of DNA transposons can be investigated using integrated genetic, 
biochemical, and structural approaches. Owing to the technological impact of 
Tc1/mariners, novel insights into the mechanism and regulation of these transposons will 
support the development of attractive tools for basic research and human therapy. 
Therefore, the overarching goal of my PhD project is to investigate the molecular 
mechanisms of Tc1/mariner transposition to design new improved transposon systems for 
genome engineering.  
 
In the first part of my work (chapter 2), I have focused on studying the structural and 
biochemical principles underlying transposition of two prominent Tc1/mariners: Hsmar1, 
the best biochemically characterized member (section 2.2), and SB, a prime genetic tool 
applied both in research and medicine (sections 2.3 and 2.4). In particular, I analysed the 
biologically relevant conformations of their associated transposase proteins and 
nucleoprotein complexes by a combination of low- and high-resolution structural biology 
methods, classical biochemistry, fluorescence-based, and biophysical techniques. 
Moreover, by establishing novel biochemical assays, I dissected the discrete DNA 
intermediates involved in SB transposition. Finally, these comparative insights gained in 
vitro have been explored in the cellular context using cell biology techniques, shedding 
first light on the molecular determinants of SB’s hyperactivity.  
 
In the second section of my work (chapter 3), I carried out the most ambitious part of my 
project, which is the rational design of novel SB transposon systems. To this aim, using 
available structural data as a resource, I generated an improved transposase variant by 
protein design and characterized its biophysical and functional properties (section 3.2), 
taking advantage of specific assays established in the previous section (chapter 2). Based 
on the use of this rationally designed protein variant, a new genetic engineering method 
was developed, utilizing cell biology methodologies such as in vivo transposition assays 
and flow cytometry (section 3.3). 
 
In brief, by learning more about the working mechanism of Tc1/mariners, and of SB in 
particular, we may open up new avenues for the development of tailor-made genome 
engineering tools for research and clinical use. 
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2 MECHANISMS OF 
TC1/MARINER 
TRANSPOSITION 
The part of my PhD work presented in this chapter focuses on elucidating the molecular 
mechanisms of Tc1/mariner transposition. Section 2.1 introduces Tc1/mariner transposons 
and their movement, and highlights the motivation of the research conducted in this part of 
my thesis. This is followed by a section presenting the structural investigation of Hsmar1 
transposition (2.2) and two sections devoted to the SB transposon, focusing on the 
biochemistry of its transposition  (section 2.3) and its self-regulation at the molecular level 
(section 2.4). In the last section (2.5), a model for Hsmar1 and SB transposition, based on 
the obtained results, is proposed and described. Finally, future perspectives in the 
investigation of the studied transposons (and of other family members) at the structural and 
biochemical level are discussed.  
 
Note: A number of the figures in this chapter are based on and modified from the following 
manuscript that is in preparation for submission. I created all figures that can be found in 
the manuscript and in this thesis.  
 
- Querques et al., (2018); “Distinct assembly pathways of Tc1/mariner transpososomes 
dictate different self-regulatory mechanisms.”   
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2.1 Introduction – Tc1/mariner transposons 
 
Tc1/mariners constitute an extraordinary group of DNA transposons characterized by an 
exceptionally widespread distribution in the tree of life, a distinctive mechanism of 
transposition and a tremendous potential for biotechnological applications (Plasterk, 1996). 
This introduction to Tc1/mariner transposons describes the main distinctive features that 
make these elements unique among DNA transposons as well as fascinating biological 
systems for biochemical and structural investigation.  
2.1.1 Evolution, life cycle, inactivation and molecular resurrection 
All identified eukaryotic DNA transpososons have been classified in ~18 superfamilies, 
according to similarities in the sequences of their associated transposases and transposon 
ends (Jurka et al., 2005; Piegu et al., 2015; Wicker et al., 2007). Among these, the 
Tc1/mariner superfamily is ubiquitously present in eukaryotes, and is named after two of 
the first identified family members: the Tc1 (Transposon Caenorhabditis 1) transposable 
element from Caenorhabditis elegans (Emmons et al., 1983) and the mariner element 
Mos1 from Drosophila mauritiana (Jacobson et al., 1986). The Tc1/mariner superfamily 
appears to constitute a monophyletic group of transposons and can be further grouped in 
the Tc1, mariner and pogo clades (Figure 2-1). 
 
Figure 2-1:  Phylogeny of the Tc1/mariner superfamily (Plasterk et al., 1999). The mariner (red), pogo 
(green) and Tc1 (blue) transposon families are monophyletic. The phylogenetic tree is based on similarities 
between Tc1/mariner transposases and represents only a subset of all known elements. Members of the 
family mentioned in this study are marked with asterisks. Next to each element, the host organism is 
indicated. 
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Tc1/mariners are the most widespread DNA transposons existing in nature. They are 
represented in all eukaryotes, spanning from rotifers, fungi, plants, and ciliates to fish and 
mammals, including humans (Plasterk, 1996). Remarkably, phylogenetic relationships of 
Tc1/mariner elements are often incongruent with those of their host species (Ivics et al., 
1996; Robertson et al., 1993) (Figure 2-1). For example, close relatives of mariner 
transposons in humans are found in insects and worms (Lampe et al., 2001). This suggests 
that Tc1/mariners have frequently crossed species boundaries by a so-called “horizontal 
transfer” process during evolution (Lohe et al., 1995).  
 
How this occurs exactly is still subject of investigation. Since transposons are not 
infectious per se, it is likely that additional genetic vehicles, like viruses and parasites, are 
needed as vectors for their transfer between organisms (Houck et al., 1991; Kidwell, 
1992). Once in the new host, Tc1/mariners can move in the newly invaded genome without 
any host-specific restrictions because the transposon-encoded transposase protein is the 
only factor strictly required for their transposition (Clayes Bouuaert et al., 2010; Lampe et 
al., 1996; Vos et al., 1996). 
 
 
Figure 2-2: Proposed life cycle of Tc1/mariner elements. The figure has been adapted from (Miskey et al., 
2005). 
Once transmitted to a new host, Tc1/mariners go through a peculiar life cycle: first, they 
must introduce themselves in the germline genome; then, they experience an exponential 
amplification of their activity and copy number; finally, more and more transposon copies 
gradually undergo vertical inactivation, ultimately leading to complete suppression of their 
activity. To circumvent complete extinction, Tc1/mariners must therefore transfer 
Introduction – Tc1/mariner transposons 
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themselves to new species repeatedly, even to rather distantly related ones (Miskey et al., 
2005) (Figure 2-2).  
 
As a consequence of repeated transposon invasions and inactivation by mutation, many 
genomes are scattered with relics of once active transposons. Out of the hundreds 
identified sequences, only ten naturally occurring Tc1/mariner elements have proven to be 
active [i.e. Tc1 and Tc3 from C. elegans (Emmons et al., 1983), Minos from Drosophila 
hydei (Franz et al., 1991), Mos1 from D. mauritiana (Hartl, 2001; Medhora et al., 1991), 
Famar1 from Forficula auricularia (Barry et al., 2004), Osmar5 from Oryza sativa (G. 
Yang et al., 2006), Fot1 and Impala from the fungus Fusarium oxysporum (Daboussi et 
al., 1992; Langin et al., 1995), ISY100 isolated in bacteria (Feng et al., 2007), and 
Mboumar-9 from the ant Messor bouvieri (Munoz-Lopez et al., 2008)]. Notably, although 
almost 3% of the human genome is built of Tc1/mariner transposons, all the estimated 
20,000 elements are inactive due to multiple mutations within the coding regions of their 
transposase genes (Munoz-Lopez et al., 2010). 
 
In some cases transposases enzymes have escaped mutational inactivation through 
domestication for a different task in the host cell. The Hsmar1 transposase provides a 
remarkable case of domestication; it has been incorporated in the SETMAR fusion protein 
upon insertion of the Hsmar1-encoding ORF downstream of the SET gene. SETMAR acts 
as a DNA repair factor in the NHEJ pathway, where the transposase-derived moiety of the 
protein provides DNA binding and processing activities (Goodwin et al., 2010; Liu et al., 
2007). 
 
In the past decades, molecular reconstruction of artificial active Tc1/mariner transposons 
has been carried out by combination of comparative sequence analysis and mutagenesis 
screens. By eliminating inactivating mutations in their transposases and transposon end 
sequences, an increasing number of Tc1/mariners have been brought back to life. Among 
these, prominent examples are the SB transposon from salmonid-type fish (Ivics et al., 
1997) and the above-mentioned Hsmar1 element from H. sapiens (Miskey et al., 2007), 
which constitute the main focus of this study. The awakening of these extinct elements 
opened the door to the exploration of Tc1/mariner transposons in basic research and 
biotechnological applications. 
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2.1.2 Transposon ends and transposases 
Tc1/mariners are about 1.3 to 2.4 kbp long elements. Their boundaries are marked by the 
two transposon ends that are conventionally referred to as Left End (LE) and Right End 
(RE). Specific inverted repeats (IRs) are present at each end and constitute binding sites for 
the transposase. They are 30-40 bp long perfect IRs in the mariners and long bipartite IRs, 
each containing two 30-35 bp direct repeats (DRs) separated by DNA segments of variable 
sequence, in some Tc1-like elements (Plasterk et al., 1999). The functional role of the 
varying and complex arrangement of DRs within the family is still uncharacterized. 
Between the two ends, Tc1/mariner transposons harbor a single ORF encoding the 
transposase. Although Tc1/mariner transposases share as little as 15% amino acid sequence 
identity (Robertson et al., 1995), they feature a conserved structural organization: the N-
terminal DNA binding domain (DBD), which specifically recognizes the IR sequences at 
the transposon ends, comprises two Helix-Turn-Helix motifs (HTH) and is connected by a 
flexible linker to the C-terminal RNase H-type catalytic domain (CAT) (Figure 2-3).  
 
Figure 2-3: General architecture of Tc1/mariner transposon ends and transposases. The transposase open 
reading frame (ORF) is represented as a yellow rectangle and is flanked by inverted repeats (IRs). Mariners 
and the Tc1 element contain only single left (grey square) and right (purple square) repeats. In the Hsmar1 
transposon, the two IRs have identical sequences (both shown as grey squares). Most Tc1-like elements 
feature bipartite IRs (so called IR-DR), where each IR contains outer (DRo) and inner (DRi) direct repeats. 
Representative Tc1/mariner transposases (right panel; SB for Tc1-like in blue and Hsmar1 for mariners in 
red)  are depicted with their bipartite DNA binding domains (DBD; small ovals) and their catalytic domains 
(CAT; big ovals). The same colour code (blue for SB; red for Hsmar1) is used to represent these transposases 
in the rest of this thesis. DDE and DDD indicate the different catalytic triads. HTH: Helix-Turn-Helix motif. 
In Tc1-like transposases, the DBD is similar to the paired domain of some transcription 
factors and thus its subdomains are also called PAI and RED (referring to HTH1 and 
HTH2 respectively) (Ivics et al., 1996; Vos et al., 1994). The CAT of all Tc1/mariner 
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transposases assembles into a typical RNase H-like fold and contains a conserved triad of 
acidic residues - three aspartates (DDD) in the mariners and two aspartates and one 
glutamate (DDE) in Tc1-like elements - that are responsible for catalysing DNA 
rearrangements in a two-metal-ion-dependent manner (Montano et al., 2011; Plasterk et 
al., 1999; W. Yang et al., 2006). Tc1/mariner transposases feature also a nuclear 
localization signal (NLS), located at varying positions in their amino acid sequence. The 
presence of the NLS indicates that these transposons can take advantage of receptor-
mediated transport of their host cells for the nuclear uptake of their transposases (Ivics et 
al., 1996).  
2.1.3 Overall transposition pathway 
Transposition of Tc1/mariner elements occurs by a cut-and-paste process. Specific binding 
of the transposase to IR sequences triggers coordinated cleavage of both transposon ends, 
excising the transposon from its original locus. Both strands of each transposon end are 
directly cut by the transposase that is therefore able to perform four distinct cleavage 
reactions for a complete transposon excision (Dawson et al., 2003). Mg+2-mediated 
hydrolysis generates 3'-hydroxyls at the transposon ends, which then attack one strand of 
the target DNA at staggered positions for transposon integration. Integration always occurs 
precisely at the 5’ of an invariant TA dinucleotide in the target DNA (Craig, 2002) (Figure 
2-4) and generates a DNA structure in which the transposon is flanked by short single-
stranded gaps. These gaps are then repaired by host machineries, creating TA target site 
duplications (TSDs) at the TE flanks characteristic of transposon integration (Craig, 2002) 
(Figure 2-4). 
 
A fundamental requirement for Tc1/mariner transposition is the coordination of the DNA 
cleavage reactions at each transposon end. This allows to avoid aberrant single-end 
cleavage events that are non-productive for the transposon and potentially genotoxic for 
the host. To ensure this, transposition occurs in the context of a specific protein-DNA 
machinery, called transpososome, which contains the two transposon ends and an even 
number of transposase subunits. This specific stoichiometry ensures that the two ends are 
held together (synapsed) by at least two protein protomers and processed in a coordinated 
fashion (Hickman et al., 2016). As transposition proceeds, the transpososome undergoes 
multiple conformational rearrangements to ensure correct and unidirectional progression of 
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the reactions (Claeys Bouuaert et al., 2010; Claeys Bouuaert, Lipkow, et al., 2013; Claeys 
Bouuaert et al., 2014; Cuypers et al., 2013; Richardson et al., 2009). 
 
Figure 2-4 Transposition mechanism proposed for Tc1/mariners. Specific binding of the transposon-encoded 
transposase to inverted repeats (IRs) at each transposon end is followed by paired-end complex (PEC) 
assembly, coordinated cleavage of both transposon termini (excision) to liberate the transposon from the 
donor locus, subsequent target recognition in the target capture complex (TCC), and finally transposon 
integration. IR binding can be carried out by monomers (forming a single-end complex 1; SEC1) or by 
dimers (forming a single-end complex 2; SEC2). Transposon integration and repair of the target locus lead to 
characteristic TA target site duplications (TSDs). The different domains of the transposases are shown as 
ovals. Large oval: catalytic domain, lighter small ovals: DNA binding domain. 
In the following paragraphs, the main steps and intermediates of the Tc1/mariner 
transposition reaction are described in the light of the biochemical and structural 
information available. 
2.1.4 Transposon end recognition and synapsis 
The first step of transposition requires sequence-specific recognition of the two transposon 
ends by the transposase, leading to transposon end synapsis in the so-called paired-end 
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complex (PEC) (Figure 2-4). Early events of this assembly process remain poorly 
understood at the molecular level. 
Tc1/mariner transposases have been reported to exist in various oligomeric states prior to 
transposon end binding, from monomers to tetramers (Brillet et al., 2007). This diversity 
might reflect differences in their transposition mechanisms, altered oligomerization 
equilibrium, or simply suboptimal conditions in vitro. Depending on the oligomeric state of 
the transposase, two main models for transposon end recognition and subsequent PEC 
assembly have been formulated (Claeys Bouuaert, Lipkow, et al., 2013) (Figure 2-4): 
1. individual transposase subunits initially bind to separate transposon ends (forming a so-
called single-end complex 1, SEC1) and subsequentially undergo oligomerization for 
transposon end pairing in the PEC; 
or 
2. a preformed transposase dimer (or higher oligomer) binds a single transposon end 
(single-end complex 2, SEC2) and then recruits the second DNA end to form the PEC. 
 
The first model was proposed based on biochemical evidences obtained with Tc1 (Vos et 
al., 1994) and Tc3 (Fischer et al., 1999). However, these two transposons differ in the 
number of DRs in their IRs [two for Tc1 and four for Tc3 (Figure 2-3)] and how the 
varying architecture of DRs influences transposon ends binding and synapsis is still 
unknown. Notably, the crystal structure of the Tc3 DBD in complex with DRs visualizes 
four subunits held together by two distinct dimer interfaces (Watkins et al., 2004). As the 
physiological relevance of these interfaces remains to be verified, it is still unclear if the 
Tc3 transposase forms dimers or tetramers in the PEC. 
The second model, implying transposon end recruitment by preformed dimers, has been 
attributed to Mos1, Mboumar-9 and Hsmar1 transposases, mainly based on their fairly 
stable dimeric state in vitro (Auge-Gouillou et al., 2005; Claeys Bouuaert et al., 2017; 
Trubitsyna et al., 2014). Based on structural studies performed by small angle X-ray and 
neutron scattering, the Mos1 transposase is an elongated dimer that binds a single 
transposon end, forming a SEC2 (Cuypers et al., 2013). However, the exact architecture of 
such single-end complexes has not been determined yet for any Tc1/mariner transposase.  
 
To sum up, due to differences in the transposon end architecture within Tc1/mariners and 
to limited structural and biochemical information on their transposases, it is still unknown 
which assembly model correctly applies to each element. Nevertheless, both proposed 
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models agree with the generally recognized principle of DNA transposition, according to 
which at least two transposase subunits are required to completely process the two 
transposon ends. This rule is also reflected in the architecture of the Mos1 transpososome, 
the only transpososome structure revealed for eukaryotic transposases to date (Dornan et 
al., 2015; Morris et al., 2016; Richardson et al., 2009) (Figure 2-5).  
 
All available structures of the Mos1 transpososome (Dornan et al., 2015; Morris et al., 
2016; Richardson et al., 2009) contain a transposase homodimer bound to the two 
transposon ends in a trans-arrangement: each IR sequence is recognized by the N-terminal 
DBD of one transposase subunit and by the C-terminal CAT of the other subunit. Thus, 
both subunits act together to carry out cleavage. Each transposase protomer establishes 
protein-protein contacts in two distinct regions: the so-called clamp loop in the CAT of one 
protomer interacts with the linker region of the other protomer, and the two HTH1 motifs 
interact with each other (Figure 2-5). Notably, Tc1-like transposases feature a different 
linker region (with a conserved KKPL/F motif) than mariners (with a WVPHEL motif) and 
a distinct essential glycine-rich strip at the base of the clamp loop, suggesting that their 
PEC architecture might be significantly different from the mariners (Voigt et al., 2016).   
 
Figure 2-5: Molecular architecture of the Mos1 paired-end complex (PEC). Left: cartoon representation of 
the Mos1 PEC crystal structure [PDB ID: 3HOT; (Richardson et al., 2009)]. Subunit A is coloured purple 
and subunit B grey. Each inverted repeat (IR) is represented as light brown dsDNA. Right: schematic 
representation of the structure and the intermolecular interactions. Large oval: catalytic domain (CAT), 
lighter small oval: Helix-Turn-Helix (HTH) subdomains. Based on (Richardson et al., 2009). 
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Perhaps the most puzzling question about the early stages of Tc1/mariner transposition 
regards how the transposase enzyme restrains itself from processing single transposon ends 
before synapsis. A model of synapsis by oligomerization implies that catalysis is not 
possible in monomers (SEC1), and thus occurs only when both transposon ends are 
brought together in an oligomeric PEC. However, in the alternative pathway of “synapsis 
by recruitment” transposases feature a dimeric state even at the first step of single end 
recognition (SEC2), and thus inhibitory mechanisms must prevent catalysis on single ends 
(Claeys Bouuaert et al., 2014; D. Liu et al., 2014) (Figure 2-4). Nevertheless, the structural 
principles underlying this regulation are still missing.  
2.1.5 Transposon excision  
Although different DD(E/D) tranposases adopt different strategies to liberate their 
transposon ends from a donor site, excision of DNA transposons always begins with the 
nucleophilic attack of an activated water molecule at or close to the transposon end, and 
follows a two-metal-ion mechanism of phosphodiester bond hydrolysis (W. Yang et al., 
2006) (Figure 2-6).  
Figure 2-6: Two-metal-ion mechanism of phosphodiester bond hydrolysis as catalysed by RNase H1 
enzymes. The nucleic acid is shown in pink ball-and-stick representation with the scissile phosphate shown in 
red and yellow. The attacking nucleophile is shown as a small red sphere and the two Mg2+ ions as purple 
spheres. Active-site carboxylates are shown in green ball-and-stick representation. Active site residues 
labelled in red and blue (D71, D132, D192) are conserved in DDD/E transposases. The additional glutamate 
(E109, green) is specific to RNase H1, RNA H2 and viral reverse transcriptases. The representations are 
based on the structures of Bacillus halodurans RNase H1 enzyme in complex with RNA/DNA hybrids (PDB 
ID: 1ZBL, 2G8H and 2G8V). The figure has been reprinted from (Nowotny, 2009). Copyright © 2009 
European Molecular Biology Organization, with permission from John Wiley and Sons (License Number 
4275220590271).  
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Protein residues in the enzyme active site coordinate two divalent metal ions (Mg2+, 
physiologically) and orient a nucleophile water molecule for SN2 in-line attack on the 
phosphorus atom of the scissile phosphate of the bound DNA substrate. The reaction 
proceeds through a pentacovalent intermediate and leads to inversion of the phosphorus 
configuration. The phosphodiester bond is broken such that the products are two free DNA 
ends, one with a 3’-OH group and one with a 5’-phosphate. Two conserved catalytic 
aspartates (the first two D-s of the DD(E/D) motif) directly coordinate the catalytic metal 
ions (labelled red in Figure 2-6). The third catalytic residue also coordinates one of the 
metal ions (labelled blue in Figure 2-6), but it is relatively tolerant to mutation (Nowotny, 
2009).  
 
Apart sharing chemistry with other transposases, Tc1/mariner transposases use a 
distinctive mechanism to generate double strand breaks (DSBs) at each transposon end 
during excision (Figure 2-7). Most cut-and-paste transposases cut just one DNA strand at 
each transposon end by hydrolysis, and the generated free 3′-OH then attacks the 
phosphodiester bond on the second strand at the same transposon end, forming a DNA 
hairpin intermediate. The hairpin may then need to be resolved by hydrolytic cleavage to 
free the 3′-OH required for the further integration reactions (Craig, 2002).  
 
No DNA hairpin intermediate was detected in Tc1/mariner transposition (Dawson et al., 
2003). Thus, excision of Tc1/mariners includes additional reactions performed by the 
transposase, which must cleave two DNA strands of opposite polarity, conventionally 
referred to as transferred (TS) and non-transferred (NTS) strands at each transposon end. 
The TS is the strand whose free 3’-OH attacks and joins the target DNA in the subsequent 
integration reactions, whereas the NTS is not directly integrated in the target DNA. 
Throughout excision, the NTS is nicked first at 2-3 nucleotides recessed position within the 
transposon end and then the TS is cleaved exactly at the transposon boundary (Claeys 
Bouuaert et al., 2014; Clayes Bouuaert et al., 2010). The DNA sequence that flanks the 
transposon, in particular the invariable TA dinucleotide, which derives from the target site 
of the last integration, seems to be crucial for excision (Claeys Bouuaert et al., 2010; Cui et 
al., 2002; Dornan et al., 2015).  
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Figure 2-7: Different mechanisms for DNA cleavage by cut-and-paste transposases. A single inverted repeat 
is represented as a grey rectangle and the green and blue lines indicate the two DNA strands. DNA strands of 
the target DNA are depicted as red lines. In most DNA transposons double strand breaks at each transposon 
end are generated via a hairpin intermediate. In the figure a 3’-OH belonging to the transposon end is 
depicted to attack the other strand for hairpin formation. In an alternative pathway, first cleavage generates a 
3′-OH at the flanking DNA that is then used as a nucleophile, producing a hairpin on the donor flank. 
Members of the Tc1/mariner superfamily, perform excision via two hydrolysis reactions at each transposon 
end, first on the non-transferred strand (NTS) and successively on the transferred strand (TS). The 
transposition reaction proceeds with target capture and strand transfer, as for all DNA transposons.  
Due to the difficulty in isolating and analysing transposition intermediates in vitro and to 
the consequent lack of informative structures, the mechanism of transposon excision in 
Tc1/mariners is still poorly understood. Open questions concern the exact steps involved in 
hydrolysis and the structural assemblies in which reactions occur. Recent reports showed 
that each active site of the Hsmar1 transposase dimer is responsible for two hydrolysis and 
one transesterification reactions at the same transposon end (Claeys Bouuaert et al., 2017). 
However, it is not clear whether some of the hydrolysis reactions (i.e. initial NTS 
cleavage) could already occur prior to transposon end-pairing, in SEC1 or SEC2 
complexes, or in yet unknown transpososome conformations.  
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Once Tc1/mariner transposons are excised, they leave DSBs behind, which can be repaired 
using a homologous chromosome or a sister chromatid as a template. The repair machinery 
can therefore recreate a new copy of the original transposon in its old site (Craig, 2002). 
This results in exponential amplification of Tc1/mariners after invasion. Alternatively, the 
donor site can be repaired via the NHEJ pathway, potentially resulting in major genome 
modifications or deletions at the donor site. Consistent with NHEJ involvement, the 
Ku70/Ku80 protein complex has been implicated to interact with the SB transposon, 
helping to ensure its efficient transposition (Izsvak et al., 2004; Yant et al., 2003). 
2.1.6 Transposon integration 
Once transposon ends have been released from their donor site, the 3’-OH group at each 
end serves as the nucleophile for the following transesterification reactions, allowing 
transposon integration into a new site (Figure 2-7). Tc1/mariners always integrate at a TA 
dinucleotide (Figure 2-4). Recent structural data on the Mos1 post-integration complex 
(Morris et al., 2016) and the catalytic domain of the SB transposase (Morris et al., 2016; 
Voigt et al., 2016) shed first light on the structural principles of this target specificity. 
However, no structure of a eukaryotic transpososome contacting target DNA before 
integration (the so-called target capture complex, TCC) has been yet determined (Figure 
2-4). Based on available structures of the related prototype foamy virus (PFV) integrase 
enzyme, catalysis of strand transfer likely uses the same active sites as for the initial step of 
DNA cleavage at the transposon ends. Only, now the 3’-OH groups at each excised TS end 
serve as activated nucleophiles attacking the two opposite strands of a target DNA at 2 nt 
staggered positions (Hare et al., 2010; Hare et al., 2012; Maertens et al., 2010).   
 
Concomitantly with formation of new phosphodiester bonds upon strand transfer, nicks are 
generated in the target DNA strands that must be repaired by the host machinery to fill in 
the 4-5 nt long gaps introduced by integration (Figure 2-7). Repair of such gaps generates 
TA TSDs on each side of the integrated transposon (Figure 2-4). TA TSDs constitute a 
specific signature of Tc1/mariner transposition and can be monitored to trace their 
movements in genomes. 
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2.1.7 Positive regulation of transposition 
Faithful progression of the transposition pathway is important to ensure successful DNA 
processing and avoid deleterious events such as DSBs formation at an isolated end, 
imprecise excision, or failure to reintegrate. Such aberrant events may also result in 
undesired genome rearrangements, and hence present a danger to the host as well. Thus, 
careful regulation of an efficient and precise cut-and-paste mechanism can be viewed as 
“structural checkpoints” in the positive regulation of the transposition pathway.  
 
A first prominent checkpoint regards the early events of transposon end recognition and 
PEC assembly, which ensure coordinated and complete excision. Small angle scattering 
data indicated that the Mos1 transposase binds one transposon end as an elongated dimer, 
assembling a SEC2 complex (Cuypers et al., 2013). Yet, how the second transposon end is 
recruited remains unclear. Based on biochemical studies, the binding of the first transposon 
end is believed to affect the affinity for the second end (Claeys Bouuaert and Chalmers, 
2013; Claeys Bouuaert, Lipkow, et al., 2013; D. Liu et al., 2014), but the mechanistic 
details are unknown. Moreover, how catalysis on single ends is mechanistically prevented 
is one of the most intriguing questions concerning transposition autoregulation.  
 
Another structural checkpoint acts concomitantly to the synapsis of the two transposon 
ends. Major conformational changes are proposed to occur in the Mos1 transposase (180 
degrees rotation of one transposase subunit relatively to the other one) for transition from 
an elongated SEC2 to a compact PEC (Cuypers et al., 2013). Available structures of the 
Mos1 PEC revealed that the trans-architecture of the complex ensures coordination of 
transposon end recognition and processing (Dornan et al., 2015; Morris et al., 2016; 
Richardson et al., 2009) (Figure 2-5). However, these structures fail to explain how the two 
ends are actively paired and correctly positioned in the complex for initial cleavage.  
 
Yet, another key checkpoint concerns the conformational changes occurring within the 
transpososome between first and second strand cleavage (Figure 2-7). These rearrangments 
are required to remove the first cut strand from an active site of the transposase and 
correctly position the second strand for cleavage and successive nucleophilic attack on the 
target DNA. This structural switch ensures that both DNA strands have been processed 
before integration can proceed. 
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2.1.8 Negative regulation of transposition 
Unregulated transposition would result in an exponential amplification of the number of 
transposon copies in the host genome, inevitably leading to genomic meltdown. To 
circumvent this, several mechanisms have evolved to down-regulate transposition. In 
addition to host defence machineries that preserve genome integrity [i.e. DNA methylation, 
heterochromatin formation and the piRNA pathway (Slotkin et al., 2007)], evidences exist 
that transposons negatively regulate their own dissemination via taming the activity of their 
transposases (Claeys Bouuaert, Lipkow, et al., 2013). 
 
First experimental evidence for autoregulation of Tc1/mariners, and eukaryotic 
transposons in general, has been provided by observation of a phenomenon called 
overproduction inhibition (OPI) for the mariner element Mos1 (Lohe et al., 1996). OPI 
manifests in a reduction in the frequency of excision above a certain transposase 
concentration and has been described to affect several Tc1/mariner transposons both in 
vitro and in vivo (Bire et al., 2013; Clark et al., 2009; Clayes Bouuaert et al., 2010; Lampe 
et al., 1998; Lohe et al., 1996). 
 
Transpososome assembly has been implicated to play a critical role in establishing OPI. 
Claeys Bouuaert and colleagues have proposed that mariner transpososomes assemble by 
initial binding of transposase dimers to one transposon end and subsequent recruitment of 
the second naked end (Figure 2-8). As the transposase concentration rises, occupation of 
both ends by transposase dimers impairs productive synapsis, and consequently causes OPI 
(Claeys Bouuaert, Lipkow, et al., 2013). Whether this so-called “assembly site occlusion” 
(ASO) model of autoregulation is conserved in other members of the Tc1/mariner 
superfamily has remained unclear. To note, SB exhibits sustained transposition even at 
high transposase concentrations (Kolacsek et al., 2014), suggesting that this transposon 
regulates its activity differently. 
 
Alternatively, OPI might arise from an alternative oligomeric state of the transposase, 
which might form inactive oligomeric species at high transposase concentrations (G. 
Carpentier et al., 2011) (Figure 2-8). In agreement, structural evidences for the Mos1 
transposase revealed that the dimer interface involved in PEC formation is different from 
the one observed in the crystal structure of the catalytic domain in the absence of DNA 
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(Richardson et al., 2006). This suggests that an alternative dimer interface in the catalytic 
domain could be involved in down-regulation of transposition by OPI.  
 
 
Figure 2-8: Autoinhibitory mechanisms proposed for Tc1/mariners. Assembly site occlusion (ASO) model: 
consistent with the “assembly by second end recruitment” pathway, occupation of both transposon ends by 
transposase dimers impairs productive synapsis, causing overproduction inhibition (OPI). Alternative 
oligomerization: several transposase conformations can co-exist in solution and some are inactive in 
transposition. Negative complementation: interaction of wild type transposase subunits with mutated ones 
(marked with green stars) result in formation of inactive oligomers. The figure follows the same schematic 
code as Figure 2-4. SEC2: single-end complex 2; PEC: paired-end complex. 
Another mechanism for transposition down-regulation might act at the stage when 
transposon copies start to accumulate mutations in their transposase sequence. 
Combination of wild type and mutated subunits of the transposases to create oligomers 
would result in impaired activity of the hetero-oligomers, leading to transposition 
inhibition (G. Carpentier et al., 2011) (Figure 2-8). Such dominant negative 
complementation is consistent with the intrinsic oligomerization properties of the 
transposases; however, no experimental evidences support a physiological role of this 
mechanism in transposon autoinhibition to date. 
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2.1.9 Human mariner 1: a representative mariner transposon 
Human mariner 1 (Hsmar1) was the first mariner transposon discovered in the human 
genome and was probably active about 50 million years ago (Cordaux et al., 2006; Liu et 
al., 2007; Miskey et al., 2007; Robertson et al., 1997). Now, all 200 copies of Hsmar1 
present in the human genome bear mutations that inactivate the transposase. Using an in 
silico phylogenetic approach, the ancestral sequence of the transposase gene was 
successfully reconstructed, providing the so-called “reconstituted ancestral transposase” 
Hsmar1-Ra (later simply referred to as the Hsmar1 transposase, Hsmar1). The 
reconstructed transposase gene is capable of catalysing precise cut-and-paste transposition 
of its specific IRs in its natural (human) host and in the zebrafish embryo, making up the 
first functional vertebrate mariner transposon system (Miskey et al., 2007). 
 
The complete Hsmar1 transposon consensus sequence is 1287 bp long. The transposon 
architecture is one of the simplest within the Tc1/mariner family. The transposon is 
bordered by two 30 bp perfect, identical IRs, each containing a single transposase binding 
site, and contains a single ORF encoding for a 343 amino acids long transposase 
(Robertson et al., 1997) (Figure 2-3). The reconstructed Hsmar1 transposase shares 94% 
sequence identity with the transposase version found in the SETMAR fusion protein and is 
37% identical to the related Mos1 transposase.  
 
Most of the mechanistic information available for mariner transposons has been derived 
from Hsmar1 and Mos1. In vitro analysis revealed that Hsmar1 transposition follows a 
typical cut-and-paste pathway. The transposase generates DSBs at each transposon ends by 
nicking first the NTS 3 nt inside the transposon end and later the TS, always exactly at the 
transposon termini (Claeys Bouuaert et al., 2010). Based on recent biochemical data, 
double strand cleavage and integration are performed by a single transposase subunit 
within the stable homodimer at each transposon end (Claeys Bouuaert et al., 2017). 
However, detailed characterization of the Hsmar1 transpososome assembly has remained 
challenging.  
 
Initial biochemical analysis of the Mos1 transpososome has also lead to several alternative 
models for the arrangement of subunits in the active complex. On the other hand, structural 
analysis of the Mos1 PEC revealed a trans dimeric assembly and recent evidences support 
a dimeric state for the Hsmar1 transposase as well [reported by (Claeys Bouuaert et al., 
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2017)]. Consistently, in my M.Sc. work in the Barabas Laboratory, we found that the 
Hsmar1 transposase is a stable dimer both before and after binding to transposon ends 
(Querques et al., manuscript in preparation). Hsmar1 dimerization is mainly driven by its 
DBD, is not required for transposon end binding, but it is strictly needed for catalysis of 
DNA cleavage in vitro and productive transposition in mammalian cells. Transposase 
dimerization thus controls both transposon end synapsis and cleavage activity in Hsmar1, 
which is consistent with the finding that catalysis in Hsmar1 transposition is strictly 
dependent on prior synapsis of the ends (Claeys Bouuaert et al., 2011). 
 
Regarding the kinetics of the transposition reaction, the Hsmar1 transposase binds rapidly 
to one transposon end; however, binding to the second end is much slower. This delay in 
synapsis might result from (i) an allosteric conformational change induced by single end 
binding, which prevents the second end to bind at comparable rates (Claeys Bouuaert and 
Chalmers, 2013; D. Liu et al., 2014) and/or (ii) electrostatic repulsion between two 
charged dsDNA molecules. Following synapsis, catalysis also occurs at different rates on 
the two DNA strands, where the NTS is nicked rapidly, whereas TS cleavage is much 
slower. This suggests that a second conformational change is required between these 
events. Target capture and integration are also relatively slow and are believed to be tightly 
coupled to the previous excision reactions (Claeys Bouuaert et al., 2010).  
 
The only structural information available for full length Tc1/mariner transposases derives 
from the structures of the Mos1 transpososome in its pre-TS cleavage, post-excision and 
post-integration conformations (Dornan et al., 2015; Morris et al., 2016; Richardson et al., 
2009). Based on sequence identity, we can hypothesize that Hsmar1 forms a similar PEC 
to Mos1. However, due to lack of structural information on other transposition 
intermediates, how the DNA breaking and ligation reactions involved in Hsmar1 
transposition occur at the atomic level has remained unclear. 
2.1.10 The Sleeping Beauty transposon and its new artificial life  
Sleeping Beauty (SB) is an artificial transposon that was resurrected from a 20 million-
years long “evolutionary sleep” by determining a consensus sequence for 12 mutated Tc1-
family transposons found in eight salmonid fish species. Its reconstruction in 1997 was the 
first demonstration that ancient transposons can be brought back to life and that they can 
actively move in vertebrates. The 340 amino acid transposase was reconstituted, in parallel 
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to the circa 230 bp IRs, to give rise to the so-called “SB10” transposase, which was proved 
to be active in fish, mouse and human cell lines (Ivics et al., 1997).  
 
The overall domain organization of the SB transposase is similar to other Tc1/mariners, 
although sequence identity is quite low (15% with the Mos1 transposase) (Figure 2-3). As 
other Tc1-like transposases, its DBD is formed by both PAI and RED subdomains (Ivics et 
al., 1996; Vos et al., 1994). The CAT of SB, in conformity with Tc1-like transposases, 
features a conserved DDE catalytic triad, a glycine rich-strip region and a conserved KKPL 
motif, differently to mariner transposases. Structures are available of the separate domains 
of the SB transposase, namely its PAI [NMR structure, (C. E. Carpentier et al., 2014)], 
RED [NMR structure, (Konnova et al., 2017)] and CAT domain [crystal structure, (Voigt 
et al., 2016)], which visualize the fold and arrangement of specific structural regions, but 
fail to explain how transposition is coordinated in the context of the SB transpososome.  
 
 
Figure 2-9: SB transposon ends architecture and sequences. Top: schematic representation of  SB transposon 
ends. Transposase binding sites (outer directed repeats-DRo and inner directed repeats-DRi) are shown as 
rectangles and are also named as left outer (Lo), left inner (Li), right inner (Ri) and right outer (Ro) repeats. 
Blue line: non-transferred strand (NTS); Green line: transferred strand (TS). Bottom: the binding sites are not 
identical even though they share a consensus sequence. DNA regions contacted by the PAI and RED 
subdomains of the SB transposase are indicated (Izsvak et al., 2002). Transposon end DNA sequence is 
shown in capital letters (bold letters indicate nucleotide differences between binding sites). Flanking DNA is 
indicated in lower case letters. TA dinucleotides (red) in the flanks of the outer repeats (Lo and Ro) represent 
Tc1/mariners-specific target site duplications. 
SB features a complex transposon end architecture. In contrast to mariner transposons, 
considerably longer IRs (ca. 230 bp) are required for transposition (Figure 2-3 and Figure 
2-9). Each IR contain two ~32 bp transposase binding sites, one at the terminus of the 
transposon (outer DR) and an interior site located ~165 bp from the outer DRs (inner DR). 
Accordingly, the binding sites are also named left outer (Lo), left inner (Li), right inner 
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(Ri) and right outer (Ro) DRs. Outer and inner DRs have similar, but not identical 
sequences (Figure 2-9) and are both necessary and not interchangeable for efficient 
transposition in vivo. Moreover, the inner DRs are thought to be bound more tightly than 
the outer DRs by the transposase, suggesting distinct roles for these binding sites in 
transposition (Cui et al., 2002).  
 
SB moves through a cut-and-paste mechanism; however, the exact products and DNA 
intermediates of SB transposition as well as the minimal protein requirements of these 
reactions have not been yet characterized. The only information concerning the nature of 
the SB cleavage reactions is in fact derived from sequencing of repaired transposon 
excision sites in mammalian cells (Luo et al., 1998): footprint analysis in several cell lines 
indicate that breakages at the transposon ends are staggered and consistent with cuts on the 
NTS  2-3 bp within the transposon. Transposition assays in HeLa cells indicate that the TA 
dinucleotide at the transposon flanks, originating from the insertion sites, also affect 
transposon excision (Cui et al., 2002). 
 
As other Tc1/mariners, SB inserts preferentially into TA sites, however, in addition to the 
TA, a palindromic AT-repeat consensus sequence in AT-rich tracts was found to constitute 
preferred target locations (Vigdal et al., 2002). Once remobilized from a chromosomal site, 
SB tends to re-integrate into cis-linked sites in the vicinity of the donor locus, according to 
a phenomenon known as “local hopping”. Nevertheless, SB integration can be considered 
fairly random at the genome level and does not show any preference for integration into 
transcription units or regulatory regions of genes (Moldt et al., 2011). This constitutes a 
distinct advantage for its applications in random mutagenesis screens as well as 
transgenesis. 
 
To optimize SB’s “jumping” activity, both the original SB10 tranposase and IRs have 
undergone a number of improvements (Ammar et al., 2012; Cui et al., 2002; Mates et al., 
2009; Voigt et al., 2016; Yant et al., 2004; Zayed et al., 2004). The most substantial 
increase of transposase activity (100-fold) has been achieved by close-to-random 
mutagenesis of the SB10 to originate the SB100X version (Mates et al., 2009). This 
hyperactive derivative, indicated simply as SB in the rest of the thesis, has been used, 
unless otherwise indicated, in all experiments reported in sections 2.3 and 2.4.  
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Since these ground-breaking studies, SB has proven to be exceptionally efficient in 
inserting into vertebrate genomes (up to 95% efficiency) (Dupuy et al., 2006) and has 
become a prime genetic tool applied in transgenesis of higher organisms (Ammar et al., 
2012), cancer gene discovery (Dupuy et al., 2006), and forward mutagenesis screening (de 
la Rosa et al., 2017; Dupuy et al., 2006; Ruf et al., 2011). It also provided the first non-
viral gene delivery vector used in ongoing clinical trials to ex vivo modify human T cells 
for cancer immunotherapy (Kebriaei et al., 2016; Singh et al., 2015) (as extensively 
reported in section 3.1). Other Tc1/mariner transposons such as Mos1 and Hsmar1 are far 
less efficient. However, the mechanistic principles of SB’s extraordinary success as genetic 
tool have remained uncharacterized.   
 
Two decades after SB’s resurrection, the crystal structure of the SB catalytic domain 
provided proof-of-concept for the rational design of new hyperactive transposase variants 
(Voigt et al., 2016). However, the current lack of knowledge on the transposition 
mechanism and regulation of SB, and of Tc1/mariners in general, greatly impairs further 
development of this transposon for basic research and clinical applications. This part of my 
work aims to fill up some of these gaps. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results – Structural principles of Hsmar1 transposition 
 30 
2.2 Results – Structural principles of Hsmar1 transposition 
 
In order to elucidate the mechanism of Tc1/mariner transposition, I used the Hsmar1 
transposon as a model for the superfamily. The Hsmar1 transposon is the best-
characterized member with respect to the biochemistry of its transposition pathway. 
Previous reports (Claeys Bouuaert et al., 2010; Claeys Bouuaert and Chalmers, 2013; 
Claeys Bouuaert et al., 2017) also indicated that the Hsmar1 transposase has particularly 
high solubility and stability appropriate for in vitro work, as compared to other related 
proteins.  
 
Despite the available biochemical information, it is still poorly understood how a single 
Hsmar1 transposase enzyme orchestrates all transposition steps, and which structural 
assemblies and conformations are involved. In particular, open question concern: 
1. Structural basis for inhibition of single end cleavage. The Hsmar1 transposase forms 
stable dimers in solution and in the PEC. So, what prevents the preformed Hsmar1 dimer 
to cleave single transposon ends before PEC assembly?  
2. Mechanism of transposon excision. How do two consecutive hydrolysis reactions (on 
the NTS and TS) occur in a single transposase active site and which transpososome 
arrangements are required for excision? 
 
I aimed to address the above questions by structural characterization of Hsmar1 
transposition. For this, I analysed the Hsmar1 transposase in its DNA-free and DNA-bound 
states by biophysical methods, crystallography, small angle X-ray scattering (SAXS), and 
structural modelling. 
2.2.1 Architecture of the Hsmar1 transposase 
Prior to my PhD work, I was involved in determining a crystal structure of the Hsmar1 
transposase together with a PhD Fellow, Franka Voigt (Barabas group, EMBL Heidelberg, 
manuscript in preparation). The structure contains the catalytic domain (CAT) of the 
transposase (aa 118-343) including most of the flexible inter-domain linker (spanning aa 
112-124) and provided preliminary insights into the architecture of the full-length Hsmar1 
transposase that I investigated further in this thesis.  
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Figure 2-10: Crystal structure of the Hsmar1 transposase catalytic domain (CAT) reveals an autoinhibited 
dimer in trans. The two molecules (Molecule A, blue and Molecule B, orange) are asymmetric and superpose 
by 175° rotation. α-helices (α), β-strands (β) and turns (η) are indicated. The clamp loops that are not visible 
in the structure are indicated as dashed lines. The three catalytic residues (D155, D247 and D282; red sticks) 
are assembled in each active site. Left insert: specific amino acid interactions involving the conserved 
WVPHEL motif (aa 118-123) in the linker region create an autoinhibited conformation. Right insert: 
interactions involving the inter-domain linkers and the clamp loops in the Mos1 PEC [PDB ID: 3HOT; 
(Richardson et al., 2009)]. Mos1 subunits are shown in purple and black. IR: inverted repeat. In both inserts, 
residues belonging to the WVPHEL motif and their interacting partners are shown as sticks. Below each 
inserts, a schematic representation of the interactions is shown. 
In the structure, two molecules of the Hsmar1 CAT form a unique dimer assembly that is 
similar, but remarkably more compact, than the one observed in the Mos1 PEC structures 
(Dornan et al., 2015; Morris et al., 2016; Richardson et al., 2009) (Figure 2-10). Moreover, 
the linker regions of the two Hsmar1 protomers interact with each other (Figure 2-10, left 
insert), whereas in the Mos1 PEC each linker contacts the clamp loop of the partner 
molecule (Figure 2-10, right insert; see also Figure 2-5 in section 2.1.4). The inter-linker 
interactions are established mainly by the conserved mariner-specific WVPHEL motif 
(spanning aa 118-123) (Figure 2-10, left insert). By these interactions, the linker of one 
molecule is tethered to the catalytic core of the other molecule in trans, covering the active 
sites and locking the catalytic domains in a closed catalytically incompetent conformation 
(Figure 2-10).  
Results – Structural principles of Hsmar1 transposition 
 32 
 
Intriguingly, mutations of the WVPHEL motif have been shown to result in hyperactivity 
of the corresponding transposase variants (D. Liu et al., 2014). For example, substitution of 
W118 with proline (W118P) results in 4-fold increase of transposition activity. In light of 
our structure, this data implies that disruption of the linker-linker interactions by 
mutagenesis allows higher accessibility of the active sites, leading to a hyperactive 
phenotype.  
 
Thus, the structure of the Hsmar1 CAT and previous mutagenesis data together suggested 
that the Hsmar1 transposase assumes a closed, inactive conformation in absence of DNA. 
In order to test this hypothesis, I first investigated the full length wild type Hsmar1 and 
hyperactive Hsmar1-W118P transposases by size exclusion chromatography (SEC). For 
this, I overexpressed both proteins in Escherichia coli (E. coli), purified them to 
homogeneity and finally analysed them on a SEC column (Figure 2-11). 
 
 
Figure 2-11: Analytical size exclusion chromatogram showing that wild type Hsmar1 (WT, blue curve) elutes 
later than Hsmar1-W118P (W118P, orange curve) from the column (Superdex 200, 3.2/30). Based on their 
elution volumes, both proteins form dimers. 
In SEC, proteins are separated on the basis of their Stokes radius, which depends on their 
molecular size. The volume at which a protein elutes from the column (elution volume) is a 
direct reflection of its size and molecular shape, where larger or more elongated entities 
elute earlier, and smaller more compact proteins elute later (Nenortas, 1995). Interestingly, 
although both proteins elute at a volume consistent with homodimers, the Hsmar1-W118P 
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mutant shows a lower elution volume than the wild type Hsmar1, indicating a more 
expanded conformation for the mutant (Figure 2-11). This is consistent with the idea that 
disruption of the W118-P120 interaction by the W118P substitution causes “opening-up” 
of the Hsmar1-W118P transposase conformation.  
 
To further confirm these findings and obtain structural insights into the different 
conformations of the Hsmar1 transposase, I then analysed the two protein variants in their 
apo state by SAXS (Figure 2-12). Based on the SAXS data, the calculated molecular 
weight (Mw) of the wild type transposase correspond to 80.59 kDa and is therefore 
consistent with a dimer in solution (theoretical Mw of the monomer is 40.5 kDa) (Figure 
2-12 A). I then performed Guinier analysis of the obtained SAXS curves (Figure 2-12 B) to 
obtain the average radius of gyration (Rg): 35.5±0.9 Å for Hsmar1 wild type and 44.6±0.5 
Å for Hsmar1-W118P (Figure 2-12 A). According to the paired distance distribution P(r) 
function, the maximum dimension (Dmax) of wild type Hsmar1 is 116.2 Å, whereas this 
parameter is significantly larger for Hsmar1-W118P (150 Å) (Figure 2-12 A and Figure 
2-12 C). Thus, analogously to SEC, SAXS analysis indicates a compact shape for the wild 
type transposase and an expanded arrangement for the mutated variant. In agreement, ab 
initio shape reconstruction of the Hsmar1 dimer from the experimental SAXS data also 
revealed a compact molecular envelope shape (Figure 2-12 D). 
 
The finding that the Hsmar1 transposase is quite compact in solution is in contrast with 
SAXS experiments performed with the Mos1 transposase, which showed that Mos1 forms 
an elongated dimer that is held together only by its N-terminal DBD (Cuypers et al., 2013). 
The Rg and Dmax values reported for the Mos1 transposase (apo state) in solution were in 
fact significantly larger (Rg=49.2 Å, Dmax=185 Å) than the ones I obtained for the 
Hsmar1 transposase (apo) (Figure 2-12 A). The experimental Dmax of the apo Hsmar1 
dimer (116.2 Å) is instead comparable to the calculated maximum length of the Mos1 
transposase in the PEC (110 Å) (Figure 2-12 A), indicating an overall similar structural 
arrangement.  
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Figure 2-12: SAXS analysis of the wild type Hsmar1 (Hsmar1-WT) and W118P Hsmar1 (Hsmar1-W118P) 
transposases. (A) Comparison of structural parameters of the Hsmar1 variants and of the Mos1 transposase 
[Mos1 apo - parameters extracted from experimental SAXS data (Cuypers et al., 2013), and Mos1 PEC - 
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parameters calculated from the atomic coordinates of the structure - PDB ID: 3HOT; (Richardson et al., 
2009)]. (B) Comparison of the experimental SAXS curves (for Hsmar1-WT, blue line, left; and for Hsmar1-
W118P, orange line, right) with calculated scattering curves for the model of apo Hsmar1 (grey line) and for 
the Mos1 PEC (black line) (see models in E below). The quality of fit to the experimental data is evaluated 
by the chi square (χ2) values, as indicated on the graphs. (C) Pair distribution function P(r) calculated from 
the SAXS data of the Hsmar1-WT (blue line) and the Hsmar1-W118P (orange line) transposases. (D) Ab 
initio shape reconstruction of the wild type Hsmar1 dimer calculated from the SAXS data using GASBOR 
(D. I. Svergun et al., 2001). χ2 value and maximum dimension (Dmax) are shown next to the model. (E) 
Structural models of the DNA-free Hsmar1 homodimer (Hsmar1 apo) predicted using the SAXS data (left), 
and of the Hsmar1 PEC (middle). Right: Superposition of the Hsmar1 catalytic domain structure (blue and 
orange molecules) with the Hsmar1 PEC model (grey dimer). Arrow illustrates the transformation (40° 
rotation) that would bring the blue subunit into the PEC conformation. IR: inverted repeat. 
To visualize how the individual domains might be arranged in the full-length DNA-free 
Hsmar1 transposase dimer, I generated a structural model based on the SAXS data (Figure 
2-12 E, Hsmar1 apo). As source of high-resolution information, I used the crystal structure 
of the catalytic domain dimer and homology models of HTH1 and HTH2 [generated using 
the Mos1 structure as template, PDB ID: 3HOT; (Richardson et al., 2009)]. An ensemble 
of the Hsmar1 domains has been iteratively constructed and minimized against the low-
resolution SAXS data. The resulting in silico model (Figure 2-12 E, Hsmar1 apo) 
approximates the experimental scattering data well [chi-square (χ2) value of 1.07] (Figure 
2-12 B, left panel) and visualizes the Hsmar1 transposase in a compact conformation, 
where both N-terminal and C-terminal domains are involved in protein dimerization, 
differently than in the Mos1 transposase.  
 
In turn, the conformation assumed by the Mos1 transposase in the PEC poorly agrees with 
the experimental SAXS data of the Hsmar1 transposase (χ2 value of 4.32, Figure 2-12 B). 
Given the significant sequence similarity and largely similar biochemistry of the two 
proteins it is reasonable to assume that Hsmar1 assembles a highly similar active PEC as 
Mos1. Consistently, I was able to confidently model the Hsmar1 PEC based on the Mos1 
PEC structure (Figure 2-12 E, middle panel). Notably, the experimental SAXS curve of 
Hsmar1-W118P is not well represented by either the Hsmar1 apo model or the PEC 
(Figure 2-12 B, right panel). This suggests that Hsmar1-W118P assumes an open 
conformation, probably due to disruption of specific inter-linker interactions by 
mutagenesis, and its assembly is distinct from the ones assumed by the wild type protein.  
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In conclusion, SAXS data and molecular modelling suggests that the Hsmar1 transposase 
forms “closed” inhibited dimers in its DNA-free state (Figure 2-12 E, Hsmar1 apo) and 
“open” active dimers in its PEC form (Figure 2-12 E, Hsmar1 PEC). Structural transition 
from one conformation to the other would mostly involve discrete movements of the 
catalytic domains (circa 40 degree rotation between the two states, Figure 2-12 E, right 
panel) and restructuring of the WVPHEL motifs in particular. We speculate that the 
Hsmar1 transposase exists as a closed, inactive dimer at early stage of the transposition 
pathway to prevent catalysis on the DNA prior to transposon end synapsis (as discussed in 
section 2.5.3). 
2.2.2 Biochemistry of Hsmar1 excision 
In order to elucidate the mechanism of Hsmar1 excision, I first focused on identifying the 
order of the DNA hydrolysis reactions performed by the Hsmar1 transposase on transposon 
ends. To this aim, I performed in vitro cleavage assays using radioactively labelled 
substrates (Figure 2-13 A). To test efficiency and specificity of cleavage on each strand, 
different substrates imitating a single intact (IR) and nicked (N1 and N2) Hsmar1 inverted 
repeats (Figure 2-13 A, top) were incubated with recombinant Hsmar1 transposase. 
Transposase-mediated cleavage products were analysed via denaturing PAGE (Figure 2-13 
A, bottom). In order to detect cleavage on a specific strand, the 5’ end of the NTS or the 
TS of the dsDNA substrate was labelled with 32P (as indicated above the gel lines). 
 
Consistently with previous reports (Miskey et al., 2007), I found that the Hsmar1 
transposase can specifically cleave both strands of an intact transposon end (IR). 
Remarkably, the protein can still perform cleavage on the TS of the N1 substrate, 
containing a nick in the NTS strand. On the contrary, the NTS could not be cut when the 
TS was nicked (N2 substrate; Figure 2-13 A, bottom). These findings indicate that NTS 
cleavage strictly precedes TS cleavage (Figure 2-13 B). None of these cleavage events 
occurs in the presence of Ca+2 (Figure 2-13 A, bottom), as reported for other RNase H-like 
nucleases (W. Yang et al., 2006).  
Several additional reaction products were detected in the in vitro cleavage reactions 
(Figure 2-13 A, bottom), which likely result from integration of the cleaved transposon end 
substrates at TA dinucleotides present in their own DNA sequence. This indicates that the 
Hsmar1 transposase is able to perform also the integration reactions in vitro. 
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Figure 2-13: Characterization of Hsmar1 cleavage activity in vitro. (A) Hsmar1 in vitro cleavage assay. Top: 
dsDNA substrates used in the assay. The inverted repeat is shaded grey and its DNA sequence is shown in 
capital letters; flanking DNA is indicated in lower case letters. The invariable flanking TA dinucleotide is in 
red. Green and blue arrowheads indicate the position of cleavage on the transferred strand (TS) and non-
transferred strand (NTS), respectively. Arrowheads with asterisks indicate the position of a nick in the N1 and 
N2 substrates. Bottom: 12% Urea PAGE resolving 32P-labelled DNA substrates (IR, N1 or N2, labelled on the 
NTS or TS, as indicated above each gel lane) and products after incubation with Hsmar1 transposase in a 
10:1 DNA to protein molar ratio. Bands corresponding to specific cleavage products are framed by red 
rectangles on the gel. The control samples, labelled C, did not contain any protein. Marker (M) sizes are 
indicated next to the gel. (B) Proposed mechanism of transposon end cleavage and strand transfer in the 
Hsmar1 transposon [adapted from (Robertson et al., 1997)]. Schematic code equivalent to A. DNA strands of 
the target DNA are depicted as red lines. 
Taken together, my biochemical data revealed that the two transposon DNA strands are 
cleaved in a specific order, with NTS preceding TS cleavage. This implies that a 
conformational change in the transposase-DNA complex occurs between these breakage 
events. For energetic reasons, it is likely that the last step, namely TS cleavage, occurs in a 
complex conformation immediately competent for successive transposon integration 
(Figure 2-13 B).  
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2.2.3 In vitro reconstitution and crystallization of pre-excision 
Hsmar1 protein-transposon end DNA complexes 
In order to identify the structural basis of Hsmar1 excision, I aimed to determine the 
structure of pre-excision Hsmar1 protein-DNA complexes by X-ray crystallography. To 
this aim, a preliminary requirement was the reconstitution of such complexes in vitro. For 
this, I designed complexes for structural studies based on my biochemical insights.  
 
 
Figure 2-14: In vitro reconstitution and crystallization of Hsmar1 protein-transposon end DNA complexes. 
(A) Top: dsDNA probe used for nucleoprotein complex formation. Schematic code equivalent to Figure 2-13. 
The asterisk indicates the position of a synthetic nick on the NTS of the dsDNA probe. Bottom: analytical 
size exclusion chromatogram (column Superdex 200, 3.2/30) showing that the Hsmar1 transposase (Hsmar1-
WT, blue curve, absorption at 280 nm) binds to the Nicked NTS probe (Free DNA, red curve, absorption at 
260 nm), forming a stable, homogeneous nucleoprotein complex (Complex, dashed blue and dashed red lines 
representing absorption at 280 and 260 nm, respectively). Elution volume of the complex shifts with respect 
to individual complex components. (B) Top: crystals of the reconstituted Hsmar1-Nicked NTS complexes. 
Maximum crystal sizes are stated on the images. Bottom: SDS-PAGE analysis of the crystals. Silver-stained 
4-12% Bis-Tris NuPAGE gel showing both the Hsmar1 transposase and the Nicked NTS DNA present in the 
crystals. The relevant molecular weights of the protein marker (M) are marked next to the gel. 
I incubated the wild type Hsmar1 transposase with a dsDNA probe representing a 
transposon end after first strand nicking in non-catalytic conditions (Ca+2). The DNA 
contained a single IR flanked by some genomic DNA sequences and was nicked at the 
cleavage site on the NTS strand (Nicked NTS, Figure 2-14 A, top). Successively, the 
samples of protein only, DNA only, and protein-DNA mixture were run separately on an 
Chapter 2: Mechanisms of Tc1/mariner transposition 
     39 
Word	T
emplat
e	by	Fr
iedman
	&	Mor
gan	20
14 
analytical SEC column to assess complex formation. In SEC-based binding assays, if a 
complex between protein and the DNA is formed, the size of the complex will be larger 
than that of the single components, resulting in a shift of the complex’s elution volume in 
comparison to the elution volumes of protein and DNA alone (Nenortas, 1995). The 
elution profile of the Hsmar1 protein-Nicked NTS DNA mixture in analytical SEC showed 
the formation of a stable and homogenous complex (Figure 2-14 A, bottom). This indicates 
that the reconstituted complex likely assumes a discrete pre-excision conformation, since 
in the presence of Ca+2 even NTS cleavage is blocked [(Figure 2-13 A and (Claeys 
Bouuaert et al., 2010)].  
 
Using this complex, I performed crystallization trials and obtained crystals that grew in 
two months in 20% (w/v) PEG3350 and 0.2 M sodium thiocyanate, pH 6.9 in sitting drops 
using the vapour diffusion method (Figure 2-14 B, top). Crystals dissolved in water, run 
and visualized on a silver-stained gel show to contain both the Hsmar1 transposase and the 
DNA probe (Figure 2-14 B, bottom).  
2.2.4 Crystal optimization and X-ray data collection 
As initial crystals grew as multiple crossing plates and diffracted X-rays poorly, I made use 
of several strategies, as listed in Table 2-1, to optimize crystal quality.   
 
Table 2-1: Summary of constructs and conditions tested in order to improve the diffraction limit of the 
crystals. The approaches resulting in diffraction improvements and/or described in details are in red. 
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Firstly, I designed and tested diverse DNA substrates aiming to improve complex 
homogeneity and stability and/or the crystal packing. New DNA substrates varying in 
length, sequence, and containing nicks and/or gaps and sticky and/or blunt ends have been 
designed and tested for crystallization. Moreover, I introduced mutations of the transposon 
end in positions surrounding the cleavage site to create “uncleavable” DNA substrates, as 
probed by in vitro cleavage assays (Figure 2-15 A), to help locking the complex in the pre-
cleavage state.  
Secondly, I tried to crystallize the protein-DNA complex using different constructs of the 
Hsmar1 transposase: catalytic mutant (where aspartate 155 in the catalytic triad was 
substituted with alanine); cysteine mutants (to prevent adventitious protein oxidation); 
Thioredoxin fusion protein (so as to form additional protein interactions in the crystal 
supporting the packing); and a TS-cleavage deficient mutant. In the latter variant, I 
substituted the residue Val 199 with Gly in the transposase, as this mutation was shown to 
block TS cleavage [(Claeys Bouuaert et al., 2014) and Figure 2-15 B], supposedly trapping 
a pre-excision complex. However, no or poorly diffracting crystals grew in these 
conditions. 
 
Figure 2-15: Effects of mutating Hsmar1 transposon ends or transposase residues on NTS and TS cleavage. 
(A) Effect of Hsmar1 transposon end mutations on NTS and TS cleavage. Arrowheads mark the specific 
positions of DNA cleavage on transposon ends by the Hsmar1 transposase. The table summarizes the results 
of Hsmar1 in vitro cleavage assays monitoring Hsmar1-mediated cleavage of mutated transposon ends [on 
the non-transferred strand (NTS) or on the transferred strand (TS)]. (B) Hsmar1 in vitro cleavage assays 
showing that the Hsmar1-V119G mutant is deficient in TS cleavage (see in vitro cleavage assay with wild 
type protein in Figure 2-13 for comparison). 12% Urea PAGE resolving 32P-labelled dsDNA substrates (IR, 
N1 or N2, as indicated) and products after incubation with Hsmar1-V119G transposase in a 10:1 DNA to 
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protein molar ratio. Positions corresponding to expected cleavage products are framed by red rectangles on 
the gel. M: marker.   
Finally, I focused on refining the crystallization conditions by exhaustive screening around 
the initial crystallogenic condition [20% (w/v) PEG3350 and 0.2 M sodium thiocyanate, 
pH 6.9] in larger drops. By this method, I obtained remarkable improvements in crystal 
size (Figure 2-16 A). Then, I applied different treatments, such as annealing, dehydration 
(Russo Krauss et al., 2012), and seeding to the obtained crystals. Since my crystals were 
highly sensitive to handling, cooling, and cryoprotection procedures, I also screened 
different cryoprotectants, I tested direct freezing of the crystals in the 100 K nitrogen gas 
stream, and I used the CrystalDirectTM technology (Cipriani et al., 2012) for automated 
crystal harvesting and cryo-cooling (together with V. Mariaule and J. Márquez, Márquez 
Laboratory, EMBL Grenoble, France). 
 
Out of these attempts, the crystal quality improved notably by applying the manual 
hanging drop setup in combination with streak seeding methods (Figure 2-16 A). In 
addition, the use of 2,3-butanediol as cryoprotectant and flash-cooling in the cryo stream 
resulted in improved diffraction quality. By these methods, I could obtain diffraction and 
collected datasets with resolution in the 4-5 Å range (Figure 2-16 A) at synchrotron 
facilities ESRF in Grenoble and PetraIII in Hamburg. The best crystals diffracted to 4.25 Å 
(Figure 2-16 B and C). Data processing by XDS and XSCALE (Kabsch, 2010) permitted 
to calculate the space group (C2) and the unit cell parameters (212.97 187.17 461.6 90 
102.51 90). Due to high diffraction anisotropy, data processing has been challenging and 
available datasets, are currently being processed by the STARANISO server alone and in 
combinations to improve data quality (Tickle et al., 2017 ). 
 
Using the available data, initial attempts to solve the structure of the Hsmar1 complexes 
were performed by using the molecular replacement (MR) method in Phaser-MR (McCoy 
et al., 2007). For this, the structure of the Mos1 PEC [PDB ID: 3HOT (Richardson et al., 
2009), 37% transposase sequence similarity with Hsmar1] has been used as search model. 
Molecular replacement solutions with high log-likelihood gain (LGG) scores were 
obtained. Inspection of the calculated electron density maps showed continuity of the 
function along all three unit cell directions, indicating a meaningful solution with compact 
packing of the molecules in the crystal lattice. However, due to the large number of 
molecules in the asymmetric unit and the limited diffraction data quality, refinement of 
Results – Structural principles of Hsmar1 transposition 
 42 
these MR solutions was challenging. Thus, the correctness and completeness of the 
solutions could not be unambiguously assessed.  
 
Figure 2-16: Optimization, X-ray data collection and derivatization of the Hsmar1-Nicked NTS crystals. (A) 
Hsmar1-Nicked NTS crystals before and after optimization by the indicated techniques. (B) Diffraction 
image of optimized Hsmar1-Nicked NTS crystals. (C) X-ray diffraction data statistics obtained from data 
processing using XDS and XSCALE (Kabsch, 2010). (D) Left: mass-spectrometry showing the calculated 
mass of the Hsmar1 selenomethionine derivative (40,788 Da) and its mass shift in comparison with the native 
protein (286 Da). Right: selenomethionine derivative crystals of the Hsmar1 protein-Nicked NTS DNA 
complex. Maximum crystal size is indicated on the image. 
To improve the confidence and quality of phases, I next focused on combining MR with 
experimental phasing methods, namely multi-wavelength anomalous (MAD) and multiple 
isomorphous replacement (MIR) phasing approaches. For applying MAD, I first produced 
recombinant selenomethionine (SeMet) derivatives of the Hsmar1 transposase in E. coli 
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grown in a minimal medium supplemented with L-SeMet. Complete derivatization of the 
protein with SeMet (incorporation of 6 SeMet residues) was confirmed by matrix-assisted 
laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) analysis 
(Figure 2-16 D, left). Crystals of the complexes formed with the SeMet protein derivative 
grew in the same conditions as the native crystals (Figure 2-16 D, right) and were 
diffracted at synchrotron facilities ESRF in Grenoble and PetraIII in Hamburg. For MIR 
experiments, I soaked native crystals with heavy atom (e.g. cadmium and platinum) 
compounds and collected datasets at the absorption edge of these elements. At PetraIII P13 
beamline, I also performed data collection on native crystals close to the absorption edge 
of calcium, since this ion is included in my complexes and likely present in my crystals. 
Derivative datasets are currently being processed in the XDS suite. Once completed, the 
use of MAD and MIR approaches will be tested to determine the correctness and improve 
the quality of the previous MR solutions. To overcome the challenges, data analysis and 
structure solution is being carried out in collaboration with A. McCarthy, EMBL Grenoble, 
France. 
2.3 Results – Biochemistry of SB transposition 
 
Despite its broad applications as a genetic tool, very little is known about the transposition 
mechanism of the SB transposon. This is mainly due to limited biochemical and structural 
information available on the SB transposase and its active complexes. To date, 
recombinant production of the full-length SB transposase in sufficient quantity and quality 
for in vitro characterization has been challenging. However, in the Barabas Laboratory, 
purification of the SB transposase and preliminary activity analysis have been successfully 
established prior to my thesis work (Voigt et al., 2016). Building on this, I focused on 
elucidating the biochemical principles governing SB transposition and on providing 
structural insights. To this aim, here I reconstituted and analysed in vitro the molecular 
species involved in each step of the transposition reaction, namely transposon end 
recognition, transposon excision and transposon integration.  
2.3.1 SB transposon end recognition 
SB transposon ends contain four transposase binding sites in total: left outer (Lo), left inner 
(Li), right inner (Ri) and right outer (Ro) direct repeats (DRs). Outer and inner DRs have 
similar, but not identical sequences (Figure 2-9 in section 2.1.10) and are both necessary 
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and not interchangeable for efficient transposition in vivo (Cui et al., 2002). Previous in 
vitro binding assays reported for SB have shown that the transposase DBD (residues 1-123) 
binds the inner DRs more tightly than the outer DRs, suggesting distinct roles for these 
binding sites in transposition (Cui et al., 2002). Thus, in order to elucidate the molecular 
features of transposon end recognition, I analysed the binding activity of the full length SB 
to the different DRs in vitro by SEC. 
 Visualization of SB protein-transposon end DNA complexes 2.3.1.1
I first overexpressed the full length SB transposase in E. coli and purified it to 
homogeneity. I then tested the purified SB protein for its ability to bind specific dsDNA 
probes comprising the distinct sequences of single DRs and some flanking DNA (Lo′, Li′, 
Ri′ and Ro′, Figure 2-17, above corresponding chromatogram) using SEC. For this, SB was 
mixed with the different DNA probes in non-catalytic conditions [with Ca2+ substituting 
the native cofactor Mg2+ in the buffer (Dawson et al., 2003)]. Then, the samples of protein 
only, DNA only, and protein-DNA mixtures were run on a SEC column (Figure 2-17).  
 
Incubation of SB with the outer DRs (Lo′ and Ro′, respectively) resulted only in a partial 
shift in elution volumes compared to DNA alone and protein alone controls. The peaks 
corresponding to the SB-Lo′ and SB-Ro′ samples are quite broad, reflecting a 
heterogeneous population of species, including protein only, DNA only and low-affinity 
nucleoprotein complexes. In turn, more stable nucleoprotein complexes have formed when 
SB was incubated with the Li′ or Ri′ probes, respectively (SB-Li′ and SB-Ri′ samples). 
This indicates that the SB transposase binds more strongly the inner DRs than the outer 
DRs. Based on the elution volumes, the estimated size of these complexes corresponds to a 
monomer of SB bound to a single DR. This is in agreement with previous observations in 
our laboratory that the SB transposase is a stable monomer and binds to transposon end 
DNA as a monomer (Franka Voigt, unpublished). 
 
Of note, the SB-Li′ complexes show higher UV absorbance than the SB-Ri′ complexes 
despite mixing equal protein and DNA amounts (Figure 2-17, Li′ and Ri′), This indicates 
that some precipitation occurred upon mixing SB and Ri′. I observed the same pattern with 
the outer DRs, where the SB-Lo′ mixture contains more protein and DNA than the SB-Ro′ 
mixture, as judged by the height of the corresponding SEC peaks (Figure 2-17, Lo′ and 
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Ro′). Based on these observations, SB seems to have higher affinity to the left DRs than to 
the right DRs.  
 
Figure 2-17: Characterization of SB binding to transposon end DNA in vitro. Analytical SEC (column 
Superdex S200 3.2/30) profile of the SB transposase (SB; blue curve, absorption at 280 nm), dsDNA probes 
(Lo′, Ro′, Li′, Ri′; red curves, absorption at 260 nm) and SB protein-DNA mixtures (dashed blue and dashed 
red lines representing absorption at 280 and 260 nm, respectively). Sequence of dsDNA probes used in the 
binding studies are shown above the corresponding chromatograms. Schematic code equivalent to Figure 2-9 
in section 2.1.10. 
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 Identification of high affinity SB binding sites at the outer repeats 2.3.1.2
After transposon end binding, the SB transposase performs DNA cleavage and ligation 
reactions exclusively at the outer DRs (Lo and Ro). However, my initial attempts to 
reconstitute functional SB transposase-outer DRs complexes in vitro have shown limited 
success, probably due to the moderate affinity of the SB transposase to these sites prior to 
catalysis (Figure 2-17, Lo′ and Ro′). Lack of stable, functional, and homogeneous SB-outer 
DRs complexes greatly hampers both biochemical and structural characterization of SB 
transposition.   
 
To overcome this, I set out to identify high affinity outer repeat substrates. To this end, I 
mixed the SB transposase with dsDNA probes representing processed outer DRs at 
different stages of the transposition reaction and tested complex formation by SEC. In 
particular, I used dsDNA probes mimicking Lo after (i) first strand nicking (Nicked Lo); 
(ii) double-strand DNA cleavage (Cleaved Lo); (iii) ligation to target DNA (Gapped Lo 1-
2-3 and Gapped Lo-Li) (Figure 2-18 and Figure 2-19). I also tested different buffer 
conditions, several DNA oligonucleotides of varying length and sequence, and various 
protein-DNA mixing ratios for optimal complex formation. In these attempts, I could 
reconstitute stable nucleoprotein complexes with various substrates, as shown in Figure 2-
18 and Figure 2-19 with the specific DNA probes indicated above each chromatogram.  
 
Interestingly, compared to pre-cleaved substrates (Cleaved Lo), the use of gapped or 
nicked substrates increased the stability and homogeneity of the corresponding complexes 
significantly, as revealed by the single, narrow peaks observed in SEC (Figure 2-18). This 
indicates that the presence of nicks or gaps at the cleavage site promotes binding to the SB 
transposase. This might be explained by specific recognition of nicks and gaps by the SB 
transposase, as a signature of specific transposition steps. Alternatively, they might confer 
higher flexibility to the DNA, facilitating its correct accommodation in the catalytic pocket 
of the transposase. Additionally, short stretches of flanking genomic DNA also increased 
transposase binding, probably due to direct interaction of specific protein surfaces with 
flanking DNA (in particular, the TA dinucleotide immediately at the transposon flanks) 
during transposon binding and target recognition (Dornan et al., 2015). 
 
Moreover, the SEC data shows that the length and position of the gaps on the NTS greatly 
affect the affinity of the SB transposase for Lo. In particular, DNA substrates with a 
Chapter 2: Mechanisms of Tc1/mariner transposition 
     47 
Word	T
emplat
e	by	Fr
iedman
	&	Mor
gan	20
14 
specific 5 nt gap spanning from the cleavage site to some flanking DNA (see Gapped Lo2, 
Lo3 and Lo-Li in Figure 2-18 and Figure 2-19), formed more stable complexes than those 
where the gap covers a longer region (7 nt, data not shown) or the cleavage site only 
(Gapped Lo1, Figure 2-18).  
 
 
Figure 2-18: Characterization of SB binding to left outer repeats (Lo) in vitro. Analytical SEC (column 
Superdex S200 3.2/30) profiles of the SB transposase (SB; blue curve, absorption at 280 nm), dsDNA probes 
(Cleaved Lo, Nicked Lo, Gapped Lo1 and Gapped Lo2; red curves, absorption at 260 nm) and SB protein-
DNA mixtures (dashed blue and dashed red lines representing absorption at 280 and 260 nm, respectively). 
Results – Biochemistry of SB transposition 
 48 
Sequence of the dsDNA probes used are shown above the corresponding chromatograms. Schematic code 
equivalent to Figure 2-9 in section 2.1.10. Blue arrowhead indicates the position of the nick on the non-
transferred strand (NTS) in Nicked Lo.  
Despite the identification of high affinity Lo DNA substrates, I detected significant 
precipitation during complex formation in all cases. To overcome these problems, I 
identified specific amino acid substitutions in the SB protein (SB100X) sequence that 
conferred high solubility and stability to the corresponding mutant. In particular, residues 
C176 and I212 were mutated into serines to obtain the SBC176S-I212S transposase variant 
(also named “high solubility SB”- hsSB). The design and characterization of this 
transposase variant is described in more detail in section 3.2. By using this specific 
transposase mutant, I successfully formed stable nucleoprotein complexes with a gapped 
DNA probe (Gapped Lo3) without significant protein precipitation (Figure 2-19, left).  
 
 
Figure 2-19: Reconstitution of high affinity SB protein-transposon end DNA complexes in vitro. Analytical 
SEC (column Superdex S200 3.2/30) chromatograms showing that the SBC176S-I212S transposase (SBC176S-I212S; 
blue curve, absorption at 280 nm) stably binds to dsDNA probes (Gapped Lo3 and Gapped Lo-Li; red curves, 
absorption at 260 nm), forming homogeneous complexes (dashed blue and dashed red lines representing 
absorption at 280 and 260 nm, respectively). Sequence of dsDNA probes used for complex formation are 
shown above the corresponding chromatograms. Schematic code equivalent to Figure 2-9 in section 2.1.10.  
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In addition, I designed a new gapped substrate containing sequences of both the outer (Lo) 
and inner (Li) repeats, named Gapped Lo-Li. In particular, specific positions (shown in 
pink in Figure 2-19) in Lo were mutated to their counterparts in Li. Use of this new 
substrate for complex formation increased the stability and homogeneity of the SB 
transposase-DNA complexes significantly, forming a single, narrow peak in analytical 
SEC (Figure 2-19, right). The obtained complexes did not show protein precipitation and 
could be concentrated up to concentration ranges suitable for crystallization. These results 
allowed me to reconstitute SB nucleoprotein complexes that are currently being screened 
for crystallization. 
 Identification of specific SB protein-transposon end DNA contacts 2.3.1.3
In order to gain structural insights into transposon end DNA recognition, I aimed to 
identify specific protein residues involved in DNA binding by site-directed protein-DNA 
disulfide crosslinking. For these experiments, cysteine residues are introduced by site-
directed mutagenesis at defined positions in the DNA-binding surface of the protein and an 
alkanethiol tether is incorporated at specific positions in the DNA backbone. If the 
cysteine-substituted residues are in close proximity to the modified DNA backbone, they 
will form disulfide bonds with the alkanethiol tethers, leading to the formation of 
covalently trapped protein-DNA complexes (Verdine et al., 2003) (Figure 2-20 A).  
 
By in silico analysis of a homology model of the SB DBD [modelled based on the Mos1 
structure, PDB ID: 3HOT, (Richardson et al., 2009)], I first identified candidate residues 
both in the PAI and in the RED domains that are likely in contact with the transposon end 
DNA (Figure 2-20 B). Subsequently, I performed a comparative analysis of transposon end 
DNA sequences of several Tc1/mariner transposons (Tc3, Tc1, Mos1, Hsmar1) to predict 
specific nucleotide positions recognized by the candidate SB residues. From this analysis, I 
identified eight different amino acids that likely interact with the transposon ends in a 
single position or two possible positions in the DNA sequence (Figure 2-21 A). 
I then expressed and purified eight single point mutants, with each of the previously 
selected candidate residues substituted to Cys. Then, I assessed the DNA binding 
properties of the soluble SB mutants (7 out of 8) by analytical SEC (Figure 2-21 A). The 
three mutants that retained DNA binding (indicated in red in Figure 2-20 and Figure 2-21) 
to a pre-cleaved left transposon end (LE) have been selected for crosslinking experiments 
(Figure 2-21).  
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Figure 2-20: Design of protein-DNA crosslinking to map SB-Lo interactions. (A) Schematic representation 
of the crosslinking strategy. Specific cysteine mutations are introduced in the SB transposase (red) and 
specific backbone phosphates are substituted with a N-thiolalkyl phosphoramidate moiety (thiol-containing 
tether in green, DNA backbone in yellow). Upon disulfide crosslinking reaction, the protein gets covalently 
attached to DNA. Adapted from (Banerjee et al., 2006). (B) Structural model of SB DNA binding domain 
(DBD) bound to two inverted repeats (IR, grey). The PAI and RED HTH motifs are indicated. The side 
chains of predicted DNA binding residues are shown in red (for residues selected for further crosslinking 
experiments) and green.  
I performed preliminary crosslinking experiments using the SBS37C, SBV106C and SBH115C 
mutants in combination with thiol-tethered Lo DNA substrates, (LE3, LE4, LE1 and LE2; 
containing the thiol modification at different positions in SB’s left outer direct repeat) 
(Figure 2-21 B). The crosslinking protocol [adjusted from the method described in 
(Gorecka et al., 2013)] is based on incubation of the cysteine-substituted SB with the 
modified DNA substrate in non-reducing conditions. The products of the reactions were 
analysed on non-reducing SDS-PAGE gels, stained for protein (or DNA where indicated; 
Figure 2-21 B). Bands having retarded mobility, corresponding to a molecular weight of 
approximately 49 kDa, appeared upon DNA addition, indicating crosslink formation 
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between the mutants (39 kDa) and the modified strand of the DNA substrates (9.9 kDa). 
The relatively low amount of the observed crosslinked complex in these experiments was 
probably due to low efficiency of the crosslinking reaction in the tested condition. 
Unspecific bands were also detected in the reactions and likely indicate adventitious 
oxidation of the protein in non-reducing conditions. 
 
Figure 2-21: Identification of specific SB protein-transposon end DNA contacts. (A) Candidate DNA binding 
residues (Cys-substituted) and predicted corresponding protein-binding positions on transposon end DNA 
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(marked with green and red arrowheads; red arrowheads mark the positions of P-cystamine modification in 
LE1, LE2, LE3 and LE4 DNA substrates used in crosslinking experiments). Mutants shown in red have been 
used in crosslinking experiments. Results of protein purification (‘+’: positive; ‘-‘: negative) and DNA 
binding assays (‘✔’: positive; ‘✖‘: negative; ‘NC’: not characterized) are indicated. (B-D) Site-directed 
protein-DNA disulfide crosslinking. 4-12% Bis-Tris NuPAGE gels separating crosslinking reactions with the 
indicated SB transposase variants and the modified DNA substrates. The resulting protein-DNA covalent 
complexes are framed by a red rectangle or indicated by a red arrow. Gels are stained for protein, unless 
otherwise indicated. Reaction buffer A, B and C contained no, 0.2 mM and 0.5 mM DTT, respectively. After 
the crosslinking procedure, samples were resuspended in loading buffer containing 300 mM DTT (DTT +) or 
no DTT (DTT -). M: marker. (E) Formation and crystallization of SB DNA binding domain-transposon end 
DNA complexes. Left panel: Left: SDS-PAGE analysis of the purified N-terminal DNA binding domain (aa 
1-117) of the SB transposase (SB DBD); M: marker. Middle: dsDNA probe (Lo-DBD) used for complex 
formation and crystallization. It contains complementary overhangs at its termini. DNA regions recognized 
by the PAI and RED domains are indicated. Right: crystals formed of SB DBD protein- Lo-DBD DNA 
complexes. 
To overcome these technical issues, I optimized the crosslinking protocol and I introduced 
the C176S and I212S mutations mentioned in the previous section, to increase solubility 
and stability of the cysteine-substituted mutants. These conditions enhanced the specificity 
of the crosslinking reaction and prevented undesired protein-protein oxidation. With the 
SBC176S-I212S-S37C (Figure 2-21 C) and SB C176S-I212S-V106C (Figure 2-21 D) variants, specific 
bands appeared upon addition of modified LE DNA, corresponding to crosslinked 
nucleoprotein complexes. This indicates that S37 in the PAI and V106 in the RED domain 
are DNA-binding residues and contact transposon end DNA at the predicted specific 
positions. 
 
In addition to the crosslinking experiments, in order to gain high-resolution insights into 
transposon end DNA recognition, I worked on structure determination of SB DBD-
transposon end DNA complexes (Figure 2-21 E). For this, I overexpressed and purified the 
DBD of the SB transposase (residues 1-117) to homogeneity (Figure 2-21 E, left panel) 
and reconstituted in vitro nucleoprotein complexes with different length transposon end 
DNA substrates (e.g. Lo-DBD in Figure 2-21 E, middle panel). From several 
crystallization attempts, I obtained crystals of the reconstituted complexes (Figure 2-21 E, 
right panel) that have been tested for diffraction. However, the diffraction limit remained 
moderate (5 Å) and the obtained datasets did not allow me to determine the structure by 
molecular replacement; the presence of protein in the crystals could also not be 
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unambiguously assed. Crystal optimization attempts resulted in thin clusters of needles, so 
far unsuitable for data collection.  
2.3.2 SB transposon excision 
The mechanism of excision of the SB transposon is still poorly characterized. To date, 
studies performed in living cells (Luo et al., 1998) have provided no direct evidence on the 
exact positions of cleavage at the transposon ends or on the minimal protein and DNA 
requirements of these reactions. To elucidate these aspects, I reconstituted and analysed the 
specific cleavage activity of the SB transposase on transposon end DNA sequences in vitro 
and mapped the positions of the DNA breaks with single nucleotide precision. 
 Mapping the specific cleavage sites of SB 2.3.2.1
Previous reports showed that the SB transposase is able to cleave dsDNA substrates 
imitating isolated Lo sites in vitro, but multiple cleavage positions were detected (Voigt et 
al., 2016). In order to increase specificity of cleavage, I first optimized the design of the Lo 
dsDNA substrate used for the cleavage assay. I thus incubated this optimized dsDNA 
substrate, referred to as Lo (Figure 2-22, top), with the purified SB transposase and I 
analysed the resulting cleavage products via denaturing PAGE (Figure 2-22, left and 
middle panels). To detect cleavage on a specific strand, the NTS or the TS of the dsDNA 
substrate was 5’ end labelled with 32P (as indicated by asterisks in Figure 2-22).  
 
The results of the assay showed that the Lo substrate is cleaved at specific positions on 
both DNA strands in the presence of the SB protein (Figure 2-22, left and middle panels). 
This indicates that the SB transposase is able to specifically cleave the outer repeats in the 
transposon ends in vitro without any additional protein factors or DNA requirements. 
Remarkably, I observed that the SB transposase cleaves the TS exactly at the transposon 
end boundary and the NTS at a 2 nt recessed position within the transposon end, generating 
2 nt staggered dsDNA breaks (Figure 2-22, top).  
 Dissecting the role of the inner repeats in SB cleavage activity   2.3.2.2
The outer and inner repeats of the SB transposon differ only in few nucleotides but likely 
have distinct roles in transposition (Cui et al., 2002). The purified SB transposase binds 
dsDNA probes imitating the left inner repeat, Li (Figure 2-17). However, I found that SB 
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does not cleave Li sites in vitro (Figure 2-22, right panel), consistently with previous in 
vivo reports (Cui et al., 2002). Therefore, recognition of specific nucleotides in the 
sequence of the outer repeat, not present in the inner repeats, is necessary for transposase-
mediated specific cleavage.  
 
Figure 2-22: Characterization of the specific cleavage activity of SB in vitro. Top: dsDNA substrates used in 
the SB cleavage assay. A single left outer (in Lo) or inner (in Li) inverted repeat is shaded grey or pink and 
its DNA sequence is shown in capital letters; flanking DNA is indicated in lower case letters. The invariable 
flanking TA dinucleotide is in red. Green and blue arrowheads indicate the position of cleavage on the 
transferred strand (TS) and non-transferred strand (NTS) of Lo, respectively. Bottom: SB cleavage assay. 
12% Urea PAGE resolving 32P-labelled DNA substrates (Lo, left and middle panels; Li, right panel, as 
indicated by cartoons next to the gels) and products after incubation with SB transposase (SB) in a 50:1 
protein to DNA molar ratio. The specific cleavage products are indicated by arrows. Marker (M) sizes are 
indicated next to the gel.  
Successively, I tested whether the presence of the inner repeats can affect cleavage on the 
outer repeat by the SB transposase in vitro. Addition of Li substrates in the Lo cleavage 
reactions (Figure 2-23, left and middle panels) or the use of a Lo-Li substrate, where the 
outer and inner sites are linked by a flexible single strand DNA linker, (Figure 2-23, right 
panel) did not affect either the specificity or the efficiency of Lo cleavage by the SB 
transposase. Therefore, the recognition of the inner repeats by the SB transposase does not 
seem to facilitate transpososome assembly and thus transposon end cleavage in vitro. 
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Figure 2-23: Testing the effect of the inner repeats on SB cleavage activity. 12% Urea PAGE resolving 32P-
labelled DNA substrates (Lo, with or without unlabelled Li, left and middle panels; linked Lo-Li, right panel, 
as indicated by cartoons next to the gels) and products after incubation with SB transposase (SB) in a 50:1 
protein to DNA molar ratio. The specific cleavage products are indicated by arrows next to the gel. Marker 
(M) sizes are indicated next to the gel. Schematic code as Figure 2-22. 
 Identifying the role of flanking DNA in SB cleavage activity     2.3.2.3
The outer repeats of the SB transposon are always flanked by TA dinucleotides sequences 
derived from the insertion sites (Figure 2-24, ‘ta’ in red). Transposition assays in HeLa 
cells indicated that the loss of this TA motif on both flanks of the transposon abolishes 
transposition and the addition of a TATA motif in the flanking sequences increases the 
overall transposition rates up to 195% (Cui et al., 2002). This suggests that these flank 
sequences also affect transposon excision.  Therefore, I analysed the effect of this 
additional TA dinucleotide in in vitro cleavage assays.  
 
The results of this assay (Figure 2-24) showed that if a double TA is present in the flanking 
DNA (as in the Lo-TATA dsDNA substrate, Figure 2-24, top), the SB transposase cleaves 
the NTS of Lo at two positions: at the canonical cleavage site (marked as 1) and, 
additionally, 2 nucleotides away from the 3’ of the additional TA (marked as 2) (Figure 
2-24, bottom). This indicates that the recognition of this flanking TA by the SB transposase 
might be essential for selecting the position of cleavage on the outer repeat 2 nucleotides 3’ 
of a TA dinucleotide. 
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Figure 2-24: Identifying the role of flanking TA dinucleotides in SB cleavage activity. Top: dsDNA 
substrate, named Lo-TATA used in SB in vitro cleavage assays. The invariant TA dinucleotide (number 1) in 
the flanks is shown in red; the additional TA (number 2) is in magenta. Bottom: 12% Urea PAGE resolving 
32P-labelled Lo-TATA DNA substrate and products, as indicated by cartoons next to the gel, after incubation 
with SB transposase (SB) in a 50:1 protein to DNA molar ratio. The specific cleavage products are indicated 
by arrows. Marker (M) sizes are indicated next to the gel.  
2.3.3 SB transposon integration 
The biochemical principles and the molecular factors involved in SB integration are yet 
uncharacterized. This is mainly due to technical challenges in reconstituting the integration 
activity of the SB transposase in vitro. To overcome this lack of knowledge, I therefore 
endeavoured to establish biochemical assays to monitor SB integration.  
 In vitro reconstitution and analysis of SB integration activity    2.3.3.1
I first focused on identifying permissive conditions in which the recombinant SB 
transposase can perform integration (i.e. strand transfer reactions) in vitro in the presence 
of transposon end DNA (Figure 2-25).  
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Figure 2-25:  Analysis of SB integration activity in vitro. (A) dsDNA substrates used in SB in vitro 
integration assay. Schematic code as Figure 2-22. (B) SB in vitro integration assays, showing that the SB 
transposase (SB) joins specifically 2 nt staggered pre-cleaved Lo DNA (2 nt) to target plasmid DNA (each 
strand shown as a red line). Strand transfer reactions generate two different products, as displayed on a native 
agarose gel: i. Single-End Joining (SEJ) products and ii. Double-End Joining (DEJ) products. (C) Time-
course SB in vitro integration assay, showing the kinetics of SEJ and DEJ product formation. Incubation 
times are shown above the corresponding lines. Control samples (C) did not contain any SB protein. 
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Reactions are run on a native or on a denaturing gel, as indicated above each gel. In (A), (B) and (C), 
asterisks indicate the positions of 32P-labelling. M: marker.  
 
For this, I incubated the SB transposase with target plasmid DNA and dsDNA substrates 
imitating SB Lo sites in different ratios and reaction conditions. Out of these attempts, I 
identified specific experimental conditions in which a pre-cleaved Lo dsDNA substrate 
(identified in my previous in vitro cleavage assay in section 2.3.2.1; referred as “2 nt” in 
Figure 2-25) is ligated to the target plasmid DNA by SB. Of note, the use of an intact, 
“uncleaved” dsDNA substrate did not support integration (data not shown). For the in vitro 
integration assays, the 5’ end of “2 nt” was 32P-labelled (specifically on the TS, as 
indicated by asterisks in Figure 2-25). Therefore, ligation of two “2 nt” dsDNA substrates 
to separate strands of the same circular plasmid (Double-End Joining-DEJ) generated a 
radiolabelled linear dsDNA product, which could be detected on a native agarose gel 
(Figure 2-25 B, see schematics).  
 
SB is able to generate such DEJ products in vitro, which accumulate rapidly over time and 
reach saturation within 3 hours (Figure 2-25 C, left native gel). “Single-End Joining” (SEJ) 
is less frequent and generates a nicked circular plasmid, in which the strand attached by a 
single “2nt” becomes radioactively labelled (Figure 2-25 B, see schematics next to the gel). 
Consistently, when I visualized the same reactions on a denaturing agarose gel, DEJ and 
SEJ products could not be differentiated from each other because only one band was 
present, corresponding to the radiolabelled strand of “2 nt” joined to a single target strand 
(Figure 2-25 C, right panel, denaturing gel). 
 
 Confirmation of specific requirements for SB integration activity 2.3.3.2
Next, I tested whether the 2 nt staggered overhangs of the pre-cleaved transposon ends are 
required for the integration step. For this, I performed the previously described integration 
assay using a Lo substrate with 3 nt overhangs at the 3’ end of its TS (named “3 nt” in 
Figure 2-25 A and B). This substrate was not able to support either DEJ or SEJ formation. 
This indicates that the 2 nt overhangs, introduced at the outer repeats during transposon 
excision, are specifically required for the successive step of transposon integration.  
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In conclusion, in this biochemical analysis of SB transposition, I showed that the 
recombinant SB transposase is completely proficient in transposon end binding, cleavage, 
and integration in vitro. Moreover, I identified specific molecular features of the process 
that were previously unrevealed for the SB transposon and will be discussed in details in 
section 2.5.6. 
2.4 Results - Role of transposase oligomerization in SB 
transposition 
 
In the previous section, the main steps of SB transposition have been reconstituted in vitro, 
but how these events are orchestrated in the context of the SB transpososome has remained 
uncharacterized. The recombinant SB transposase is prevalently monomeric on its own 
(Franka Voigt, manuscript in preparation; see also section 2.3.1.1). However, the active 
forms of DNA transposases are protein-DNA assemblies that are at least dimeric, since two 
subunits of the transposase are always required to act on two transposon ends (Hickman et 
al., 2016). For this reason, in this part of my thesis, I investigated oligomerization of the 
SB transposase and its regulatory role in transposition. 
2.4.1 In vitro analysis of SB transposase oligomerization 
The first question I asked is whether SB monomers can form oligomers and what 
conditions influence oligomer assembly. Thus, I analysed SB oligomerization by 
employing different oligomerization assays, based on fluorescence (section 2.4.1.1) as well 
as on crosslinking techniques (section 2.4.1.2).  
 In vitro fluorescence-based oligomerization assay 2.4.1.1
Prior to this thesis work, to study SB oligomerization in living cells, an assay has been 
designed that relies on red fluorescent protein (RFP) derived biosensors, named A1 and B1 
(Alford et al., 2012) (Franka Voigt, manuscript in preparation). A1 and B1 are 
dimerization-dependent fluorescent proteins that interact with very low affinity (Kd = 33 
µM) and thus exist mainly in their dissociated state at the concentrations used in the 
experiments. Due to the low affinity of their interaction, they only light up when they are 
brought into close proximity upon association of proteins that are genetically fused to them 
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(Figure 2-26 A). These properties make them well suited to study the potentially low-
affinity or transient interactions between SB monomers. 
 
For establishing in vivo oligomerization assay, fusion proteins were generated between the 
SB transposase and the A1 and B1 proteins. The resulting constructs (A1-SB and B1-SB) 
were then overexpressed in HeLa cells. Notably, a strong fluorescent signal could be 
detected in the nuclei of cells expressing both A1-SB and B1-SB fusion proteins, 
indicating that the SB transposase is capable of oligomerization in vivo (Franka Voigt and 
Cecilia Zuliani-Lab Manager, Barabas Laboratory, EMBL Heidelberg, manuscript in 
preparation).    
 
In order to corroborate these findings and identify permissive conditions, I then probed and 
analysed oligomerization of the SB transposase in vitro, together with Cecilia Zuliani. For 
this, we established an in vitro oligomerization fluorescence-based assay, conceptually 
similar to the one used in vivo (Figure 2-26 A). We first overexpressed in E. coli and 
purified recombinant SB fusion proteins, A1-SB and B1-SB, as well as A1 and B1 
proteins, used as negative controls. We then mixed the purified proteins in pairs (A1 with 
B1; A1-SB with B1-SB) in presence (+ DNA) or absence of transposon end DNA 
(Cleaved Lo, see Figure 2-19, section 2.3.1.2). Finally, the fluorescence signal emitted 
from the mixtures was measured in a plate reader at different time points (Figure 2-26 B, 
left). 
 
Consistently with previous reports (Alford et al., 2012), the A1 and B1 pair exhibited 
close-to-background fluorescence, even 72 hours after protein mixing. Interestingly, this 
was also true for the A1-SB/B1-SB pair. In fact no significant increase of fluorescence 
signal was detected when A1-SB and B1-SB fusion proteins were mixed together, 
indicating that SB oligomerization is quite weak in these conditions. However, the A1-
SB/B1-SB pair exhibited significantly high fluorescence signal upon addition of 
transposon end DNA (+ DNA), as compared to the condition without DNA. As expected, 
fluorescence of the A1/B1 controls was not affected by the presence of DNA. A strong 
fluorescence signal of the A1-SB/B1-SB pair, together with transposon end DNA, was 
already detectable after 5 minutes of incubation and increased at 24 hours of incubation 
(Figure 2-26 B, left).  
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These findings indicate that the SB transposase does form oligomers in vitro and that its 
oligomerization depends on the presence of transposon end DNA. Moreover, SB oligomers 
are progressively assembled in time, but, once formed, result quite stable in the conditions 
tested.  
 
 
 
Figure 2-26: In vitro fluorescence-based oligomerization assay. (A) Schematic representation of the assay 
[adapted from (Alford et al., 2012)]. A1 and B1 proteins come in close proximity and emit fluorescence only 
upon dimerization of the transposase (SB or Hsmar1), genetically fused to them. The transposase is depicted 
with its bipartite DNA binding domain (small light purple ovals) and its catalytic domain (big dark purple 
ovals). (B) Left: in vitro SB oligomerization-dependent fluorescence measurements of fusion proteins in 
absence and presence (+ DNA) of SB transposon end DNA. For each condition, mean values of three 
experiments are shown and error bars represent the standard deviation. Statistical analysis was performed by 
a two-sample t-test comparing fluorescence of A1-SB/B1-SB mixtures in presence and in absence of DNA. A 
single asterisk indicates P values ≤0.05; two asterisks indicate P values ≤0.01. Right: in vitro Hsmar1 
oligomerization-dependent fluorescence measurements of fusion proteins in absence and presence (+ DNA) 
of Hsmar1 transposon end DNA. For each condition, mean values of three experiments are shown and error 
bars represent the standard deviation. Statistical analysis was performed by a two-sample t-test comparing 
fluorescence of A1-HM/B1-HM mixtures at two different time points. Three asterisks indicate P values 
≤0.001. 
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As a positive control, we then performed similar assays using recombinant A1 and B1 
proteins fused to the Hsmar1 transposase, which is a stable dimer by itself (Figure 2-26 B, 
right). We did not detect any significant increase of fluorescence signal 5 minutes after 
mixing the A1-Hsmar1 and B1-Hsmar1 proteins in comparison to the A1/B1 controls. 
However, the A1-Hsmar1/B1-Hsmar1 pair emitted very strong fluorescence 72 hours after 
mixing, and the fluorescence of the protein pair was not significantly affected by the 
presence of Hsmar1 transposon end DNA (Figure 2-26 B, right). The results of this 
experiment can be interpreted as follows. The A1-Hsmar1 and B1-Hsmar1 transposases are 
purified as stable homodimers, as the wild type Hsmar1. Thus, no heterodimer formation 
between A1-Hsmar1 and B1-Hsmar1 monomers, and consequently fluorescence emission, 
likely occurs immediately after mixing (5 minutes). Consistently with this hypothesis, long 
incubation times (72 hours) would allow exchange of Hsmar1 monomers in solution, 
resulting in heterodimerization and consequent detection of a strong fluorescence signal. 
 
Taken together, the data reported in this section indicate that the SB transposase, 
differently to the Hsmar1 transposase, exists both in a monomeric and oligomeric form. 
Binding to the transposon end DNA is likely the switch regulating the transition between 
these states throughout the transposition pathway (as discussed in section 2.5). 
 Disuccinimidyl suberate (DSS)-mediated crosslinking of SB  2.4.1.2
In order to further confirm oligomerization of the SB transposase in vitro, I tested the 
formation of covalent bonds between subunits of the purified SB transposase using 
chemical crosslinking. For this, I incubated the SB protein with or without transposon end 
DNA and then treated the samples with disuccinimidyl suberate (DSS), a chemical 
crosslinker for primary amines present in the side chains of lysine residues and the N-
terminus of the proteins (Wong, 1993). By resolving the reactions by SDS-PAGE, I could 
detect DSS-mediated crosslinking of two SB subunits both in the presence and in the 
absence of transposon end DNA (Figure 2-27 A). Moreover, higher molecular weight 
species, likely corresponding to tetramers, could also be detected in the sample containing 
DNA (Figure 2-27 A). This shows that oligomerization of SB occurs in vitro under these 
experimental conditions and it is compatible with complex formation. 
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Figure 2-27: In vitro analysis of SB transposase oligomerization by crosslinking. (A) Chemical crosslinking 
of the SB transposase by disuccinimidyl suberate (DSS). SDS-PAGE analysis of the SB transposase treated 
with DSS in absence or presence of transposon end DNA (DNA). Orange arrow indicates a band with 
retarded mobility, corresponding to the molecular weight of a SB dimer. (B) Site-directed cysteine-based 
crosslinking of the SB transposase. Left: structural model of the dimer interface in the SB PAI, showing 
residue Asp17 in sticks. Right: SDS-PAGE analysis showing covalent SB dimers (indicated by the yellow 
arrow) obtained by disulfide protein-protein crosslinking of the SBC176S-I212S-D17C  mutant with or without 
transposon end DNA (DNA). SDS-PAGE analysis of the SBC176S-I212S  protein in the same conditions is 
shown for comparison.  
 Specific residues in the PAI mediates SB oligomerization 2.4.1.3
In order to dissect specific amino acids involved in SB oligomerization, I identified 
candidate residues of the SB transposase and tested their location on the transposase dimer 
interface by site-specific cysteine-based crosslinking.  
 
The work done on the Hsmar1 transposase during my M.Sc. thesis let me identified several 
residues in the HTH1 motif that are involved in its dimerization. I therefore analysed an in 
silico model of the SB PAI [generated based on the Mos1 structure, PDB ID: 3HOT, 
(Richardson et al., 2009)] (Figure 2-27 B, left), and identified candidate amino acids in this 
specific region of the SB transposase that could be involved in its dimerization, likely 
forming salt bridges between the two protein protomers (Asp 10, Arg 14, Asp 17, Lys 20 
and Arg 31). I then mutated these candidate residues one by one into cysteine in the SB 
protein sequence. Additionally, these cysteine-substituted mutants contained the mutations 
C176S and I212S, described in sections 2.3.1.2 and 2.3.1.3, to increase transposase 
stability and decrease adventitious oxidation. Successively, I overexpressed in E. coli and 
purified two of these cysteine-substituted mutants (SBC176S-I212S-D17C and SBC176S-I212S-R14C) 
as recombinant proteins and I incubated them with transposon end DNA in reducing 
conditions (0.2 mM tris(2-carboxyethyl)phosphine-TCEP). Once stable nucleoprotein 
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complexes have been formed, I removed completely the reducing agent by dialysis and 
incubated the samples for two days at 25° C to favour the formation of disulfide bonds 
between cysteines.  
 
I then analysed the reactions on non-reducing SDS-PAGE gels. A band having retarded 
mobility corresponding to a molecular weight of approximately 80 kDa appeared after the 
described treatment of the SBC176S-I212S-D17C both as protein alone and in complex with 
DNA (Figure 2-27 B) (less prominent for the SBC176S-I212S-R14C mutant; data not shown). 
This is indicative of disulfide bond formation between two SB protomers and is specific to 
the incorporation of the cysteine in position 17 in the PAI of the SB transposase (compare 
with SBC176S-I212S transposase under same conditions; Figure 2-27 B). The formation of a 
disulfide bond between specific cysteines belonging to different SB subunits is indicative 
of the high proximity of the PAIs of the two protomers (the S-S bond length is about 2.05 
Å). This suggests that the specific residue Asp 17 in the PAI of the SB protein is involved 
in protein dimerization (Figure 2-27, B).  
2.4.2 Oligomerization-based strategies for in vitro reconstitution of 
SB protein-DNA complexes 
Experimental data presented in the previous sections indicate that the recombinant SB 
transposase is predominantly monomeric by itself, but it transiently forms oligomers upon 
binding to transposon end DNA. Lack of stable oligomerization might greatly impair 
formation of functional SB complexes in vitro and, consequently, crystallization. To 
overcome this, I explored different strategies to stabilize SB oligomerization for functional 
complex formation, towards crystallization and structure determination. Higher symmetry 
of oligomeric complexes might also increase per se the chances of crystallization.  
 
I therefore aimed to generate stable dimeric SB derivatives. For this, I first substituted the 
PAI of the SB transposase with the HTH1 motif of the homologous Tc3 and Mos1 
transposases, creating transposase chimeras. Differently to SB, Tc3 [PDB ID: 1U78; 
(Watkins et al., 2004)] and Mos1 [PDB ID: 3HOT; (Richardson et al., 2009)] form in fact 
fairly stable dimers by their HTH1 motifs. After successful protein overexpression in E. 
coli, the Tc3-based chimeric constructs showed very low solubility, whereas one constructs 
of the Mos1-SB transposase (comprising residues 1-56 of Mos1 and residues 53-340 of 
Chapter 2: Mechanisms of Tc1/mariner transposition 
     65 
Word	T
emplat
e	by	Fr
iedman
	&	Mor
gan	20
14 
SB) could be purified at high protein yields and eluted as a dimer in SEC experiments 
(Figure 2-28 A).  
However, I could not identify any transposon end DNA substrate that would support 
correct complex formation (tested by SEC) or activity (probed by in vitro cleavage and 
integration assays, described in sections 2.3.2 and 2.3.3) by the obtained dimeric Mos1-SB 
chimera. To note, the design of such DNA substrates (represented in Figure 2-28 A, 
bottom) is particularly challenging because they should contain mostly SB transposon ends 
sequences, apart from the predicted SB PAI-binding site, which has to be substituted with 
the HTH1-binding site of Mos1. However, no structural information is available on the 
exact contacts established by the SB transposase with transposon end DNA.  
 
 
Figure 2-28: Dimeric derivates of the SB transposase. (A) Analytical SEC (column Superdex 200 3.2/3.0) 
chromatogram showing that the Mos1-SB chimera elutes as a dimer. Below the chromatogram, a chimeric 
dsDNA substrate is shown containing the Mos1 HTH1-binding site (purple) and the SB RED and catalytic 
domain-binding sites (grey). (B) Formation of GST-hsSB transposase-DNA complexes. Analytical SEC 
(column Superdex 200 3.2/3.0)  chromatogram showing that the GST-hsSB transposase binds to Gapped Lo-
Li dsDNA substrates. Elution volumes of complex peaks (dashed red and dashed blue lines, absorbance at 
260 nm and 280 nm respectively) shift with respect to individual complex components (GST-hsSB protein, 
blue line, absorbance at 280 nn; Free DNA, red line, absorbance at 260 nm). GST-hsSB protein elutes as a 
dimer and mantains its dimeric state upon binding to DNA. (C) In vitro integration assays, showing that the 
GST-hsSB transposase (GST-hsSB), similarly to the hsSB transposase (hsSB), joins pre-cleaved Lo DNA to 
target plasmid DNA generating SEJ  (Single-End Joining) and  DEJ  (Double-End Joining) products, as 
displayed on a native agarose gel. M, marker. 
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I therefore employed another strategy to form dimeric SB derivatives, based on the use of 
the glutathione transferase (GST) tag. GST is commonly used as an affinity tag for protein 
purification, and is dimeric by itself. Moreover, as previously mentioned, I could identify a 
new SB transposase variant (SBC176S-I212S or hsSB, extensively described in section 3.2), 
which exhibits higher solubility and stability than the SB transposase. Therefore, I 
expressed and purified the hsSB transposase as a GST-tagged fusion protein and assessed 
its oligomeric state by SEC. The GST-tagged hsSB transposase (GST-hsSB) elutes as a 
stable, homogeneous dimer from the analytical SEC column (Figure 2-28 B, blue curve). 
Upon addition of the Gapped Lo-Li dsDNA substrate (see substrate sequence in Figure 
2-19) to the protein, I detected a shift in the elution volume of the mixture in SEC 
experiments, indicating formation of a dimeric nucleoprotein complex (Figure 2-28 B). 
Functional characterization of GST-hsSB showed that this derivative is active both in 
cleavage and integration assays in vitro, similarly to the untagged protein (integration 
assays shown in Figure 2-28 C). In summary, I was able to generate a functional, stable 
GST-tagged-SB dimeric variant and I used this to form dimeric nucleoprotein complexes 
in vitro that are currently being screened for crystallization.  
2.4.3 Interfering with SB transposase oligomerization affects 
transposition efficiency in living cells 
The data presented in this thesis indicate that the SB transposase is predominantly a stable 
monomer, which binds transposon end DNA and sequentially undergoes oligomerization. 
SB would therefore behave differently from mariner transposases (as Hsmar1 and Mos1), 
which form fairly stable dimer by themselves. Thus, in this part of my work, I asked which 
is the functional role of SB’s unusual oligomerization in transposition. Experiments 
described in this section were performed together with Cecilia Zuliani (Lab Manager, 
Barabas lab, EMBL Heidelberg).  
 
To answer the above question, we tested the effects of inducing stable dimerization of the 
SB transposase on transposition efficiency in HeLa cells (Figure 2-29). To manipulate SB 
oligomerization in vivo, we took advantage of the chemically-inducible dimerization 
system constituted by the FRB and FKBP12 (FKBP Rapamycin Binding domain and 
FK506 Binding Protein 12) proteins, which form stable heterodimers solely upon addition 
of the chemical dimerizer rapamycin (Figure 2-29) (Putyrski et al., 2012). We expected 
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that monomers of the SB transposase genetically fused to FRB and FKBP12, respectively, 
(FRB-SB and FKBP-SB fusion proteins) would be brought together in the presence of 
rapamycin, thus resulting in very stable SB heterodimers and leading to alterations in SB 
transposition efficiency. 
 
 
Figure 2-29: Rapamycin-based SB transposition assay in HeLa cells. Left: schematic representation of the 
assay. Donor plasmid is shown with neomycin resistance cassette (neor, magenta rectangle), flanked by SB 
transposon ends (grey rectangles). The SB transposase is depicted as a fusion protein with its bipartite DNA 
binding domain and its catalytic domain. The FRB-SB and FKBP-SB fusion proteins are expressed from 
plasmids. Right: transposition activity of FRB-SB and FKBP-SB proteins in HeLa cells, showing that stable 
rapamycin-induced oligomerization of the SB transposase negatively affects transposition rates. Mean values 
of three independent experiments are shown and error bars represent the standard error of the mean. 
Statistical analysis was performed by a one-sample t-test. Two asterisks indicate P values ≤0.01; ns - not 
statistically significant difference from 100% (P values >0.05). Rapamycin (Rap.). 
The FRB-SB and FKBP-SB proteins were co-expressed from plasmids in HeLa cells 
treated with increasing concentration of rapamycin and their activity was assessed using in 
vivo transposition assay [based on assays established by (Ivics et al., 1997)]. The assay 
monitors the transposition of a neomycin resistance gene (neor) flanked by the SB 
transposon ends from a donor plasmid. Upon transposition, the neomycin cassette 
undergoes genomic integration and provides long-lasting drug resistance to the cells. 
Following neomycin selection, transposition efficiency is calculated from the numbers of 
neomycin-resistant colonies in the presence versus absence of the transposase (Figure 2-
29). As expected, no significant alteration of transposition activity was detected in HeLa 
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cells expressing only the FRB-SB or the FKBP-SB protein in the presence of rapamycin, 
showing that rapamycin per se does not influence transposition rates. On the contrary, 
transposition efficiency was drastically reduced in the cells co-expressing the FRB-SB and 
FKBP-SB proteins together in the presence of rapamycin (Figure 2-29). This indicates that 
rapamycin-mediated induction of stable SB oligomers negatively affects SB transposition.  
 
We next performed similar assays using the FRB and FKBP12 proteins fused to the 
Hsmar1 transposase (Figure 2-30). We did not detect any significant alteration of the 
transposition activity of the FRB-Hsmar1 and FKBP-Hsmar1 proteins, expressed alone or 
together in HeLa cells, upon rapamycin treatment (Figure 2-30, right). This is consistent 
with the Hsmar1 transposase being a preformed stable functional dimer, whose activity is 
not perturbed by rapamycin-induced dimerization.  
 
Figure 2-30: Rapamycin-based Hsmar1 transposition assay in HeLa cells. Left: schematic representation of 
the assay. Donor plasmid is shown with neomycin resistance cassette (neor, magenta rectangle), flanked by 
Hsmar1 transposon ends (grey rectangles). The Hsmar1 transposase is depicted as a fusion protein with its 
bipartite DNA binding domain and its catalytic domain. The FRB-Hsmar1 and FKBP-Hsmar1 fusion 
proteins are expressed from plasmids. Right: transposition activity of FRB-Hsmar1 and FKBP-Hsmar1 
proteins in HeLa cells, showing that rapamycin treatment does not affect transposition rates. Mean values of 
three independent experiments are shown and error bars represent the standard error of the mean. Statistical 
analysis was performed by a one-sample t-test. No samples (apart from the negative control containing no 
proteins) show statistically significant difference from 100% (P values >0.05). Rapamycin (Rap.). 
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Taken together, these findings indicate that the distinctive oligomerization of the SB 
transposase plays an essential role in correct transpososome assembly and remarkably 
regulates the efficiency of SB transposition in the cellular context. The functional 
consequences of these insights are discussed in details in sections 2.5.7 and 2.5.9. 
2.5 Discussion – Tc1/mariner transposition 
 
Among DNA transposons, Tc1/mariners are unique because they ubiquitously invaded 
eukaryotic genomes during evolutionary time, they move through a distinctive and yet 
incompletely characterized mechanism, and have been resurrected for genome 
manipulation in research and medicine (Hudecek et al., 2017; Plasterk, 1996). 
Comprehensive structural and biochemical understanding of these transposons will provide 
invaluable insights into their transposition mechanisms and promote their further 
development in biotechnological and therapeutic applications. 
 
In this part of my work, I have investigated the molecular mechanism and regulation of 
two prominent transposons of the Tc1/mariner superfamily: Hsmar1 (Miskey et al., 2007), 
a representative transposon of the mariner clade (in section 2.2), and the Tc1-like element 
SB (Ivics et al., 1997), a popular genetic tool applied in research and in clinical settings (in 
sections 2.3 and 2.4). 
2.5.1 Summary of experimental findings 
With support from colleagues in the Barabas Laboratory, I have employed a 
multidisciplinary approach, including bioinformatics, structural biology, biochemistry, and 
cell biology to investigate the mechanism of Hsmar1 and SB transposition. 
 
i. Hsmar1 transposition. Structural analysis of Hsmar1 transposition revealed that the 
Hsmar1 transposase exists as a compact, autoinhibited dimer in its apo state. This dimer 
conformation differs from the PEC assembly and is not compatible with DNA binding and 
processing. Consistently, mutagenesis of the WVPHEL motif, which holds the catalytically 
incompetent state, results in an elongated conformation (as shown by SAXS and SEC 
analysis of the W118P mutant) and hyperactivity of the resulting transposases [as reported 
by (D. Liu et al., 2014)]. Based on these findings, we hypothesize that the WVPHEL motif 
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acts as a structural “zipper”, which prevents DNA catalysis in the transposase active site 
prior to transposon end synapsis in the PEC.  
 
By biochemical analysis of Hsmar1 excision, I have established that a specific order exists 
in the DNA hydrolysis reactions at the transposon ends, where NTS nicking strictly 
precedes TS cleavage. This supports the hypothesis that conformational changes are 
required in the transpososome between these two cleavage events. To gain high-resolution 
insights into these structural rearrangements, I have reconstituted in vitro and crystallized 
Hsmar1 transposase-transposon end DNA complexes in pre-excision conformations. 
Following successful X-ray data collection, structural determination is currently in 
progress. High-resolution structures of Hsmar1 pre-excision complexes, and their 
comparison with available post-excision structures (Richardson et al., 2009), will reveal 
unprecedented insights into the mechanism of Tc1/mariner transposon excision. 
 
ii. SB transposition. I have reconstituted in vitro the entire set of SB transposition events, 
from transposon end binding to integration, and this allowed to reveal unique molecular 
features of the process. For transposon recognition, the SB transposase binds with higher 
affinity to the inner binding sites than the outer sites at the ends. Then it performs two 
DNA hydrolysis reactions exclusively on the outer sites to liberate the transposon from its 
donor locus, generating 2 nt staggered transposon termini. TA dinucleotides in the 
transposon flanks are likely involved in establishing cleavage specificity. The 2 nt 
overhangs at the excised transposon ends represent specific molecular signatures, which 
are strictly required for the following step of transposon integration into a target DNA.  
 
By combining biochemical, fluorescence, and functional in vivo assays, we provided 
evidence that the SB transposase assumes different oligomeric states throughout the 
transposition pathway. SB exists prevalently as a monomer by itself and can recognize 
transposon ends as a monomer; however, it forms oligomers following transposon end 
binding. We propose that this allows synapsis and coordinated cleavage of two transposon 
ends in the active transpososome. Remarkably, we also found that the unusual assembly 
mode of the SB transposon largely contributes to its exceptional efficiency. In fact, 
interfering with this specific pathway reduces transposition rates in vivo. 
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2.5.2 Proposed model of Hsmar1 and SB transposition 
Building on the presented comparative analysis, the following mechanistic model can be 
proposed for Hsmar1 and SB transposition and autoregulation (Figure 2-31).  
 
 
 
Figure 2-31: Proposed model for SB and Hsmar1 tranposition. IR binding is performed by monomers 
(coloured blue; forming single-end complexes 1-SEC1) for SB; by dimers (coloured red; forming a single-
end complex 2-SEC2) for Hsmar1 and is followed by paired end complex (PEC) assembly (transposase 
subunits shown in purple). If two Hsmar1 transposase dimers contemporarily occupy the two transposon 
ends, productive synapsis is impaired and overproduction inhibition (OPI) arises. In the PEC, excision of the 
SB transposon generates 2 nt staggered DSBs, while Hsmar1 is excised by producing 3 nt staggered 
breakages. Structural models of the Hsmar1 inactive dimer and PEC are shown. Transposase domains are 
depicted as ovals. Large oval: catalytic domain, lighter small ovals: DNA binding domain. Transposase 
binding sites are shown as rectangles, and are named left outer (Lo), left inner (Li), right inner (Ri), right 
outer (Ro) and simple inverted repeats (IRs). Blue line: non-transferred strand (NTS); green line: transferred 
strand (TS). 
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i. Hsmar1 transposition. The Hsmar1 dimer (shown in red in Figure 2-31) initially assumes 
an autoinhibited trans conformation, mediated by interactions between the WVPHEL 
motifs in the interdomain linker (Figure 2-31, structural model of the inactive trans dimer). 
Hsmar1 transposition starts with such a dimer binding to a single transposon end (SEC2). 
At this stage, the Hsmar1 dimer maintains its catalytically incompetent state, thereby 
preventing aberrant single end cleavage. Then, recruitment of the second end will resolve 
the inhibited transposase conformation, allowing coordinated cleavage of both transposon 
ends in the PEC (modeled in Figure 2-31). However, at high transposase concentrations, 
two transposase dimers can simultaneously occupy both transposon ends. In these 
conditions, PEC assembly is prohibited and, as a consequence, transposition is inhibited 
(overproduction inhibition-OPI) (Claeys Bouuaert, Lipkow, et al., 2013). According to our 
structural data and models, only second end binding will trigger the unzipping of the 
WVPHEL motifs, which is required for catalytic activation of the transposase. This is 
consistent with the finding that the Hsmar1 dimer can occupy, but not cleave single 
transposon ends, both in transposition initiation and in OPI conditions. Following PEC 
assembly, catalysis occurs on transposon end DNA in a specific order, where NTS strictly 
precedes TS cleavage. Coordination and ordered progression of the excision reactions 
requires major conformational changes in the transpososome. After NTS nicking, TS 
cleavage likely occurs in a complex conformation immediately competent for successive 
target binding and transposon integration. 
 
ii. SB transposition. SB follows an alternative mechanism of traspososome assembly, as 
compared to Hsmar1. Monomers of the SB transposase (shown in blue in Figure 2-31) 
bind the direct repeats at the two transposon ends separately. The inner repeats are likely 
bound first, the outer sites later. Transposon end binding then triggers oligomerization of 
the SB transposase to assemble a synaptic complex that is immediately active for catalysis. 
In comparison to Hsmar1, this constitutes a different mechanism for ensuring that cleavage 
activity is tightly coupled to transposon end synapsis, which relies on DNA-mediated 
assembly rather than autoinhibition. By this specific assembly pathway, SB can escape OPI 
and optimize its efficiency even at high transposase concentrations. Transposition proceeds 
with transposon end cleavage, resulting in 2 nt staggered processed ends, which are finally 
ligated to target DNA during transposon integration. 
 
Specific aspects of this proposed model are discussed in the following sections. 
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2.5.3 Structural principles of Hsmar1 transposition: inhibition of 
single end cleavage 
One of the most unexpected findings is the autoinhibitory conformation assumed by the 
Hsmar1 transposase in its apo state. In the crystal structure of the Hsmar1 CAT, the 
WVPHEL motifs of the transposase subunits are tangled, each covering the active site of 
the other subunit in a trans arrangement mediating autoinhibition of the Hsmar1 
transposase. Consistently, specific mutations in the WVPHEL motif generate hyperactive 
variants of both Hsmar1 (D. Liu et al., 2014) and the homologous Himar (Lampe, 2010) 
transposases.  
 
According to the proposed structural model, single transposon ends are first contacted only 
by the DBD and not by the catalytic domain of the transposase (see structural model of the 
inactive trans dimer in Figure 2-31). This is consistent with the work that I performed 
during my M.Sc. thesis showing that the DBD of Hsmar1 is capable of transposon end 
binding alone. Single end binding appears not to be energetically sufficient to impair 
stability of the inhibitory interactions that link the two WVPHEL motifs. Only the 
subsequent second end recruitment will trigger the untangling of the two intertwined 
WVPHEL motifs and catalysis in a trans PEC (see structural model of the trans PEC in 
Figure 2-31). This is consistent with previous biochemical findings that second end 
binding is the rate-limiting step of synapsis and transposition (Clayes Bouuaert et al., 
2010), allocating major conformational changes to this reaction step. 
 
In fact, in the PEC conformation the WVPHEL motif is involved in an alternative set of 
interactions: each WVPHEL contacts the conserved YSPDL motif of the partner subunit 
and the transposon end DNA that is bound to the DBD of the other transposase molecule in 
trans (based on homology with Mos1; see Figure 2-5 and Figure 2-10). Our model strongly 
agrees with previous data showing that Hsmar1 transposases mutated in the WVPHEL 
motif synapse and cleave transposon ends faster, but less accurately, than the wild type 
protein (D. Liu et al., 2014). We propose that these mutations destroy interactions of the 
WVPHEL motifs, increasing the rate of PEC assembly and synapsis, while loosening 
inhibition of aberrant cleavage reactions.  
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The WVPHEL motif is conserved in mariner transposases and has been proposed to 
execute several functions in their transposition (Bouuaert et al., 2014). Our findings 
strongly indicate a structural role of the WVPHEL motif in transposition autoinhibition and 
regulation. This motif appears to play a central role in transposon regulation, establishing 
mutually exclusive interactions with itself, with transposon end DNA intermediates and 
with other specific protein regions throughout the transposition process, orchestrating the 
ordered progression and fidelity of the reactions.  
 
High-resolution structures of the full length Hsmar1 dimer on its own and/or bound to a 
single transposon end DNA would provide final experimental proof of our model for 
Hsmar1’s autoinhibition. Such structures would also reveal for the first time how a 
eukaryotic transposon initiates and regulate its movement at the structural level.  
2.5.4 Structural principles of Hsmar1 transposition: OPI 
In the previous section, the structural principles preventing aberrant single end cleavage in 
Hsmar1 transposition are proposed. These molecular constrains ensure efficient and 
precise cut-and-paste transposition and at the same time reduce potential genotoxicity of 
transposons in their hosts. Another inhibitory mechanism that is encoded in the transposon 
itself is OPI (see section 2.1.8).  
Two main models have been proposed to explain OPI: 
1. Formation, of transposase oligomers that are inactive in transposition at high 
transposase concentration (G. Carpentier et al., 2011). 
2. Assembly site occlusion (ASO) model, where OPI arises from the multimeric 
state of the transposase and is mediated by competition for the two transposon ends 
(Claeys Bouuaert, Lipkow, et al., 2013). 
 
The presented structural and functional data for Hsmar1 now provide evidence supporting 
the second model, where OPI is connected to the specific mechanism of transpososome 
assembly. The autoinhibited conformation of the Hsmar1 transposase explains how, at high 
transposase concentrations, two dimers could block both transposon ends without cleavage, 
preventing synapsis.  
Nevertheless, the two models are not mutually exclusive and could both contribute to 
establishment of the OPI phenomenon. Similarly to the previous Mos1 crystal structures 
(Richardson et al., 2006), the structure of the Hsmar1 catalytic domain revealed several 
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dimer interfaces in the crystal, which are different from the autoinhibitory interface and 
from the one observed in the Mos1 PEC. These alternative interfaces might be involved in 
higher oligomerization and/or formation of inactive assemblies, as postulated in Model 1. 
Consistently, I observed formation of Hsmar1 transposase aggregates at high protein 
concentration in SAXS experiments (data not shown). Whether alternative inactive 
oligomers exist as functional intermediates in Hsmar1 transposition remains to be 
investigated.  
2.5.5 Structural principles of Hsmar1 transposition: transposon end 
cleavage 
My biochemical data [together with (Claeys Bouuaert et al., 2014)] indicate a specific 
order of the DNA hydrolysis reactions involved in transposon end cleavage, and imply that 
discrete conformational changes in the transpososome are required to execute and order 
these events. The specific cleavage order, NTS followed by TS ensures that after 
transposon excision the TS strand remains in the transposase active site and can directly 
integrate into a target DNA [as suggested by (Robertson et al., 1997)]. Due to lack of 
informative structures, how these reactions are coordinated in the context of the 
transpososome have so far remained unknown. Structure determination of the crystallized 
pre-excision complexes described in this thesis will allow to elucidate these aspects at 
high-resolution. However, preliminary hypotheses can be drawn based on available 
biochemical data.  
 
In my M.Sc. thesis work, I showed that monomers of Hsmar1 are catalytically incompetent 
even in the first step of NTS nicking. This indicates that the Hsmar1 cannot cleave DNA in 
cis and all reactions occur only in a trans synaptic complex. Of note, our structural model 
supports the notion that the Hsmar1 transposase assumes a trans conformation both in its 
autoinhibited and in its PEC state (see structural models in Figure 2-31). Thus, it is 
unlikely that Hsmar1 would act in cis on the NTS after DNA binding, and then reassume a 
trans assembly to cleave the TS and integrate. We therefore propose that monomers of the 
transposase are always in a trans arrangement and specific structural changes in distinct 
regions (as in the WVPHEL) guide the transposition reactions forward to completion.  
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Moreover, it is worth noting that the Hsmar1 transposase can cleave the TS when the NTS 
is already cut (e.g. contains a synthetic nick). This suggests that it is the recognition of a 
cleaved NTS, rather than the actual cleavage by the transposase that is required to enable 
progression towards TS cleavage. Thus, DNA is probably the main factor that, by changing 
its structural and biochemical properties upon processing, dictates ordered remodelling of 
the transpososome throughout the transposition reaction.  
2.5.6 Biochemistry of SB transposition  
Concerning the SB transposon, my biochemical analysis showed that the SB transposase 
mediates transposon end binding, excision and integration in vitro and these events are 
characterized with unprecedented, distinctive features. 
 
Regarding transposon end binding, SB binds DRs as a monomer and exhibits higher 
affinity to the inner repeats than to the outer repeats. This might dictate a specific order in 
recognition and assembly of active complexes, as will be discussed in detail in section 
2.5.7. Moreover, left DRs seem to bind more tightly than right DRs. These differences 
probably reflect a distinct role of the left and right transposon ends in transposition and 
provide an explanation for previous in vivo transposition assays. In these studies, a 
modified symmetric SB transposon containing left end sequences at both ends (LoLi-LiLo) 
was nearly as active as the standard transposon, while a construct made up of right sites 
only (RoRi-RiRo) retained only 50% of SB’s original activity (Cui et al., 2002). Taken 
together, these findings suggest that the left binding sites are strictly required, while the 
right ones are dispensable for successful SB transposition.   
 
By reconstituting the excision and integration activity of SB in vitro, I demonstrated that 
synaptic assembly and catalysis only requires the transposase enzyme and no additional 
host-derived protein factors [in contrast to bacterial transposases as Tn7, Tn10 and the 
bacteriophage Mu transposase (Nesmelova et al., 2010)]. This is also true for all 
biochemically characterized Tc1/mariners to date (Clayes Bouuaert et al., 2010; Lampe et 
al., 1996; Vos et al., 1996) and agrees with the hypothesis that Tc1/mariners’ widespread 
distribution in the tree of life reflects their independence from host-encoded factors. 
Accessory proteins, such as DNA bending proteins (e.g. the high mobility group protein 
HMGB1) or repair factors (e.g. the Ku heterodimer), might still facilitate and/or cooperate 
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with SB transposition in the cellular context (Izsvak et al., 2004; Zayed et al., 2003), but 
are not critical for movement per se.  
 
Using cleavage assays, I showed that SB specifically cuts single outer repeats, but not 
inner repeats in vitro for transposon excision. Thus, recognition of specific DNA 
nucleotides at the outer repeats dictates specificity of cleavage, rather than the position of 
the repeats in the full transposon end architecture. Perhaps the most apparent difference 
between DRs is the presence of an invariable TA dinucleotide exclusively at the outer 
repeat flanks. Mutational analysis showed that altering the dinucleotide flanking the 
repeats completely abolished transposition in vivo (Cui et al., 2002), demonstrating the 
critical role of the flanking TA in the reaction. Thus, the absence of TA dinucleotide does 
not seem the only reason why inner repeats are “uncleavable”, at least in vivo. 
Consistently, I observed that the SB transposase cleaves outer repeats always 2 nucleotides 
3’ of the TA dinucleotide. With two consecutive TAs (TATA) in the flank, two cleavage 
positions were observed. Notably, higher transposition rates were obtained in vivo with the 
TATA motif, perhaps due to an increased flexibility of NTS cleavage (Cui et al., 2002). 
Thus, recognition of the flanking TA dinucleotide by the transposase seems to be strictly 
required for cleavage. Consistently, the Mos1 transposase makes specific contacts with the 
flanking TA dinucleotide through its WVPHEL motif in the crystal structure, positioning 
the transposon ends precisely for cleavage (Dornan et al., 2015). Since the WVPHEL motif 
is not conserved in SB, the structural principles of flank recognition remain to be explored 
for this transposon. 
 
I demonstrated that the SB transposase generates 2 nt staggered dsDNA breaks at the 
transposon ends, which are essential for subsequent transposon integration (as highlighted 
in Figure 2-31). This is particularly interesting because the excision of other Tc1-like 
transposons, as Tc1 and Tc3, also leads to the formation of 2 nt staggers on their 
transposon ends (van Luenen et al., 1994; Vos et al., 1996), whereas members of the 
mariner clade, as Hsmar1 and Mos1, excise by producing 3 nt staggered DSBs (Claeys 
Bouuaert et al., 2010; Dawson et al., 2003). These differences might reflect distinctive 
structural and mechanistic features of the two transposon subfamilies within the 
Tc1/mariner superfamily. Regarding the structural determinants of these differences, it can 
be speculated that the DDE catalytic triad in the Tc1-like transposases allows 
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accommodating only 2 nucleotides of the TS in the catalytic pocket, whereas the mariner-
specific DDD motif fits 3 nucleotides better.  
 
Concerning the final step of transposon integration, I noticed that SB integrates the 
transposon end DNA only into target DNA plasmids in vitro. In turn, Hsmar1 (this thesis 
work) and Mos1 (Morris et al., 2016) transposases can use linear DNA as targets. This 
indicates that integration by SB greatly depends on DNA topology, where more bendable 
structures are favoured [in agreement with computational analysis of unique SB insertions 
in HeLa cell genomes (Vigdal et al., 2002)]. Consistently, it has been shown that DNA 
flexibility has a strong positive effect on transposition of many transposons. Structural 
studies on several DDE/D transposases revealed that these proteins strongly bend their 
target DNA prior to integration (Montano et al., 2012; Morris et al., 2016). Such target 
bending may be required to avoid immediate re-excision of the integrated transposon: a 
bent target would snap away from the transposase active site immediately after strand 
transfer, thereby rendering the reaction irreversible (Montano et al., 2012).  
 
Finally, I observed that coordinated ligation of both transposon ends in a target DNA 
occurs preferentially over aberrant single end integration in vitro. This is quite striking 
because other integrases, such as the HIV integrase (Li et al., 2006), and transposases, like 
piggyBac (Mitra et al., 2008), Hermes (Zhou et al., 2004), and Mu (Haapa et al., 1999), 
produce both integration products at similar rates in in vitro assays. This suggests that SB 
regulates its transposition more tightly than other integrases. Such increased coordination 
of integration might result from SB’s unique transpososome assembly pathway (see next 
section, 2.5.7), as integration of a single end by SB monomers or transient dimers is likely 
very limited.  
2.5.7 The unique assembly mode of the SB transpososome 
In this thesis work, the most surprising difference found between Hsmar1 and SB concerns 
their mechanisms of transpososome assembly. While Hsmar1 (and other mariner 
transposases) achieves synapsis by sequential transposon end recruitment (Claeys 
Bouuaert, Lipkow, et al., 2013), the SB transposase brings the two ends together by protein 
oligomerization (Figure 2-31). Both mechanisms are consistent with the generally accepted 
principle that coordinated, complete processing of the two transposon ends requires at least 
two transposase subunits in the transpososome (Hickman et al., 2016). Transpososome 
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assembly by oligomerization is a very effective mechanism to directly coordinate catalysis 
with synapsis and has been reported to be used extensively by prokaryotic transposases (as 
Tn7, Tn10 and Mu). For example, the Mu transposase is also purified in a monomeric form 
but forms tetramers in vitro upon DNA recognition for transpososome assembly (Baker et 
al., 1994). Eukaryotic transposases have been generally thought to employ sequential end 
recruitment, which provides an opportunity for sensitive autoregulation. This work now 
shows that eukaryotic elements can also conform with the prokaryotic pathway, allowing 
them to escape OPI. 
 
Several structural explanations for the difference between Hsmar1 and SB can be 
proposed. The crystal structure of the SB catalytic domain (Voigt et al., 2016) has pointed 
out that SB complex assembly likely involves Tc1-like specific structural regions that are 
not present in mariner transposases. These include the distinct glycine rich strip at the base 
of the clamp loop and the conserved KKPL linker region, which differs from the mariner-
specific WVPHEL. I discussed above how the WVPHEL motif contributes to CAT 
dimerization (and autoinhibition) of the Hsmar1 transposase; thus, its absence in SB might 
contribute to its primarily monomeric state.  
 
I could also show that oligomerization of the SB transposase is likely mediated by 
hydrophilic interactions in its PAI domain (especially by residue Asp17). This differs from 
the largely hydrophobic character of the HTH1 dimerization interfaces of Hsmar1 and 
Mos1 [PDB ID: 3HOT, (Richardson et al., 2009)]. Hydrophilicity of SB’s PAI domain 
might destabilizes initial homodimers, while allowing to alter the oligomeric state upon 
DNA binding.  
 
Of note, the data presented establish that binding to outer repeats triggers oligomerization 
of the transposase in vitro; however, how this occurs in the context of the full transposon 
end remains uncharacterized. In particular, it is still unknown whether the inner repeats can 
trigger transposase oligomerization and how cooperative binding to the four repeats is 
established. In this respect, two possible mechanisms of transposition initiation can be 
proposed (based also on binding studies in section 2.3.1.1):  
1. Two SB monomers bind with high affinity to inner repeats and form oligomers, 
bringing the outer repeats into close proximity. Outer repeats could be occupied by 
SB monomers before or after these events. Oligomerization at the inner repeats 
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facilitates oligomerization at the outer repeats, triggering assembly of the excision-
competent complex. 
2. Two SB monomers bind the inner repeats first and sequentially recruit additional 
monomers at the outer sites by specific protein-protein interactions. Binding of the 
second pair of monomers at the outer repeats then destroys the previous protein 
interactions and favours transposase oligomerization in the PEC. 
 
 
 
 
 
 
 
 
 
Figure 2-32: Proposed model for the role of the inner repeats in SB transposon end recognition and assembly. 
Model 1: SB transposase monomers bound to inner repeats oligomerize first, triggering oligomerization of 
protomers also at the outer sites. Model 2: SB transposase monomers bound to inner repeats recruite 
protomers to the outer sites by protein-protein interactions. Colours and shapes as in Figure 2-31.  
 
In this work I specifically identified the PAI domain to be involved in transposase 
oligomerization. This is consistent with previous biochemical data based on isolated SB 
DNA binding domains (Izsvak et al., 2002). Thus, similarly to Mos1 and Hsmar1, SB 
protomers interact through their N-terminal domain upon binding to outer repeats in the 
PEC. However, several alternative dimer interfaces might be involved in SB transposition. 
A discrete, inactive dimer interface was identified in the structure of the SB catalytic 
domain and has been proposed to link two monomers during the putative recruitment step 
described in Model 2 (Voigt et al., 2016). Structural studies of complete transposon ends in 
complex with the SB protein (for example by Cryo-electron microscopy or crosslinking 
mass spectrometry techniques) are required to characterize the exact stoichiometry of the 
transpososome and elucidate these aspects at the molecular level. 
 
Furthermore, it is still unclear whether any DNA cleavage and/or ligation reactions can 
occur in SB monomers. In the light of what I have discussed for the Hsmar1 transposase 
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(see section 2.5.5), it is expected that even the first strand cleavage occurs in assembled 
transpososome. In addition, insertion of single transposon ends barely occurs in the 
established SB integration assays even in vitro, despite the abundance of monomeric 
species in this setting, indicating that oligomers are strictly required for correct transposon 
integration. 
2.5.8 Conservation across Tc1/mariners 
This work reveals a remarkable mechanistic diversity between the Hsmar1 and SB 
transposons. This raises the question if characteristic mechanistic principles hold true for 
other Tc1/mariners. 
 
Mariner transposases (like Mos1, Mboumar-9, Himar1 and Hsmar1) share circa 40% 
sequence similarity, suggesting they might follow similar transposition pathway as 
Hsmar1. Consistently, the Mos1 and Mbourmar-9 transposases have been described as 
stable dimers that first cleave the NTS and then the TS generating 3 nt staggered 
transposon ends (Trubitsyna et al., 2014), analogously to Hsmar1. Conservation of the 
mariner-specific WVPHEL motif also points to the idea that this structural region has a 
role in dimer formation and autoinhibition of other mariner transposases. Nevertheless, the 
Mos1 transposase has been described to form an elongated dimer prior to DNA binding 
that is held together only by its DBD. Thus, second end recruitment and synaptic complex 
formation would require rotation of one transposase subunit around its DBD (Cuypers et 
al., 2013). In contrast, our structural data indicate that minor conformation rearrangements, 
mostly in the WVPHEL motif, trigger the activation of the Hsmar1 transposase. For these 
reasons, the inter-WVPHEL interactions in the Hsmar1 transposase might represent a 
specific and unique layer of autoregulation among the Tc1/mariners.  This means that, 
despite its conservation, the WVPHEL motif might play different roles in distinct mariner 
elements, resulting in different levels of control and autoregulation. Of note, the Hsmar1 
transposase is considered to be the most specific and tightly controlled Tc1/mariner 
transposase studied so far (Tellier et al., 2015), perhaps related to the extensive inter-
WVPHEL interactions observed in this thesis.  
 
About Tc1-like transposons, no experimental evidences are available to support a shared 
mechanism of synapsis by protein oligomerization among the clade. SB and Tc3 have been 
proposed to form tetramers, based mainly on their transposon ends architecture (Brillet et 
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al., 2007) and available data on isolated DNA binding domains (Izsvak et al., 2002; 
Watkins et al., 2004). The PAI domain is also only weakly conserved in Tc1-like 
transposases, such as SB, Tc1, Tc3 and Frog Prince. Therefore, the interesting idea of a 
correlation between hydrophilicity of the dimer interface and DNA-promoted 
oligomerization would need further investigation. It is worth noting that SB is an 
artificially resurrected transposase; therefore, its specific sequence and structural features 
might be due to the molecular reconstruction process and may thus differ from the original 
native protein and from other Tc1-like transposases.  
 
On the other hand, SB contains the canonical Tc1-like specific catalytic triad (DDE) and 
shares the same cleavage specificity (2 nt staggered DSB) at transposon ends with other 
biochemically characterized Tc1-like transposases, like Tc1 (Vos et al., 1996) and Tc3 
(van Luenen et al., 1994). Whether this cleavage specificity extends to all Tc1-like 
transposases, it is still unknown. In addition, the monomeric state of SB and the conserved 
absence of the WVPHEL motif in Tc1-like transposases suggest a different structural basis 
for excision regulation compared to the mariners, which may be shared in Tc1-like 
transposases. 
 
In conclusion, due to low sequence conservation and sparseness of experimental data, it is 
difficult to evaluate conservation across Tc1-like elements. Thus, many open questions 
remain about the working mechanism of these transposons. To shed light on these aspects, 
comparative biochemical and structural characterization of SB and other Tc1-like 
transposases and transpososomes is needed. This thesis provides methods, assays and 
strategies (including for crystallization) that could be specifically employed for this 
purpose. 
2.5.9 Regulation of SB transposition 
One of the most puzzling questions about SB transposition regards the mechanistic 
principles behind its extraordinary efficiency. In this work, first experimental evidences is 
provided that the specific pathway of transpososome assembly directly dictates the high 
transposition rate.  
 
Previous reports indicated that SB is susceptible to very limited, if any, OPI (Kolacsek et 
al., 2014). In this work, we show that forcing SB dimerization, and thus interfering with its 
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synapsis by oligomerization, strongly reduces transposition efficiency in living cells. This 
data indicate that SB employs a specific assembly mechanism, which allows it to escape 
OPI, largely contributing to its extraordinary high transposition efficiency. In agreement 
with these findings, computer simulations also predicted that transposons using the 
synapsis by oligomerization mechanism would sustain long-lasting high transposition 
levels in eukaryotes (Claeys Bouuaert, Lipkow, et al., 2013) and can only be inactivated by 
mutations.  
 
SB’s unique assembly pathway also provides a distinctive advantage for its technological 
use, since the transposase is generally overexpressed in these applications. Thus, in this 
work, we shed first light on the molecular principles behind SB’s extraordinary success as 
a genetic tool. Furthermore, the presented mechanistic findings provide a unique 
opportunity to control SB transposition in living cells. For example, we were able to 
artificially reduce insertion rates by chemically modulating transposase oligomerization in 
HeLa cells. By creating dimerization defective SB mutants that retain DNA binding 
properties and are fused to heterologous inducible dimerization domains, one could trigger 
transposase activation at specific desired time points. Such dimerization-dependent 
strategies could provide the basis for regulating time, efficiency and conditions of SB 
transposition on demand in its genetic engineering applications.aaaaaaaaaaaaaaaaaaaaaaaaa                  
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3 DEVELOPMENT OF NOVEL  
SB-BASED GENETIC TOOLS 
The part of my PhD work presented in this chapter focuses on the development of novel 
genetic tools based on the SB transposon system. The first section (section 3.1) introduces 
the use of SB as a prominent genetic tool both in research and in clinical trials and 
highlights advantages and current limitations of its applications. Based on this 
introduction, the motivation and aims of my research are stated. Section 3.2 presents the 
design and functional characterization of a novel SB transposase variant, named hsSB. 
This provided the basis for the development of a new genome engineering method based 
on direct cellular delivery of the hsSB protein, named SBprotAct (described in section 3.3). 
In the last section (section 3.4), the advances and impacts offered by SBprotAct are 
discussed in comparison to the state-of-start technologies and future directions in the 
further development of the method are proposed.  
 
Note: A number of the figures in this chapter are based on and modified from the following 
manuscript and patent application.  
 
- Querques, Mades, Zuliani et al., (2018); “Genome engineering by direct delivery of 
engineered Sleeping Beauty transposase protein.”, submitted 
- Barabas, Querques and Zuliani (filed August 2017); “Improved Transposase Polypeptide 
and Uses Thereof”, European Patent Application 17187128.8 
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3.1 Introduction – SB transposon system as a genetic tool 
 
Transposons can be viewed as natural DNA transfer vehicles that are capable of efficient 
genomic insertion. In this respect, SB is the element that has advanced the fastest and 
furthest in research and the clinics, with applications spanning from cancer gene discovery 
to even gene therapy in humans. This introduction describes the “story” of the SB 
transposon as a genetic tool, including successes and pitfalls, highlighting the importance 
of further development of the technology, especially for clinical use. 
3.1.1 Overview of SB’s applications 
The potential of the SB transposon for genome manipulation in vertebrates has been 
recognized concomitantly to its resurrection from fish (Ivics et al., 1997). The possibility 
to externally control transposition by separating the two obligatory components: the IR 
sequences and the SB transposase is critically important. This allows virtually any DNA of 
interest (a fluorescent marker, a mutagenic gene trap, or a therapeutic gene) placed 
between the IR sequences in the transposon to be stably inserted in a target genome by the 
transposase conditionally provided in trans (Figure 3-1).  
 
Figure 3-1: Schematic representation of genetic engineering with the SB transposon system. The transposon-
carrying and the transposase-encoding plasmids are co-delivered into target cells, where overexpression of 
the SB transposase leads to transgene insertion into the target cell genome by transposition. LE and RE 
indicate transposon end sequences. LE: left end; RE: right end; black arrow: promoter. 
This engineered two-component entity, referred to as the SB transposon system, can be 
placed on various DNA carriers, such as plasmids or minicircles (Monjezi et al., 2017) 
(non-viral vectors) or can be combined with various viruses (hybrid transposon/virus 
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vectors) (Grabundzija et al., 2013). The typical set-up for delivery into cells is by 
supplying both components as conventional plasmids (Ammar et al., 2012; Ivics et al., 
2009). However, the transposase can be also provided in the form of a messenger RNA 
(mRNA) synthetized in vitro (Monjezi et al., 2017; Wiehe et al., 2007; Wilber et al., 2006; 
Wilber et al., 2007). 
 
Since its discovery, SB has proven to support highly efficient transgene integration in 
various cell types, including somatic and germ cells, differentiated and stem cells. It is very 
efficient in cells of all vertebrate species (Izsvak et al., 2000) as well as in preclinical 
animal models (Hackett et al., 2010) and livestock. Consequently, it has been extensively 
applied for creating transgenic cell lines and gene knockdowns, also in combination with 
other genetic engineering tools (Grabundzija et al., 2013; Petrakis et al., 2012) and various 
delivery techniques (viral or non-viral). Of particular biotechnological interest is its use for 
generating commercial cell lines, such as Chinese hamster ovary (CHO) cells, for large-
scale production of recombinant proteins (Balasubramanian et al., 2016).  
 
One of SB’s most prominent applications is its use as insertional mutagen in cancer 
research. It was used to generate cancer-causing mutations, where analysis of its insertions 
allowed identification of cancer genes (Collier et al., 2005; Dupuy et al., 2005) and 
important cell signalling pathways involved in different cancer types (Bermejo-Rodriguez 
et al., 2015; Moriarity et al., 2015; Takeda et al., 2016; Wu et al., 2016). In addition to 
functional oncogenomics, incorporating a regulatory sensor within the transposon allowed 
mapping the regulatory architecture of chromosomes in mice (Ruf et al., 2011). 
 
Additionally, SB has been successfully used to introduce reprogramming factor-encoding 
cassettes for generating induced pluripotent stem cells (iPSCs) in various organisms and 
models (Davis et al., 2013) (Talluri et al., 2015). Once reprogrammed, engineered iPSCs 
can be expanded and differentiated into multiple cell types for use in research and gene 
therapy applications. Moreover, SB has been also extensively probed and utilized to 
generate transgenic animals [including fish, frog, rat, mouse, rabbit, pig, cow and others, 
reviewed in (Narayanavari et al., 2017)].  
 
Importantly, several preclinical gene therapy trials have been carried out using the SB 
transposon system, aimed at treating hematologic disorders, lysosomal storage diseases, 
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pulmonary, dermatological, metabolic and neurologic disorders, and cancer (Aronovich et 
al., 2007; Escobar et al., 2016; Eyjolfsdottir et al., 2016; X. Huang et al., 2008; Latella et 
al., 2016; Singh et al., 2008; Turunen et al., 2016; Yant et al., 2000). These studies have 
paved the way for SB’s breaking on through to the clinical side, which is discussed in the 
following paragraph. 
3.1.2 Clinical applications of the SB transposon system 
Among SB-based applications, the ones that trigger perhaps most excitement at the 
moment relate to in human gene therapy.  
In the last years, important steps have been made toward the application of SB for 
treatment of neovascular age-related macular degeneration (AMD). AMD refers to the 
degeneration of retinal pigment epithelial (RPE) cells in the macula area of the eye and is a 
major cause of acquired irreversible blindness in adults worldwide. One form of this 
disorder, the neovascular AMD (nvAMD), can be successfully treated by replacing 
degenerated RPE cells with genetically modified ones that overexpress the pigment 
epithelium-derived factor (PEDF). In recent preclinical trials, the hyperactive SB100X was 
used to efficiently deliver a human PEDF transgene cassette to cultured RPE cells. These 
modified cells were subsequently transplanted, and significantly suppressed the 
characteristic neovascularization associated with nvAMD both in rabbit (Kuerten et al., 
2015) and rat (Johnen et al., 2015) models. Following these pioneering studies and recent 
developments of optimized protocols (Thumann et al., 2017), clinical trials have been 
approved (in Switzerland) and will soon be initiated. In these trials, pigment epithelial cells 
isolated from iris biopsies of nvAMD patients will be transfected with a PEDF-carrying SB 
vector and transplanted back by a simple surgical session (Hudecek et al., 2017). 
 
Even more advanced is the use of SB-mediated gene transfer for engineering human T 
cells for anticancer immunotherapy. Adoptive immunotherapy is based on genetic 
modification of human T cells (derived from patients in autologous therapies or healthy 
donors in allogenic ones) ex vivo by incorporating the genetic information for a chimeric 
antigen receptor (CAR) against malignancy-specific antigens. CARs are artificial receptors 
that are used to provide T cells with new specificities and trigger effector functions after 
antigen encounter (Fesnak et al., 2016; Sadelain et al., 2017). The engineered CAR T cells 
are then re-infused in the cancer patient to seek and kill cancer cells. In particular, CAR T 
cell therapy targeting CD19, a biomarker overexpressed on the surface of malignant B 
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cells, has shown unprecedented high response rates (70%-90%) in the treatment of acute 
lymphoblastic leukemia (ALL) (Turtle et al., 2016) and B cell lymphomas (Locke et al., 
2017). Although CD19 is expressed also in healthy B cells, the global destruction of the B 
cells can be compensated with a globulin treatment. 
 
Figure 3-2: General procedure for autologous chimeric antigen receptor (CAR) gene therapies targeting 
malignant antigens using the SB system. The specific CAR gene that confers reactivity against the cancer-
specific antigen is cloned into the transposon. T cell subsets isolated from the peripheral blood of the patient 
are modified by the dual SB transposon/transposase system upon nucleofection of the two vectors, expanded 
in vitro, and re-infused into the patient. The figure has been adapted from (Klebanoff et al., 2016). 
SB has been applied as a non-viral gene delivery vector in several CAR T clinical trials at 
the MD Anderson Cancer Center (MDACC) (Clinical Trials.gov NCT00968760, 
NCT01497184, NCT02529813 -still ongoing-; and NCT01362452, NCT01653717 -
concluded), using SB to introduce a CAR against the CD19 antigen into (both autologous 
and allogenic) T cells. First published results [related to Clinical Trials.gov NCT00968760 
and NCT01497184; (Kebriaei et al., 2016)] for patients with relapsed B cell ALL or 
lymphoma showed a promising outcome, establishing proof-of-concept for the feasibility 
and safety of SB-mediated CAR T engineering, and initiating a follow-up trial (Clinical 
Trials.gov NCT02529813) with further optimized protocols. 
 
Isolation of patient T cells
Peripheral 
blood Mutation-specific CAR
Transposase-encoding
vector
Transposon-carrying 
plasmid
Re-infusion of gene engineered
mutation-specific T cells to patients
SB gene CAR gene
Nucleofection
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On the 30th August 2017, the first CAR T therapy treatment (named Tisagenlecleucel, 
using viral vectors for CAR delivery) has obtained FDA (Food and drug administration) 
approval for the treatment of young patients with B cell ALL. This approval represents a 
milestone in the history of anticancer therapy, but it has important implications for health-
care systems owing to its considerable logistical, toxicological, and financial challenges 
("CAR T cells - what have we learnt?," 2017). In the approved approach, T cell 
modification is achieved via the use of viral vectors that are produced via an extremely 
cumbersome and expensive manufacturing process. Due to the elaborate treatment 
procedures, very few specialized cancer centers in the world can offer the therapy. This 
results in the enormously high cost of Tisagenlecleucel (US$ 475,000 for a single infusion) 
and clearly impairs access to the technology for a large number of patients. In addition, 
adverse effects associated with CAR T cell therapy, for example the cytokine-release 
syndrome, are largely uncharacterized and poorly predictable to date. Even more 
concerning is the fact that ∼50% of patients who responded to Tisagenlecleucel in the first 
pediatric global trial (ELIANA Clinical Trials.gov NCT02435849) relapsed within 1 year. 
 
Therefore, to enable CAR T therapies to enter routine clinical practice, there is a pressing 
need to improve manufacturing feasibility, efficacy, and safety, which are critical 
requirements of gene therapy in general. The use of SB for gene delivery helps to 
overcome several limitations in these aspects, as described in the following section. 
3.1.3 Advantages of the SB system for clinical use 
SB transposon-based gene delivery provides distinctive advantages for clinical use in 
comparison to viral vectors and to other non-viral delivery vehicles (e.g. naked DNA 
molecules).  
 
SB is a simple synthetic DNA-based binary system, which is cheaper, easier, and faster to 
produce and implement than viral vectors. This provides a particular advantage especially 
for single-use and personalized applications. In addition, it offers high scalability of 
production as well as easy quality control for clinical applications. The use of the non-viral 
SB vector also reduces the risks of undesired immune response activation in patients (Yant 
et al., 2000), which constitutes a major safety concern related to the use of viral proteins 
and nucleotides in viral delivery approaches.   
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Due to the transposition mechanism, SB belongs to the class of integrating vectors, which 
directly insert the transgene in the target cell’s genome. Among non-viral delivery 
vehicles, SB is the only one that offers sufficient insertion efficiency to allow stable 
transgene incorporation suitable for medical use. Even some viral vehicles such as 
adenoviral and adeno-associated viral vectors remain episomal, requiring several doses for 
sustained transgene acquisition, which in turn can lead to uncontrolled immune responses 
(Basner-Tschakarjan et al., 2014).  
 
Moreover, standard gamma-retroviral and lentiviral vectors preferentially insert into 
actively transcribed or regulatory regions creating a risk for insertional mutagenesis and 
genotoxicity (Cesana et al., 2012; Hargrove et al., 2008). In contrast, SB presents a close-
to-random integration pattern, greatly reducing the risk of genomic aberrations. It has been 
also reported that retroviral stock can accumulate mutations at significant frequencies as a 
consequence of reverse transcription (Menendez-Arias, 2009). As transposition involves 
exclusively DNA intermediates, the risk of mutagenesis of the SB vector is very limited. 
Furthermore, since SB’s cargo capacity is large (Zayed et al., 2004) and not subjected to 
physical constrains (e.g. by DNA packaging in capsids as for viruses), it provides a distinct 
advantage over viral vectors for delivery of large transgenes or multigene cassettes (e.g. 
CARs). 
 
Compared with integrating viral vectors, the SB system has generally lower gene-transfer 
efficiency. However, in the last years, novel strategies, as improved design and delivery 
methods for its components as well as selective propagation of CAR positive cells, have 
increased the success of SB-mediated T cell engineering (Hudecek et al., 2017). For 
example, the use of minicircle vectors as carriers of the SB transposon system components 
has resulted in an improved efficiency (up to fivefold) in genome modification, as well as 
an increase (up to threefold) of T cell survival rates due to decreased cytotoxicity upon 
nucleofection (Monjezi et al., 2017). 
 
Finally, differently to other genome editing nucleases as zinc-finger nucleases, TALENs 
(Transcription activator-like effector nucleases) and Cas9, the SB transposase directly and 
precisely integrates its cargo into chromatin. Designer nucleases generate DSBs at the 
target locus and co-opt the cellular repair machinery to integrate exogenous genetic cargos. 
This mechanism limits integration efficiency, induces excessive DNA damage responses 
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(Ihry et al., 2017) and can also cause undesired genome modifications, limiting the utility 
of nuclease-based systems in the clinical setting to date. In contrast, SB’s insertion rates do 
not depend on the efficiency of the repair machinery in the target cells and its transposition 
does not generate genomic DSBs, making it a more efficient and safer alternative. These 
advantages make SB the only non-viral vehicle currently used for CAR T cell engineering 
and soon also in other clinical trials.  
3.1.4 Limitations and desired improvements 
Despite the advantageous features of the SB system, important limitations remain and 
specific technological improvements are highly desirable, especially for advancement in 
the clinic: 
1. Improved efficiency. Several current and past efforts have been directed towards 
the further enhancement of SB’s insertion efficiency, and lead to substantial 
successes. However, transgenesis rate is still limiting in several medically relevant 
primary cell types and has remained below the ones reported in clinical trials using 
viral vectors. 
2. Targeted integration. As discussed above, SB integrates its gene cargo randomly 
across the genome. If SB-based insertions could be directed to specific genomic 
sites (such as ‘safe harbour sites’), that would further increase its safety profile in 
the clinical setting. A targeted (and ideally programmable) integrase that combines 
the advantages of genome editing nucleases (programmable site-specific 
modification of the genome) with those of the current SB system (high integration 
rate and safety) would be of at most interest for research and medicine.  
3. Tight copy number control. Especially in therapeutic applications, it is extremely 
desirable to limit and tightly control the number of transgene copies inserted into 
the genome of the target cell. This is not possible with the current SB system (or 
with viral vectors), due to long-term exposure to the gene delivery system. 
4. Direct delivery of the SB transposase protein. Current SB-based applications 
exclusively depend on administration of the system components in the form of 
nucleic acids. Direct delivery of the transposase would greatly improve control over 
the genome engineering procedure and increase the safety profile of the SB system. 
However, recombinant production of the SB transposase for cellular delivery could 
not been established before. 
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Regarding the last point, the form in which the transposase is supplied has a major impact 
on the outcome and safety of the SB-based engineering procedure. Long-term transposase 
expression from a plasmid vector in the target cells can result in uncontrolled ongoing 
transposition, potentially leading to transgene remobilization, undesired insertion events, 
genome instability, and cytotoxicity (Cai et al., 2014; Galla et al., 2011; Hackett et al., 
2013; X. Huang et al., 2010; Q. Liang et al., 2009). Moreover, insertion of the SB 
transposase gene from the expression vector (e.g. by homologous recombination) would 
result in infinite transposase production and activity. Acquisition of the transposase 
promoter might also cause activation of oncogenes or disrupt gene regulatory networks in 
the target cells.  
 
To circumvent the concerns associated with the use of transposase-coding plasmids, the 
use of mRNA as transposase source has been explored (Galla et al., 2011; X. Huang et al., 
2006; Jin et al., 2011; Wilber et al., 2006; Wilber et al., 2007). However, these mRNA-
based delivery approaches resulted in heterogeneous and drastically reduced transposition 
efficiency (Galla et al., 2011; Jin et al., 2011), probably due to the intrinsic instability of 
mRNA and difficult delivery to cells. The requirement of cumbersome in vitro synthesis 
procedures and the lack of quality control methods for mRNA further limit its use in a 
commercial or clinical setting. Moreover, with mRNA-based delivery, SB transposition is 
strictly dependent on cellular translation efficiency that varies in different cell types and 
conditions. Thus, the use of mRNA does not permit direct control of the engineering 
procedure. 
 
An alternative to the use of nucleic acid as source of transposase is to directly provide the 
cells with the SB protein. Delivery of the SB transposase is highly desirable to achieve 
tighter efficiency/temporal control of transposition-based cell engineering and improve 
safety, in particular for gene therapy applications. However, the intrinsic instability of the 
SB protein in vitro has limited its large-scale recombinant production, and thus prohibited 
cellular delivery to date. The specific objective of this part of my thesis was to overcome 
the difficulties related to SB transposase production, and to develop a novel SB system 
based on the application of the recombinant protein. 
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3.2 Results –The high solubility SB (hsSB) variant 
 
In this part of my work (sections 3.2 and 3.3), I set out to develop a SB-based genetic 
engineering strategy based on direct delivery of the transposase protein to target cells. To 
this end, I first aimed to produce the SB transposase in suitable quality and quantity to 
enable efficient protein delivery (section 3.2).  
3.2.1 Identification of the hsSB variant by structure-based design 
The successful application of currently available protein delivery strategies [e.g. based on 
cell-penetrating peptides, lipidic and polycationic carriers, or electroporation (Fu et al., 
2014)] depends greatly on specific features of the protein sample. The protein has to be 
provided in high amounts and must be stable in the low volumes and specific buffers used 
for the delivery procedure. In addition, high stability of the protein at physiological 
temperature is strictly required, so that the delivered molecule is fully folded and 
functional in the target cells. 
 
In this respect, the SB100X transposase (referred to simply as “SB” in this thesis) is not a 
promising candidate for protein delivery. It provides only modest yields after purification 
and it is unstable in low salt containing buffers (that are required for example for 
electroporation), impairing protein delivery attempts. To overcome these challenges, I 
sought to generate a novel SB variant with improved protein solubility and stability. To 
this aim, I employed a rational design approach based on the crystal structure of the SB 
catalytic domain and on a homology model of its TCC (Voigt et al., 2016).  
 
I identified and introduced specific amino acid substitutions into SB to increase the 
hydrophilic character of the protein surface (Figure 3-3). First, I substituted isoleucine 212 
in the target DNA binding surface with a serine. This mutation was previously associated 
with hyperactive phenotype (Voigt et al., 2016) (Figure 3-3 A) and also increased protein 
solubility in vitro. Then, I proceeded with mutagenesis of all cysteines (C176, C197, C304 
and C316) into serines one by one. This approach can help reduce protein aggregation as 
shown for other systems (Avramopoulou et al., 2004; Cozzolino et al., 2008; Slusarczyk et 
al., 2000; Xie et al., 2009). 
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Figure 3-3: Rational mutagenesis of the SB transposase. (A) Hyperactive I212 mutants. Left: model of the 
SB TCC [target capture complex (Voigt et al., 2016)], where two SB molecules (blue) contact the transposon 
end sequences (IR- inverted repeats, grey) and target DNA (tDNA, red). Insert shows that residue I212 is 
located on the target-binding interface. Right. I212 mutants are hyperactive in in vivo transposition assays 
(Voigt et al., 2016). (B) Solubilizing mutations in SB. Schematic representation of SB’s domain composition 
(top) and crystal structure of the catalytic domain (Voigt et al., 2016) (bottom left) with the analyzed amino 
acid substitutions marked. Bottom right: amino acid sequence of the full length hsSB transposase variant. 
Bold underlined characters in red and green indicate serines substituting C176 and I212, respectively. 
Residues colored in blue have been introduced at the N-terminus for cloning. 
I found that the C197S, C304S and C316S mutations largely compromised protein 
solubility, consistent with their role in assembling the core fold of the catalytic domain 
(Figure 3-3 B). In turn, mutation of C176 that is located in the surface-exposed flexible 
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clamp loop, in combination with the I212S substitution, generated a remarkably highly 
soluble SB variant (hsSB), as described in detail in the following paragraphs.  
3.2.2 Functional characterization of the hsSB variant 
I overexpressed the hsSB variant in E. coli fused to N-terminal purification and solubility 
tags and purified it by Ni-affinity chromatography, followed by tag removal and SEC 
(Figure 3-4 A and B). SDS-PAGE analysis of purified recombinant hsSB showed that the 
protein variant is highly pure (Figure 3-4 A). SEC analysis also revealed a single 
symmetric peak, showing that the recombinant hsSB is highly homogenous chemically and 
conformationally. hsSB was produced at significantly higher yields compared to the SB 
transposase (Figure 3-4 B), yielding up to 5 mg of 99.9% pure transposase protein from 
1liter E. coli culture.  
 
Following purification, I concentrated the purified hsSB protein using ultrafiltration 
devices. Remarkably, the hsSB protein could be concentrated up to 20 mg/ml final 
concentration, whereas SB precipitates at concentrations higher than 7 mg/ml (Figure 3-4 
C). Moreover, hsSB is highly soluble in low salt containing buffers, including the R buffer 
used for electroporation with the Neon® transfection system (Figure 3-4 C). While SB 
heavily precipitates in these conditions, the vast majority of hsSB remains soluble upon 
concentration in R buffer. 
 
I then tested the stability of hsSB at physiological temperature in which protein delivery is 
performed. SDS-PAGE analysis of purified SB proteins upon incubation at 37 °C revealed 
that hsSB is less prone to degradation than SB (Figure 3-4 D, left). SB exhibits degradation 
even upon short incubation at physiological temperature, whereas hsSB does not show 
significant degradation even after 18 hours. The improved solubility of hsSB does not 
seem related to decreased protein oxidation, as hsSB and SB were similarly affected by 
oxidation when incubated at 37 °C (Figure 3-4 D, right).  
Chapter 3: Development of novel  SB-based genetic tools 
     97 
Word	T
emplat
e	by	Fr
iedman
	&	Mor
gan	20
14 
 
Figure 3-4: Purification and characterization of the hsSB protein variant. (A) SDS-PAGE analysis of hsSB 
purification. hsSB is highly pure after tag removal and size exclusion chromatography (SEC). (B) Size 
exclusion chromatogram (column Superdex 200, 16/600) showing that recombinant hsSB (red curve) is 
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homogenous and yields at significantly higher level compared to SB (black curve). (C) SDS-PAGE analysis 
of purified SB proteins after concentration. hsSB can be concentrated up to 50 fold (corresponding to 20 
mg/ml), whereas SB undergoes precipitation at concentrations higher than 7 mg/ml. hsSB is highly soluble in 
the low salt R buffer, even at high protein concentration. (D) SDS-PAGE analysis of purified SB protein 
samples upon incubation at 37 °C with (left, 300 mM DTT) or without DTT (right, NO DTT). SB exhibits 
degradation (major degradation products marked with asterisks) even upon short incubation at physiological 
temperature, while hsSB does not. Oxidation patterns are similar for both proteins regardless of DTT 
concentration. (E) Stability of SB variants upon freezing. Left: SDS-PAGE analysis of purified SB proteins 
following long-term storage at -80 °C. SB undergoes significant degradation, while hsSB does not. Right: 
mass spectrometry analysis of the product bands (black boxes and asterisks on the left) confirms degradation.  
Remarkably, I was able to show that hsSB is more stable than SB also during storage at 
low temperatures. SDS-PAGE analysis of SB proteins subjected to long-term storage 
(several months) at -80 °C revealed that hsSB is well preserved after freezing and thawing, 
whereas SB undergoes significant degradation (Figure 3-4 E, left) as confirmed by mass 
spectrometry analysis (Figure 3-4 E, right). Taken together, my data shows that hsSB is 
more resistant to degradation at different temperatures compared to SB, indicating 
increased conformational integrity and stability. 
 
To further investigate hsSB’s reduced susceptibility to degradation, I performed limited 
proteolysis of the SB proteins. Limited proteolysis is a simple biochemical method that can 
be used to analyse protein structure and conformational flexibility. Upon incubation of the 
target protein with a limited amount of protease, this cleaves at exposed flexible regions. 
Detected cleavage products allow to map stable subdomains and flexible linker regions. 
Among the different enzymes used for limited proteolysis, trypsin is widely applied, and 
breaks the peptide bond at C-terminus of basic amino acids such as arginine and lysine 
(Fontana et al., 2004). With this assay, I observed similar trypsin-mediated degradation 
patterns for hsSB and SB, indicating that the overall protein fold is conserved between the 
two variants (Figure 3-5 A).  
 
To confirm this hypothesis, I investigated the folding and secondary structure of the SB 
proteins by circular dichroism (CD) spectroscopy. The method is based on the difference in 
the absorption of left-handed and right-handed circularly polarised light by chiral 
chromophores, such as the amides of the polypeptide backbone in proteins. Secondary 
structure also imparts a distinct CD feature to proteins, so that all proteins have CD 
spectral signatures that are representative of their individual structures (Greenfield, 2006).  
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CD measurements of SB and hsSB proteins in close to physiological (1x PBS, 200 mM 
NaCl, pH 7.5) buffer conditions confirmed that the folding of hsSB is indistinguishable 
from the folding of SB (Figure 3-5 B, left). Thus, mutation of residues 176 and 212 does 
not affect the overall folding of the protein and hsSB’s improved solubility and stability are 
not due to major changes in the protein structure. However, collecting the CD signal of the 
two proteins as a function of temperature, revealed that hsSB is partially folded even at 95 
°C and thus is significantly more thermostable than SB (Figure 3-5 B, right). Considering 
that electroporation heats the sample, hsSB provides a distinct advantage over SB for direct 
protein delivery by this method. 
 
 
Figure 3-5: Folding and thermostability of SB proteins. (A) SDS-PAGE analysis of SB proteins upon 
treatment with trypsin for indicated times at room temperature (RT). ON: overnight. (B) Circular dichroism 
measurements of SB proteins in close to physiological (1x PBS, 200 mM NaCl, pH 7.5) buffer condition. CD 
spectra show that hsSB has the same fold as SB (left panel). However, hsSB is significantly more 
thermostable, as it still does not completely unfold at 95 °C (CD values at 206 nm plotted against 
temperature, right panel).  
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After establishing the improved solubility and stability of the hsSB variant, I tested its 
transposition activity in vitro. Using the cleavage and integration assays described in 
chapters 2.3.2 and 2.3.3, respectively, I confirmed that the hsSB transposase cleaves 
(Figure 3-6 A) and integrates transposon end DNA (Figure 3-6 B) in vitro with similar 
efficiencies as SB. hsSB was also able to mediate transposition in living HeLa cells [when 
provided from an expression plasmid, assays performed by Cecilia Zuliani, Lab Manager, 
Barabas Laboratory, EMBL Heidelberg] with identical efficiency and specificity as SB 
(Figure 3-6 C). This shows that the amino acid substitutions introduced in the hsSB variant 
did not affect transposition activity.  
 
 
Figure 3-6: Characterization of hsSB’s transposition activity. (A) In vitro cleavage assays showing that hsSB 
cleaves Lo sequences specifically. 12% Urea PAGE resolving 32P-labelled Lo DNA substrates (see assays in 
Figure 2-22) and products after incubation with SB or hsSB (in a 50:1 protein to DNA molar ratio) or no 
protein (-). Blue arrow indicates the specific cleavage product (17 nt on NTS). Marker (M) is 17 nt long. (B) 
In vitro integration assay showing that hsSB can integrate 2 nt staggered pre-cleaved Lo DNA into a target 
plasmid (see assays in Figure 2-25). Products are detected on a native agarose gel. Bands indicated by arrows 
correspond to concerted integration products (DEJ, Double-End Joining products). (C) Transposition assays 
(Ivics et al., 1997) in HeLa cells demonstrate identical activity of SB and hsSB (provided on an expression 
plasmid). Mean values of three independent experiments are shown and error bars represent standard error of 
the mean. Difference between SB and hsSB samples is not statistically significant as extimated by a two-
sample t-test (P value >0.05).  
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3.3 Results – Direct transfection of the hsSB protein for 
mammalian cell engineering 
The studies described in the previous paragraphs led to the identification of the hsSB 
transposase variant (section 3.2). hsSB is characterized with extraordinary solubility, 
stability and purification yields and is fully active in all steps of transposition, both in vitro 
and in HeLa cells. Following up on this, we aimed to explore the possibility to directly 
deliver this variant into mammalian cells for transposition-mediated genome engineering. 
The experiments described below in this section (3.3) have been designed and performed 
together with Cecilia Zuliani (Lab Manager, Barabas Laboratory, EMBL Heidelberg). 
3.3.1 Genome engineering of HeLa cells by hsSB delivery  
We first focused on delivering the purified hsSB transposase into HeLa cells. Several 
methods have been described in literature for protein delivery into mammalian cells (Fu et 
al., 2014). Electroporation currently provides highest success, and has been successfully 
used for direct delivery of genome editing nucleases [as TALENs (J. Liu et al., 2014; Ru et 
al., 2013) and Cas9 (Kim et al., 2014; Ramakrishna et al., 2014) proteins]. Thus, we tested 
the delivery of the hsSB protein via electroporation using the Neon® system.  
 
Figure 3-7: Schematic representation of the hsSB delivery and testing procedure using the neomycin-based 
reporter system. LE and RE indicate transposon end sequences. LE: left end; RE: right end; black arrow: 
promoter; neor: neomycin-resistance cassette. hsSB is depicted with its domain representation. Green and red 
stars indicate the C176S and I212S mutations, respectively. 
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In order to probe successful protein delivery into HeLa cells, we made use of a neomycin-
based reporter system [protocols adapted from (Ivics et al., 1997)]. For this, we transfected 
HeLa cells with a neomycin-resistance (neor) cassette-carrying transposon plasmid. Upon 
successful transposase delivery, the neor-transposon can undergo genomic integration and 
provides long-lasting drug resistance in the modified cells. Following drug selection, the 
number of neomycin-resistant colonies provides a measure of transposition efficiency 
(Figure 3-7).  
 
 
Figure 3-8: Neomycin-based transposition assay in HeLa cells using direct delivery of hsSB protein. Top: 
pictures of neomycin (neo) resistant colonies obtained in a single experiment. Bottom: graph showing the 
number of neomycin-resistant colonies obtained in the assay. Mean values of three independent experiments 
are shown and error bars represent the standard error. 
No transposition was detected when the transposon donor plasmid was delivered alone. 
Delivery of hsSB protein together with transposon donor plasmid by electroporation (in a 
single electroporation step) also did not result in detectable transposition (data not shown). 
In turn, we observed efficient transposition using a sequential delivery protocol, where the 
donor plasmid was first transfected using a cationic transfection reagent (JetPei®), followed 
by hsSB protein delivery via electroporation (Figure 3-7 and Figure 3-8). Using this 
strategy, we obtained robust and dose-dependent transposition, as demonstrated by the 
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gradually increasing number of neomycin resistant HeLa cell colonies with increasing 
transposase concentration. Maximum activity was achieved using 5-10 µg protein (Figure 
3-8).  
 
To better quantify hsSB-mediated transposition, we then took advantage of a fluorescent 
reporter system (Izsvak et al., 2009) (Figure 3-9). We first transfected HeLa cells with a 
Venus gene-carrying transposon plasmid (using JetPei®) and subsequently delivered the 
hsSB protein by electroporation. Green fluorescent cells (expressing the fluorescent Venus 
protein) were selected and sorted by flow cytometry two days post-transfection to obtain a 
pure population of cells containing the transposon plasmid. These cells are able to undergo 
cargo gene insertion into the genome in the presence of the hsSB protein. Three weeks 
later, we quantified by flow cytometric analysis the number of green fluorescent cells that 
stably expressed Venus as a consequence of genomic insertion by hsSB (Figure 3-9). By 
this method, we could precisely determine the efficiency of hsSB’s delivery and 
transposition, independently from the efficiency of transposon plasmid transfection.  
 
 
Figure 3-9: Schematic representation of hsSB delivery and quantification using the fluorescence-based 
reporter system. LE and RE indicate transposon end sequences. LE: left end; RE: right end; black arrow: 
promoter; Venus: Venus fluorescent protein-encoding gene. hsSB is depicted with its domain representation. 
Green and red stars indicate the C176S and I212S mutations, respectively. 
Two days post-transfection, we observed similar amounts of fluorescent cells among 
different treated cell populations, irrespective of the amount of hsSB protein used (Figure 
Results – Direct transfection of the hsSB protein for mammalian cell engineering 
 104 
3-10, top row). This shows that donor plasmid transfection occurred at roughly equal levels 
in all successfully transfected cells, resulting in similar numbers of Venus expressing cells. 
Venus positive cells were then cultured for three weeks and probed for successful 
transposition. After three weeks, the plasmid-carried Venus gene is lost from the cells, 
unless it is integrated in the HeLa cell genome by hsSB. Consistently, we barely detected 
fluorescent cells (0.19%) among those that were electroporated without hsSB. In turn, we 
detected a clear dose-dependent increase in the percentage of fluorescent cells with 
electroporation of the hsSB transposase, reflecting efficient transposition. Maximum 
efficiency (42%) was achieved with 10-20 µg of protein (Figure 3-10, bottom row).  
 
Figure 3-10: Representative graphs of flow cytometric analysis of HeLa cells transfected with Venus-
carrying transposon plasmid and electroporated with increasing amounts of hsSB (hsSB concetration 
indicated above each graph). Venus-positive cells are sorted 2 days post-transfection (top row), so as to select 
the population bearing the transposon plasmid, and 3 weeks post-transfection (bottow row), so as to quantify 
the percentage of cells that underwent transposition. Y axis: propidium iodide (PI) staining to exclude dead 
cells. X-axis: green fluorescence from Venus expression. NT: non-transfected with transposon plasmid. 
3.3.2 Characterization of the engineered HeLa cells 
Once we achieved efficient and stable engineering of HeLa cells by hsSB delivery, we 
focused on characterizing the cell product obtained by our novel method.  
We first identified the positions where the neomycin-resistance gene was inserted in the 
HeLa cell chromosomes. For this, we performed sequence analysis of isolated neor-
positive cells with the help of the EMBL Genomics Core facility (T. Rausch and V. Benes, 
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EMBL Heidelberg). This analysis showed that insertions occurred at TA dinucleotides, 
following the typical integration pattern of SB transposition (Figure 3-11). The identified 
insertions mapped to different positions in the HeLa cell genome (Figure 3-11), indicating 
a close-to-random integration pattern at the genome level, as previously described for the 
SB transposon in general (Turchiano et al., 2014). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11: Insertion sites identified by sequence analysis of isolated neomycin resistant HeLa cell clones. 
Insertions of both SB transposon ends correctly occur at TA dinucleotides (underlined). Red: left end. Blue: 
right end. 
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Next, we investigated the time frame in which the hsSB transposase is present in the HeLa 
cells, when it is (a) provided as protein or (b) expressed from plasmid DNA. By Western 
blot analysis, we monitored at different time points the presence of hsSB protein in HeLa 
cells transfected with transposon donor plasmid together with (a) 10 µg of hsSB protein or 
(b) 500 ng of hsSB-encoding plasmid.  
 
Figure 3-12: Retention of hsSB delivered into HeLa cells as protein or expressed from plasmid DNA. 
Western blot analysis shows almost complete loss of directly delivered hsSB protein 48 hours after 
electroporation, whereas cells transfected with hsSB expression plasmids produce high level of protein 
continuously from 24 hours to over 5 days after transfection. Western blot was performed on lysate from 
HeLa cells that were transfected with 500 ng of neomycin-carrying transposon plasmid and electroporated 
with 10 µg hsSB protein or transfected with 500 ng hsSB expression plasmid. Samples were taken at the 
indicated time points, and 20 µg of the total cell lysate was separated by electrophoresis and transferred to a 
nitrocellulose membrane. hsSB was detected with anti-SB antibody. The internal loading control was 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) detected with anti-GAPDH antibody. Right: plot 
showing the intensity of the Western blot bands at the analyzed time points. 
We observed substantial loss of directly delivered hsSB protein 24 hours after it was 
electroporated to the cells. In turn, cells transfected with hsSB expression plasmids 
produced high level of protein continuously from 24 hours to over 5 days post transfection 
(Figure 3-12). This shows that direct delivery of hsSB protein drastically reduces the 
retention of the SB transposase in the cells and, ultimately, the time span of active 
transposition.  
 
Finally, in collaboration with C. Miskey (Ivics Laboratory, Paul-Ehrlich-Institut, Langen, 
Germany), we analyzed the number of insertions in the HeLa cell genome when hsSB is 
provided (a) as protein or (b) as expression plasmid. For this, we first performed 
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transposition experiments using different amounts of hsSB or hsSB-encoding plasmid and 
selected positive cells using the neomycin-based assay as described in section 3.3.1. For 
each condition, we extracted genomic DNA from a pool of neomycin-resistant HeLa cells, 
and subjected it to insertion copy number analysis in the Ivics Laboratory. We found that 
the number of insertions gradually increased by electroporation of increasing amounts of 
hsSB protein into the HeLa cells (Figure 3-13 A, courtesy of C. Miskey). Such direct 
correlation was not observed when providing the protein from an expression plasmid. 
Moreover, direct protein delivery generally generated fewer insertions (on average) per cell 
and a reduced variation of integrated copy numbers compared to the plasmid-based 
strategies. 
 
 
Figure 3-13: Comparative analysis of the number of SB-mediated insertions. (A) Average number of 
transposon insertions in HeLa cells, resulting from hsSB delivered as protein or expressed from plasmids. 
Copy number is measured by digital droplet PCR of HeLa cell genomic DNA (C. Miskey, Ivics Laboratory, 
Paul-Ehrlich-Institut, Langen, Germany). (B) Transposition assay in HeLa cells showing comparable 
transgenesis rates in cells where hsSB was directly delivered as protein (2.5 µg) or expressed from plasmids 
(1 ng). Mean values of three independent experiments are shown and error bars represent the standard 
deviation. Difference between hsSB protein and plasmid samples is not statistically significant as extimated 
by a two-sample t-test (P value >0.05). 
In order to properly compare insertion copy numbers generated by the two methods, we 
identified the specific amounts of (a) the hsSB protein and (b) the hsSB-encoding plasmid 
(2.5 µg and 1 ng respectively) that produce similar transposition rates (i.e. similar number 
of engineered cells as quantified by neomycin-based transposition assays in HeLa cells) 
(Figure 3-13 B). We observed that at identical transposition efficiencies, hsSB protein 
delivery results in 7-fold less insertions than plasmid delivery (Figure 3-13). This shows 
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that the protein-based strategy creates fewer modifications and hence less perturbation in 
the HeLa cell genome.  
3.3.3 Genome engineering of CHO cells by hsSB delivery 
To explore the range of applicability of our technique, we then used hsSB for genome 
engineering of CHO cells. CHO cells are widely used in biological and medical research as 
well as for commercial production of therapeutic proteins. CHO cells are in fact the most 
commonly used mammalian hosts for industrial production of recombinant protein 
therapeutics (Omasa et al., 2010). Thus, strategies for efficient and stable genome 
engineering of CHO cells are in high demand. 
 
CHO cell lines used in this study are intrinsically resistant to neomycin. Therefore, in order 
to test hsSB delivery and transposition, we exclusively used the fluorescence-based 
reporter assay (previously established for HeLa cells, see section 3.3.1). Briefly, we 
applied a sequential delivery protocol, where CHO cells were first transfected with the 
Venus-carrying transposon plasmid using the non-liposomal transfection reagent 
FuGENE® and consequentially electroporated with the hsSB protein.  
 
Figure 3-14: Representative flow cytometric graphs of Chinese Hamster Ovary (CHO) cells that were 
transfected with Venus-carrying transposon plasmid and electroporated with hsSB (amount indicated above 
each graph). Venus-positive cells are sorted 2 days post-transfection (top row), so as to select the population 
bearing the transposon plasmid, and 3 weeks post-transfection (bottow row), so as to quantify the percentage 
of cells that underwent transposition. Y axis: propidium iodide (PI) staining to exclude dead cells. X-axis: 
green fluorescence from Venus. NT: non-transfected with transposon plasmid. 
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Cytofluorimetric analysis performed after two days revealed relatively low efficiency of 
transposon plasmid transfection (Figure 3-14, top row). Nonetheless, three weeks post-
transfection we observed a strong dose-dependent increase in green fluorescent CHO cells 
to a maximum of the 73% with 20 µg of hsSB protein (Figure 3-14, bottom row), revealing 
a remarkably high efficiency of the delivered hsSB in CHO cell engineering. 
3.3.4 Genome engineering of mESCs and human primary cells by 
hsSB delivery 
Next, we tested the efficacy of our hsSB-based engineering procedure for the genetic 
modification of stem cells. Stem cells are extensively used in research to study processes 
like differentiation (e.g. haematopoiesis) and development and as in vitro systems for 
toxicology testing (Trounson et al., 2016). The efficient engineering of stem cells, and in 
particular of embryonic stem cells, is also critical to establish animal model lines for 
laboratory usage. In addition, due to their ability to differentiate into any cell type, stem 
cells and progenitor cells exhibit high potential for regerative medicine. 
 
Figure 3-15: Representative neomycin-based transposition assay in mouse embryonic stem cells (mESCs), 
performed by direct delivery of hsSB protein. Top: pictures of mESCs neomycin-resistant colonies. Bottom: 
graphic showing the number of neomycin-resistant mESCs colonies obtained in the experiment. 
In order to provide proof-of-concept for the use of hsSB delivery for stem cell engineering, 
we applied our protocol to mouse embryonic stem cells (mESCs). We first tested hsSB in 
these cells using the neomycin-based transposition assay (see section 3.3.1). Here, mESCs 
were transfected with the neomycin resistance-carrying transposon plasmid using the 
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FuGENE® reagent and then electroporated with the hsSB protein. Upon neomycin 
selection, we observed robust and dose-dependent transposition, as estimated by the 
number of neomycin resistant mESC colonies, with maximum activity achieved using 20 
µg protein (Figure 3-15). To quantify transposition efficiency in a more accurate manner, 
we then applied the fluorescence-based reporter system (Figure 3-9, see also section 3.3.1 
for the assay design). 
 
 
Figure 3-16: Genetic engineering of mESCs using the fluorescence-based reporter system and 
characterization of the modified cells. (A) Representative flow cytometric graphs of mESCs that were 
transfected with Venus-carrying transposon plasmid and electroporated with different amounts of hsSB 
(indicated on top of each graph). Venus-positive cells are sorted 2 days post-transfection (top row), so as to 
select the population bearing the transposon plasmid, and 3 weeks post-transfection (bottow row), so as to 
quantify the percentage of cells that underwent transposition. Y axis: propidium iodide (PI) staining to 
exclude dead cells. X-axis: green fluorescence from Venus. NT: non-transfected with transposon plasmid. 
(B) Flow cytometric analysis of engineered mESCs; Oct4 staining confirms that the large majority of 
engineered mESCs retain pluripotency. 
The same delivery procedure was used as in the neomycin-based assay (transposon 
plasmid transfection by FuGENE®, followed by hsSB protein electroporation), except that 
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the transposon plasmid contained the Venus-encoding reporter gene. Two days after 
transfection, we observed comparable transposon plasmid transfection efficiencies as for 
the CHO cells (circa 5%) (Figure 3-16 A, top row). Three weeks post-transfection, we then 
identified up to 18% of genetically modified mESCs (green fluorescent cells) using 20 µg 
hsSB (Figure 3-16 A, bottom row). The engineered cells fully maintained pluripotency 
after treatment, as confirmed by immunofluorescent detection of the Oct4 self-renewal 
marker (Zeineddine et al., 2014) (Figure 3-16 B). 
 
Collectively, our data show that the hsSB transposase is effectively transfected into a 
variety of cell lines from different organisms - including HeLa cells, CHO cells, and 
mESCs -,  and allows for stable and efficient genetic engineering of these cell types (as 
summarized in Figure 3-17). Our findings provide proof-of-concept for the use of hsSB for 
stem cell engineering (Figure 3-15, Figure 3-16 and Figure 3-17) that is quite remarkable 
since stem cells are generally hard-to-transfect and are considered refractory to genetic 
modification by nature. 
 
Figure 3-17: Plot showing the efficiency of hsSB-mediated genome engineering in different cell types 
quantified by flow cytometric analysis. Mean values of two independent experiments are shown. Error bars 
represent the standard deviation. 
Using our purified hsSB variant and adapting our protocol, our collaborators (Ivics 
Laboratory, Paul-Ehrlich-Institut, Langen, Germany and Hudecek Laboratory, 
Uniklinikum Würzburg, Würzburg, Germany) were recently also able to demonstrate the 
functionality of the hsSB-based procedure for engineering of human primary cells. In the 
Ivics Laboratory, they achieved successful introduction of a reporter gene in primary 
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human Hematopoietic Stem and Progenitor Cells (HSPCs, CD34+) (E. Grueso, Ivics 
Laboratory, unpublished). In the Hudecek Laboratory, they were able to generate 
genetically modified CD19-targeted human CAR T cells (A. Mades, Hudecek Laboratory, 
unpublished), which exerted powerful anti-tumor activity in murine xenograft models of 
human lymphoma.  
 
In conclusion, we developed a new SB variant suitable for large-scale recombinant protein 
production and transfection, which allows us to successfully engineer a range of 
mammalian cell lines and even human primary cells. We named our engineering strategy 
SBprotAct, since it is based on the direct delivery and action of the active (Act) SB protein 
(SBprot). The name also showcases the increased safety associated with the use of this 
method, because SBprotAct provides a novel approach to alleviate safety issues and to 
enable maximal control of the SB system in clinical applications (as discussed in the 
following section section 3.4). 
 
Note: A patent application (“Improved Transposase Polypeptide and Uses Thereof”, 
Europe Patent Application 17187128.8) related to the content of sections 3.2 and 3.3 has 
been filed in August 2017 to the European Patent Office. 
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3.4 Discussion – The SBprotAct system 
 
The SB system is the most clinically advanced non-viral genetic engineering approach 
used in gene therapy; however, important issues remain related to its use. For example, 
long-term expression of SB transposase and/or its genomic integration from an expression 
vector can result in uncontrolled transposition and genotoxicity. To circumvent the risks 
associated with the use of transposase-coding plasmids, direct delivery of the SB 
transposase protein is highly desired. However, the production of active recombinant SB 
transposase in a quantity and quality required for cellular delivery has been challenging to 
date.  
 
In this part of my work, I have designed and characterized a new SB transposase variant 
(hsSB) (see section 3.2), which allowed efficient genetic engineering of various 
mammalian cell types and primary cells by direct SB protein delivery for the first time (see 
section 3.3). The specific advantages of this technology and the opportunities it offers for 
research and medical application will be discussed in the following paragraphs. 
3.4.1 Summary of experimental findings 
Using structural analysis and modelling, I first selected and engineered specific amino 
acids in the SB transposase to generate a new transposase variant, hsSB. While preserving 
full functionality in transposition, these mutations conferred extremely valuable properties 
to hsSB for protein delivery. These include easy recombinant production, increased 
solubility, reduced susceptibility to degradation, resistance to freezing and long-term 
storage, and outstanding thermostability. Following strategic optimization of conditions 
and nucleofection protocols, hsSB was then successfully delivered to a number of 
mammalian cell types, allowing genetic engineering of HeLa, CHO, mESC cells, and 
primary cells. This established a new cell engineering platform, named SBprotAct, that is 
based on the direct delivery of the hsSB transpososase.  
 
SBprotAct avoids the use of the SB gene for transgene delivery, thereby prohibiting 
genomic integration of the transposase cassette in the engineered cells. Remarkably, we 
found that SBprotAct reduces exposure of the engineered cells to the transposase protein 
down to 2 days, and thereby allows to sensitively modulate the rates of transgenesis and to 
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adjust the integrated gene copy number to few copies per genome. We further 
demonstrated that SBprotAct provides a reliable tool to engineer a broad range of 
mammalian cell lines, spanning from biotechnology-relevant cells (CHO) to stem cells and 
human primary cells.  
3.4.2 Advances of SBprotAct  
SBprotAct exhibits several valuable properties, which advance the state-of-the-art in the 
use of SB and transposons in general for biotechnological and medical applications. In 
particular, novel features and technological advances of SBprotAct concern: 
 
Development of SB by rational protein design. Generation of the hsSB variant - as well as 
previously reported hyperactive derivatives (Voigt et al., 2016) - demonstrates that 
structure-based protein design is a valuable approach for the development of custom-made 
SB transposases and improved SB systems. Therefore, availability of structural and 
biochemical data on SB is of key importance to support current efforts in improving SB’ 
efficiency, specificity and/or safety for clinical applications.  
 
Direct delivery of active transposases. Delivery of purified genome engineering nucleases 
is an effective strategy to avoid regulatory complications, safety concerns and financial 
limitations connected to the use and the manufacture of viral vectors. This approach has 
been employed for Cre recombinase (Pfeifer et al., 2001), TALENs (J. Liu et al., 2014; Ru 
et al., 2013), zinc finger (Gaj et al., 2012), and Cas9 (Kim et al., 2014) proteins. Yet, direct 
delivery of transposases to mammalian cells has proven challenging. Recently, the mariner 
Mos1 and Mboumar-9 transposases could be directly delivered in HeLa and HEK cells, but 
the transposition activity of the transfected proteins was very low (Trubitsyna et al., 2017). 
To date, high-efficiency mammalian cell engineering by transposase delivery has been 
only achieved for the piggyBac transposase, but required incorporation of the protein into 
lentiviral particles (Cai et al., 2014). Thus, our work provides the first completely virus-
free system for efficient delivery of a transposase protein. 
 
No need for gene or mRNA as transposase sources. In current SB-based applications, 
expression of the SB transposase is achieved either from an expression plasmid (Izsvak et 
al., 2000) or from protein-encoding mRNA (Galla et al., 2011) delivered into target cells. 
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Thus, SBprotAct establishes a new generation of the SB transposon system, based on the 
use of purified transposase, which is unprecedented. 
 
In comparison to transposase gene delivery, direct hsSB protein delivery provides no risks 
of transposase-gene or promoter insertion from the expression vector (e.g. by homologous 
recombination) into the genome of target cells. Unintended integration of the SB gene may 
result in infinite transposase production and uncontrolled transposition. Moreover, 
acquisition of the transposase promoter might cause undesired transcriptional activation (of 
e.g. oncogenes) or disruption of gene regulatory networks in the target cells. Thus, delivery 
of SB in form of protein, instead of DNA, ensures that the engineered cells are free of 
undesired exogenous DNA and proteins derived from the vector, reducing the risks of 
genome instability or phenotypic perturbations in the target cells. For therapeutic cells, 
exogenous DNA and proteins can also trigger undesired immunogenic responses in the 
patients. It is particularly important to circumvernt these aberrant effects for therapeutic 
cells, such as CAR T cells, which are reported to persist for years in the treated patients. 
 
hsSB protein delivery offers several advantages also in comparison to the use of mRNA as 
source of transposase, including: 
i. Independency from cellular translation efficiency and regulation;  
ii. Maximal, direct and fast control of transposition efficiency, since the transposase 
works immediately after transfection;  
iii. Possibility to probe protein activity prior to application in vitro, which is of 
particular relevance for quality control procedures in a commercial or clinical 
setting. Intrinsic instability of mRNA raises quality control issues that could hinder 
widespread use for therapy. 
Finally, since the rates and time frame of transgene insertion do not depend on transposase 
expression (from plasmids) and translation (from plasmids or mRNAs) by the cellular 
machinery, SBprotAct expands the applicability of SB-mediated engineering to cells in 
which protein overexpression is difficult and/or compromises cell viability. 
 
Short retention times of the protein in the target cells. As the hsSB protein is immediately 
available and rapidly clears from the cells (less than 2 days), SBprotAct enables fast and 
safe engineering. In fact, the hsSB protein acts in a hit-and-run fashion, minimizing the 
temporal window of transposition and thus the associated off-target activities such as 
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transgene remobilization, insertional mutagenesis, and cytotoxicity. Moreover, since the 
protein is rapidly degraded, we expect that the immunogenic potential of the SBprotAct 
system is essentially reduced to that of the genetic cargo alone.  
 
Control of transgenesis rates and copy numbers. As a consequence of direct delivery and 
fast transposase turnover, we found that SBprotAct allows maximal control of the cell 
engineering procedure. By varying the hsSB protein dose, transposition efficiency as well 
as the discrete number of insertions per genome can be tightly controlled. Remarkably, 
SBprotAct allows adjusting the copy number of the integrated gene to potentially a single 
copy per genome, reducing variance between individual cells and minimizing the risk of 
insertional mutagenesis and of undesired recombination events between multiple genomic 
copies. This fine tuning is not possible to achieve using viral and transposon-based vectors, 
including the current SB plasmid system, that typically generate high and variable number 
of integrations per genome in the cell population. Controlling copy numbers and 
minimizing aberrant genomic events is of critical importance for therapeutic applications 
to prevent potential post-therapeutic oncogenic transformation of the treated cells in the 
patients. 
 
Applicability in different cells. We showed that SBprotAct finds broad applicability for 
engineering of several mammalian cell lines and primary cells. Its potency in CHO cells is 
of high interest for the industrial production of protein therapeutics (or biologics, e.g. 
therapeutic antibodies). In particular, the ability of SBprotAct to tightly control the number 
of inserted transgene copies constitutes a special benefit, as optimal gene dosage is directly 
linked to the yield of the therapeutic product (Chusainow et al., 2009). Furthermore, 
SBprotAct can be efficiently used in difficult-to-engineer embryonic and hematopoietic 
stem cells and thus may facilitate engineering of stable stem cells for both research and 
therapy. 
3.4.3 Potential impacts of SBprotAct on CAR T cell therapy 
Safety, efficacy, and accessibility are the aspects currently limiting the translation of CAR 
T cell therapy into time- and cost-effective treatments for a large number of patients 
(Fesnak et al., 2016; Kebriaei et al., 2017; Sadelain et al., 2017). SBprotAct can help 
overcome specific technical issues in all these three areas. 
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Safety. SBprotAct reduces exposure of the engineered cells to the transposase protein 
down to 2 days. In turn, in the first clinical trials the SB transposase gene was detected in 
CAR T cells even 21 days after modification. Recent developments in the ex vivo cell 
manufacturing process will allow reinfusion of the engineered cells in upcoming clinical 
trials after less than 2 days (Kebriaei et al., 2017). The use of SBprotAct would guarantee 
that the transposase protein is not present in the cells at the time of administration, 
prohibiting post-infusion genotoxic events and minimizing immunogenic reactions in the 
patient. Moreover, by enabling tight control of the discrete number of insertions, 
SBprotAct generates a better-defined therapeutic cell product with constant transgene 
expression levels and minimal copy number variation between cells. Together, these 
properties will increase safety, consistency, and reproducible efficacy of CAR T cells 
produced by SBprotAct.  
 
Efficacy. Currently, long waiting times before CAR T cell administration greatly limit the 
fitness of the therapeutic cells and their treatment success in cancer patients both in early 
and advanced cancer progression stages (Kebriaei et al., 2016). The SBprotAct strategy is 
independent of transposase expression by the cellular machinery, which reducing the time-
frame of genetic modification and the burden on the fitness of the target cell. In addition, 
the possibility to reinfuse transposase-free CAR T cells 2 days after engineering (as 
discussed in the previous paragraph) will ensure shorter waiting times and higher efficacy 
of the therapy, without compromising safety. 
 
Different responses observed among patients restrain broad application of CAR T therapy 
to date. Generation of a more homogeneous population of engineered CAR T cells by 
SBprotAct (with minimal transgene copy number variation) could increase robustness and 
reproducibility of therapies. Moreover, by generating well-defined cell products, 
SBprotAct could help to identify engineered cell pools with the highest fitness and anti-
tumour activity to be used as ‘off-the-shelf’ universal CAR T cells (Poirot et al., 2015) or 
in personalized treatments. 
 
Accessibility. Treatment delays and huge costs of CAR T therapy are mainly associated to 
the fact that vector generation, T cells modification and expansion and quality control of 
the final cell product are costly, time-consuming and possible only in small number of 
highly-specialized centers. The use of the simple SB system minimizes the time and cost of 
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vector manufacture, and evades laborious testing for replication-competent virus in the 
infusion product. Additionally, SBprotAct would provide a higher quality and safer cell 
product (as discussed above), thus reducing cost per treatment and improving 
scalable/exportable vector production to serve large numbers of patients.  
 
Moreover, hsSB is well amenable for large-scale, automated and cost-effective 
manufacture. Its production and handling is also simple and could be performed even in 
point-of-care facilities, like hospitals and clinics. Moreover, the possibility to store the 
hsSB protein without compromising the efficacy allows easy delivery to de-centralized 
medical facilities for personalized treatment procedures. Thus, SB’s use is not restricted to 
specialized centers, and together with the reduction in T cell culturing times (see above), it 
can help facilitate the dispersal of CAR T technologies to regular hospitals and regular 
patients. 
3.4.4 Future directions 
This study has paved the way for the development of genetic engineering methods based 
on direct delivery of the SB protein.  
 
A current limitation of the SBprotAct system lies in the application of two successive 
transfection steps. Although electroporation constitutes one of the most efficient method 
for DNA and/or protein delivery, especially in hard-to-transfect cells, it greatly 
compromises cell viability. Thus, optimization of protocols for direct delivery of pre-
formed SB transposase-transposon DNA complexes by a single electroporation event is 
highly desirable, especially for engineering sensitive cell lines. In this regard, different 
DNA carriers, such as minimalistic transposon-carrying vectors [minicircles (Monjezi et 
al., 2017)], might provide an advantage for concerted protein-DNA delivery in comparison 
to plasmids. In fact, DNA charge, size and shape are key determinant for efficient 
transfection and can greatly influence the success of co-delivery. 
 
Furthermore, alternative delivery methods to electroporation could be explored. For 
example, delivery of Cas9 protein has been achieved using a plethora of protocols, with 
variable success rates in different target cells (Kim et al., 2014; X. Liang et al., 2015; 
Ramakrishna et al., 2014). In addition to different delivery methods, many strategies to 
increase protein’s uptake across the cell and nuclear membranes have been described in 
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literature. Most of them are based on the use of cell-penetrating peptides (CPPs) [e.g. the 
transactivator of transcription (TAT) peptide from human immunodeficiency virus] that 
can be either associated by non-convalent interactions or covalently linked to the protein of 
interest (Fu et al., 2014). In the case of SB, these extra moieties could be genetically fused 
to the N-terminus of the protein, as modification of the C-terminus generally compromise 
protein activity. 
 
Most of the advantageous features of SBprotAct derive from the rapid turnover of the hsSB 
protein in the target cells. In order to achieve an even tighter control of protein clearance 
and thus of transposition, the engineering of faster degrading protein variants could be 
tested. Moreover, we provided proof-of-concept that SBprotAct is a versatile method that 
can be applied to different cells. Further application to a larger portfolio of cell lines and 
primary cells will strongly support this idea. Notably, the current SB system is used to ex 
vivo modify retinal pigment epithelium (RPE) cells to treat patients affected by macular 
degeneration (Hudecek et al., 2017). If SBprotAct could be successfully applied to RPE 
cells, this will further expand its potential in gene therapy applications. 
 
In conclusion, while preserving all advantages of the current SB system, including 
simplicity, ease and low cost, SBprotAct enables maximal control and enhanced safety of 
gene delivery and we anticipate that its valuable features will promote the advance of SB-
mediated genetic engineering applications both in research and in the clinics.   
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4 CONCLUSIONS 
                               ‘DNA neither cares nor knows. DNA just is. And we dance to its music.’ 
                                                                                                                     R. Dawkins, 1995 
 
This thesis describes the results obtained during my PhD work, where I investigated the 
molecular mechanisms of a prominent group of DNA transposons, the Tc1/mariners, 
aiming to develop new transposon systems for genome engineering. In conjunction with 
being natural wide-host-range gene carriers, Tc1/mariners are extraordinarily powerful 
artificial vectors for genome manipulation in vertebrates. Hence, mechanistic insights into 
Tc1/mariner transposition and regulation will guide the rational design of novel genetic 
tools for basic research and human therapy. 
 
The first part of my work focused on the molecular principles underlying transposition of 
two representative Tc1/mariners: Hsmar1, the best biochemically characterized family 
member, and SB, a prime genetic tool currently applied in gene therapy clinical trials. A 
combination of structural biology methods, biochemistry, fluorescence-based, and 
biophysical techniques allowed to characterize the early steps of Hsmar1 and SB 
transposition. Comparative in vitro analysis revealed that SB assembles its transposition 
machinery (or transpososome) differently to Hsmar1. Remarkably, the unexpected 
assembly pathway of SB seems to underlie its exceptionally high transposition efficiency, 
as demonstrated by cell biology assays. Additionally, I characterized the key steps 
involved in SB transposition, namely transposon end binding, excision and integration, in 
vitro, revealing previously unknown features of the process. Taken together, these results 
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allow to build a mechanistic model for SB and Hsmar1 transposition and provide first 
insights into the molecular reasons behind SB’s extraordinary success as a genetic tool.  
 
The second part of my work addresses the most ambitious objective of my research that is 
the development of novel SB-based systems for genome engineering. Taking advantage of 
assays established above and of available structural data, I generated a novel SB 
transposase variant (hsSB) by rational protein design. hsSB exhibited unmatched solubility 
and stability in comparison to previous versions laying the foundation for the development 
of a new genome engineering platform, named SBprotAct. SBprotAct is based on the 
direct delivery of recombinant SB protein to cells and allows for efficient genome 
modification of several cell types (including stem cells and human T cells) in a more 
controlled and secure manner than the state-of-art technology. Thus, SBprotAct constitutes 
a promising strategy to improve the safety and performance of SB in its genetic 
engineering applications. 
 
In summary, this work exemplifies the general principle inspiring biomolecular 
engineering: knowledge on molecular systems is used to guide their rational design for 
applications. By learning more about the working mechanism of Tc1/mariners, and of SB 
in particular, via an integrated multi-disciplinary approach, we provided an invaluable 
resource for the development of tailor-made transposon-based tools.  On the long term, we 
expect these novel genetic engineering technologies to have tremendous implications for 
life sciences and human health. 
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5 MATERIALS AND METHODS 
This chapter describes the experimental methodologies employed in the thesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials 
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5.1 Materials 
5.1.1 Chemicals and reagents 
Unless otherwise indicated, all chemicals used in this study were purchased from Sigma-
Aldrich or Merck Millipore. All restriction enzymes were supplied by New England 
Biolabs (NEB) apart from DpnI, which was purchased from Thermo Scientific. Enzymes 
and reagents used for molecular biology were supplied by NEB, Bioline, and Thermo 
Scientific as stated in the text. Antibiotics were purchased from Sigma-Aldrich and Carl 
Roth. All buffers and stocks were made using deionized, distilled water. 
5.1.2 Bacterial growth media 
All media for bacterial growth were prepared by EMBL Media Kitchen Facility. Liquid E. 
coli cultures were grown in Lysogeny Broth (LB) medium containing 10 g tryptone, 5 g 
yeast extract, and 5 g sodium chloride per litre (pH 7.2) or in Super Optimal Broth (SOB) 
medium containing 20 g tryptone, 5 g yeast extract, 0.585 g sodium chloride, and 0.186 g 
potassium chloride per litre (pH 7.2). Solid medium for E. coli growth consisted of 10 g 
tryptone, 5 g yeast extract, 10 g sodium chloride, and 15 g agar per litre (pH 7.2). When 
applicable, the following antibiotics were added to the growth media: kanamycin 
(kanamycin sulphate, 50 µg/ml), ampicillin (ampicillin sodium salt, 100 µg/ml) and 
chloramphenicol (33 µg/ml). Bacterial growth was monitored by measuring the optical 
density at the wavelength of 600 nm (OD600). 
5.1.3 Bacterial strains 
E. coli strain Rosetta™ 2 (DE3) cells [Genotype: F- ompT hsdSB(rB- mB-) gal dcm pRARE2 
CmR- Chloramphenicol resistant] were purchased from Novagen. E. coli strain XL10-Gold 
cells [Genotype: TetR Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 
gyrA96 relA1 lac Hte [F′ proAB lacIqZDM15 Tn10 (TetR- Tetracycline resistant) Amy 
CmR ] were purchased from Stratagene. 
 
Chapter 5: Materials and methods 
 125 
5.1.4 Plasmids 
Table 5.1 contains a list of plasmids used in this study together with the description, 
carried antibiotic resistance, origin of replication, and source of each plasmid.  
 
Table 5-1: Plasmids used in this study 
 
 
5.1.5 Oligonucleotides 
All oligonucleotides used in this study were purchased from Integrated DNA Technologies 
(IDT, Leuven, Belgium) and were resuspended in distilled water or Tris-EDTA (TE) buffer 
[10 mM tris(hydroxymethyl)aminomethane (Tris), pH 8, and 1 mM 
Plasmid Description Resistance* Origin Source
pETM-22 T7 expression vector with N-terminal TRX-6xHis tag Km pBR322 PEP-core EMBL Heidelberg 
Hsmar1_fl_pETM-22 T7 expression vector encoding TRX-6xHis tag-Hsmar1_fl Km pBR322 I. Querques, M.Sc. thesis
Hsmar1_fl_W118P_pETM-22 T7 expression vector encoding TRX-6-His tag-Hsmar1_fl_W118P Km pBR322 This study
Hsmar1_fl_V119G_pETM-22 T7 expression vector encoding TRX-6xHis tag-Hsmar1_fl_V119G Km pBR322 This study
SB_fl_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl Km pBR322 Voigt et al., 2016
SB_fl_R36C_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_R36C Km pBR322 This study
SB_fl_S37C_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_S37C Km pBR322 This study
SB_fl_S55C_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_S55C Km pBR322 This study
SB_fl_S99C_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_S99C Km pBR322 This study
SB_fl_T102C_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_T102C Km pBR322 This study
SB_fl_V106C_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_V106C Km pBR322 This study
SB_fl_H115C_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_H115C Km pBR322 This study
SB_fl_S116C_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_S116C Km pBR322 This study
SB_fl_C176C-I212S_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_C176S-I212S Km pBR322 This study
SB_fl_S37C-C176C-I212S_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_S37C-C176S-I212S Km pBR322 This study
SB_fl_V106C-C176C-I212S_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_V106C-C176S-I212S Km pBR322 This study
SB_fl_R14C-C176C-I212S_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_C176S-I212S-R14C Km pBR322 This study
SB_fl_D17C-C176C-I212S_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_fl_C176S-I212S-D17C Km pBR322 This study
A1_SB_fl_pETM22 T7 expression vector encoding TRX-6xHis tag-A1-SB_fl Km pBR322 F. Voigt, PhD thesis
B1_SB_fl_pETM22 T7 expression vector encoding TRX-6xHis tag-B1-SB_fl Km pBR322 F. Voigt, PhD thesis
A1_pETM22 T7 expression vector encoding TRX-6xHis tag-A1 Km pBR322 F. Voigt, PhD thesis
B1_pETM22 T7 expression vector encoding TRX-6xHis tag-B1 Km pBR322 F. Voigt, PhD thesis
A1_Hsmar1_fl_pETM22 T7 expression vector encoding TRX-6xHis tag-A1-Hsmar1_fl Km pBR322 This study
B1_Hsmar1_fl_pETM22 T7 expression vector encoding TRX-6xHis tag-B1-Hsmar1_fl Km pBR322 This study
SB_1-117_pETM-22 T7 expression vector encoding TRX-6xHis tag-SB_1-117 Km pBR322 F. Voigt, PhD thesis
Tc3_1-135_SB_110-340_pETM-22 T7 expression vector encoding TRX-6xHis tag-Tc3_1-135_SB_110-340 Km pBR322 F. Voigt
pCFJ601 - Peft-3 Mos1 transposase Template plasmid for amplification of Mos1 gene Amp pBR322 Addgene
Mos1_1-56_SB_53-340_pETM-22 T7 expression vector encoding TRX-6xHis tag-Mos1_1-56_SB_53-343 Km pBR322 This study
GST_SB_fl_pETM33 T7 expression vector encoding 6xHis tag-GST-SB_fl_C176S-I212S Km ColE1 O. Barabas, NIH Bethesda, USA
TEV_GST_SB_fl_pETM33 T7 expression vector encoding 6xHis tag-TEV cleavage site-GST-SB_fl Km ColE1 This study
TEV_GST_SB_fl_C176S-I212S_pETM33 T7 expression vector encoding 6xHis tag-TEV cleavage site-GST-SB_fl_C176S-I212S Km ColE1 This study
pETMCN-YC Target plamid used for in vitro integration assays Cm p15a Romier et al., 2006; courtesy of C. Müller, EMBL Heidelberg
A1_SB_fl_EWS Mammalian expression vector encoding 6xHis-HA-Strep-Tag_A1-SB_fl Amp ColE1 F. Voigt, PhD thesis
A1_Hsmar1_fl_EWS Mammalian expression vector encoding 6xHis-HA-Strep-Tag_A1-Hsmar1_fl Amp ColE1 F. Voigt, PhD thesis
FRB_CMV Template plasmid for amplification of FRB gene Km pUC Varnai et al., 2006; courtesy of D. Yushchenko, EMBL Heidelberg
FKBP_CMV Template plasmid for amplification of FKBP gene Km pUC Varnai et al., 2006; courtesy of D. Yushchenko, EMBL Heidelberg
FRB_SB_fl_EWS Mammalian expression vector encoding 6xHis-HA-Strep-Tag_FRB-SB_fl Amp ColE1 This study
FKBP_SB_fl_EWS Mammalian expression vector encoding 6xHis-HA-Strep-Tag-FKBP-SB_fl Amp ColE1 This study
FRB_Hsmar1_fl_EWS Mammalian expression vector encoding 6xHis-HA-Strep-Tag-FRB-Hsmar1_fl Amp ColE1 This study
FKBP_Hsmar1_fl_EWS Mammalian expression vector encoding 6xHis-HA-Strep-Tag-FKBP-Hsmar1_fl Amp ColE1 This study
pUC19 Filler plamid used for in vivo transposition assays Amp pBR322 Addgene
pHsmar1-neo Reporter plasmid with neomycin resistance gene flanked by the Hsmar1 transposon ends Amp pMB1 Miskey et al., 2007
SB_fl_pCMV(CAT)T7 Mammalian expression vector encoding 6xHis-SB_fl Cm pBR322 Mates et al., 2009
SB-C176S-I212S_pCMV(CAT)T7 Mammalian expression vector encoding 6xHis-SB_fl_C176S-I212S Cm pBR322 This study
SB_PGK-neo Reporter plasmid with neomycin resistance gene flanked by the SB transposon ends Amp ColE1 Neuromics; courtesy of F. Spitz, EMBL Heidelberg
SB_T2/Venus Reporter plasmid with Venus-encoding gene flanked by the SB transposon ends Amp ColE1 Mates et al., 2009
fl-full length
* Km-kanamycin; Cm-Chloramphenicol; Amp-ampicillin
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ethylenediaminetetraacetic acid (EDTA)] to a final concentration of 1 mM or 100 µM. 
Oligonucleotides used as primers in polymerase chain reaction (PCR) are listed in Table 
5-2. Melting temperature of the primers was estimated using the IDT OligoAnalyzer tool 
(http://eu.idtdna.com/calc/analyzer). Oligonucleotides used as DNA substrates in 
biochemical assays, crystallization and binding studies are shown in the method sections 
for individual experiments.  
 
Table 5-2: Primers for PCR reactions used in this study. 
 
5.2 Molecular biology methods 
5.2.1 Constructs for protein overexpression 
The open reading frame coding for amino acids 1-343 of the reconstituted full length 
Hsmar1 transposase as reported by Miskey and colleagues [(Miskey et al., 2007); 
GenBank accession code EF517118] was kindly provided by Csaba Miskey and Zoltán 
Ivics. The Sleeping Beauty 100X (SB) gene [encoding amino acids 1-340 of the hyperactive 
SB100X; (Mates et al., 2009)] was kindly provided by Zoltán also  and Zsuzsanna Izsvák. 
The Hsmar1- and SB-encoding genes were cloned into vectors pETM-22 for 
No Primer Sequence** Purpose
1 Hsmar1_W118P [Phos]GCAAATTGGAAAGGTGAAAAAGCTCGATAAGCCGGTGCCTCATGAGCTGAGTG Site-directed mutagenesis of Hsmar1_fl_W118P
2 Hsmar1_V119G [Phos]GAAAGGTGAAAAAGCTCGATAAGTGGGGTCCTCATGAGCTGAGTGAAAATCAAAAAAATCG Site-directed mutagenesis of Hsmar1_fl_V119G
3 SB_R36C [Phos]GCCTGGCGGTACCATGCTCATCTGTACAAACAATAGTACGCAAA Site-directed mutagenesis of SB_R36C
4 SB_S37C [Phos]CTGGCGGTACCACGTTGCTCTGTACAAACAATAGTACGCAAGT Site-directed mutagenesis of SB_S37C
5 SB_S55C [Phos]GACCACGCAGCCGTGCTACCGCTCAGGAAGGAGAC Site-directed mutagenesis of SB_S55C
6 SB_S99C [Phos]TGGAGGAAACAGGTACAAAAGTATGCATATCCACAGTAAAACGAGTCCTATATC Site-directed mutagenesis of SB_S99C
7 SB_T102C [Phos]GGAAACAGGTACAAAAGTATCTATATCCTGCGTAAAACGAGTCCTATATCGACATAAC Site-directed mutagenesis of SB_T102C
8 SB_V106C [Phos]ACAAAAGTATCTATATCCACAGTAAAACGATGCCTATATCGACATAACCTGAAAGGC Site-directed mutagenesis of SB_V106C
9 SB_H115C [Phos]GTCCTATATCGACATAACCTGAAAGGCTGCTCAGCAAGGAAGAAGCCACT Site-directed mutagenesis of SB_H115C
10 SB_S116C [Phos]ATATCGACATAACCTGAAAGGCCACTGCGCAAGGAAGAAGCCACTGCT Site-directed mutagenesis of SB_S116C
11 SB_C176S [Phos]AGGAAGAAGGGGGAGGCTTCCAAGCCGAAGAACACCATCCC Site-directed mutagenesis of SB_C176S
12 SB_I212S [Phos]GGTGCACTTCACAAAATAGATGGCAGCATGGACGCGGTGCAGTAT Site-directed mutagenesis of SB_I212S
13 SB_R14C [Phos]GCCAAGACCTCAGAAAATGCATTGTAGACCTCCACAAG Site-directed mutagenesis of SB_R14C
14 SB_D17C [Phos]GACCTCAGAAAAAGAATTGTATGCCTCCACAAGTCTGGTTC Site-directed mutagenesis of SB_D17C
15 Hsmar1_fl_for ACAAGTTTGTACAAAAAAGCAGGCTGCATGGAAATGATGTTAGACAAAAAGC Cloning of Hsmar1_fl in A1_SB_fl_pETM22 (to substitute SB)
16 Hsmar1_fl_rev GCTCGAGTGCGGCCGCAAGCTTCTAATCAAAATAGGAACCATTACAA Cloning of Hsmar1_fl in A1_SB_fl_pETM22 (to substitute SB)
17 Hsmar1_fl_for ACAAGTTTGTACAAAAAAGCAGGCTGCATGGAAATGATGTTAGACAAAAAGC Cloning of Hsmar1_fl in B1_SB_fl_pETM22 (to substitute SB)
18 Hsmar1_fl_rev GCTCGAGTGCGGCCGCAAGCTTCTAATCAAAATAGGAACCATTACAA Cloning of Hsmar1_fl in B1_SB_fl_pETM22 (to substitute SB)
19 Mos1_1-56_SB_53-340_for AGTTCTGTTCCAGGGGCCCATGATGTCGAGTTTCGTGCCG Cloning of Mos1_1-56 in SB_fl_pETM22 
20 Mos1_1-56_SB_53-340_rev AGCGGTATGACGGCTGCGTGGTACCACTTTTGAAGCGTTGAAA Cloning of Mos1_1-56 in SB_fl_pETM22 
21 TEV_GST_SB_fl_pETM33 [Phos]CCATCACCATCACAACACTAGTGAGAACCTGTACTTCCAAGGCATGTCCCCTATACTAGG Cloning of TEV cleavage site in GST_SB_fl_pETM33
22 FKBP_SB_for ACCATCACCATCACCTCGAGACCATGGGAGTGCAGGTGGAA Cloning of FKBP in A1_SB_fl_EWS (to substitute A1)
23 FKBP_SB_rv TGTACAAACTTGTGATATCGGCCGCTTCCAGTTTTAGAAGCTCCACA Cloning of FKBP in A1_SB_fl_EWS (to substitute A1)
24 FRB_SB_for ACCATCACCATCACCTCGAGACCTCTAGAATCCTCTGGCATGAGA Cloning of FRB in A1_SB_fl_EWS (to substitute A1)
25 FRB_SB_rv TGTACAAACTTGTGATATCGGCCGCACTAGTCTTTGAGATTCGTCGG Cloning of FRB in A1_SB_fl_EWS (to substitute A1)
26 FKBP_Hsmar1_for ACAAGTTTGTACAAAAAAGCAGGCTGCATGGAAATGATGTTAGACAAAAAG Cloning of FKBP in A1_Hsmar1_fl_EWS (to substitute A1)
27 FKBP_Hsmar1_rv ACCACTTTGTACAAGAAAGCTGGGTCCTAATCAAAATAGGAACCATTACAA Cloning of FKBP in A1_Hsmar1_fl_EWS (to substitute A1)
28 FRB_Hsmar1_for ACAAGTTTGTACAAAAAAGCAGGCTGCATGGAAATGATGTTAGACAAAAA Cloning of FRB in A1_Hsmar1_fl_EWS (to substitute A1)
29 FRB_Hsmar1_rv ACCACTTTGTACAAGAAAGCTGGGTCCTAATCAAAATAGGAACCATTACAA Cloning of FRB in A1_Hsmar1_fl_EWS (to substitute A1)
** [Phos]- 5' Phosphorylation
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overexpression in E. coli prior to this thesis work, to give vectors Hsmar1_fl_pETM-22 (I. 
Querques, M.Sc. thesis) and SB_fl_pETM-22 (Voigt et al., 2016) respectively.  
All prokaryotic expression constructs contained in pETM-22 vectors were cloned in frame 
with N-terminal ThioredoxinA (TRX) and 6XHis tags that could be removed from the 
protein constructs via incubation with PreScission protease (3C; Protein Expression and 
Purification Core Facility, EMBL Heidelberg). The GST_SB_fl construct in pETM-33 
vector contained a N-terminal 6XHis- GST tag that could be removed via incubation with 
PreScission protease (3C; Protein Expression and Purification Core Facility, EMBL 
Heidelberg). Additionally, a TEV protease cleavage site was inserted between the 6XHis 
tag and the GST tag in vector GST_SB_fl_pETM33 via a specific loop-in restriction-free 
cloning protocol (described in section 5.2.3) to generate vector 
TEV_GST_SB_fl_pETM33 (using primer 21). In this way, the 6XHis tag only could be 
removed from the GST-SB protein construct through incubation with TEV protease 
(Protein Expression and Purification Core Facility, EMBL Heidelberg). 
All mutations of the Hsmar1 and SB protein sequences were introduced via site-directed 
mutagenesis (following protocols described in (Makarova et al., 2000) and in section 
5.2.3). 
The genes for the dimerization-dependent fluorescent fusion proteins ddRFP-A1 (A1, 
GenBank accession code:  JN381545) and ddRFP-B1 (B1, GenBank accession code: 
JN381546) (Alford et al., 2012) were cloned in frame with the SB transposase gene into 
vector SB_fl_pETM-22 to obtain vectors A1_SB_fl_pETM-22 and B1_SB_fl_pETM-22 
prior to this thesis work (F. Voigt, PhD thesis). The Hsmar1 transposase gene was 
substituted to the SB gene in vectors A1_SB_fl_pETM-22 (using primers 15/16) and 
B1_SB_fl_pETM-22 (using primers 17/18) via restriction-free cloning (as described in 
section 5.2.2) to generate vectors A1_Hsmar1_fl_pETM-22 and B1_Hsmar1_fl_pETM-22 
respectively. A1-SB, B1-SB, A1-Hsmar1 and B1-Hsmar1 proteins contain a 13 amino 
acids long flexible linker (AADITSLYKKAGC) connecting the N-terminal fluorescent 
proteins with the respective transposases. A1 and B1 proteins were overexpressed from 
vectors A1_pETM-22 and B1_pETM-22, respectively (F. Voigt, PhD thesis). 
 
The DNA sequence encoding for amino acids 1-56 of the Mos1 transposase (UniProtKB 
accession code: Q7JQ07.1) was cloned from vector pCFJ601 - Peft-3 Mos1 transposase 
(purchased from Addgene) to vector SB_pETM22 via restriction-free cloning (protocol in 
section 5.2.2) (using primers 19/20) to generate vector Mos1_1-56_SB_53-340_pETM-22.  
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The genes of FKBP12 and the FRB proteins (Varnai et al., 2006) from vectors FKBP-
CMV and FRB-CMV (courtesy of D. Yushchenko, EMBL Heidelberg, Germany) were 
substituted via restriction free cloning to the A1 genes into vectors A1_SB_fl_EWS and 
A1_Hsmar1_fl_EWS respectively, to generate vectors FKBP_SB_fl_EWS (primers 
22/23), FRB_SB_fl_EWS (primers 24/25), FKBP_Hsmar1_fl_EWS (primers 26/27) and 
FRB_Hsmar1_fl_EWS (primers 28/29). The resulting vectors are used for mammalian cell 
expression of FKBP-SB, FRB-SB, FKBP-Hsmar1 and FRB-Hsmar1 fusion proteins, 
respectively. All constructs were cloned in frame with N-terminal 6XHis-, HA- (Human 
influenza hemagglutinin) and Strep-tags into EWS vectors. No cleavage site was present to 
remove the tags from the protein constructs. 
5.2.2 Restriction-free (RF) cloning 
Restriction-free (RF) cloning hybrid primers containing complementary sequences to both 
the desired insert and target plasmids were generated using the primer design tool at 
www.rf-cloning.org. All DNA concentrations were determined by UV spectroscopy at 260 
nm using a NanoDrop instrument (Thermo Scientific).  
 
The first PCR mix contained 1x Phusion Flash High-Fidelity PCR Master Mix (Thermo 
Scientific), 500 nM of each forward (for) and reverse (rev) primer, and 20 ng of template 
vector in a total volume of 50 µl. The thermocycling conditions are shown in Table 5-3. 
The resulting product, so-called Mega Primer, was purified using a GenElute PCR Clean-
Up Kit (Sigma-Aldrich) according to the manufacturer’s instructions and used in a second 
PCR reaction, with the target plasmid acting as template in a reaction with 1x Phusion 
Flash High-Fidelity PCR Master Mix, 350 ng of Mega Primer, and 50 ng of template DNA 
in a total volume of 50 µl. Thermocycling conditions of second PCR are also shown in 
Table 5-3. The reaction products were purified using a GenElute PCR Clean-Up Kit 
(Sigma-Aldrich) and eluted in 17 µl of distilled water. In order to degrade any remaining 
parental plasmid DNA, the sample was incubated with 2 µl of 10x FastDigest Buffer and 2 
µl of FastDigest DpnI restriction enzyme (both from Thermo Scientific) at 37 °C for at 
least 4 hours. 10 µl of the sample was then transformed into E. coli XL10-Gold chemically 
competent cells (Stratagene). 
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Table 5-3: Thermocycling conditions in restriction-free cloning PCR. 
 
 
The presence of the insert in single colonies of E. coli transformants was validated by a 
standard colony PCR protocol. The reaction mix consisted of 1x MangoMixTM (Bioline), 
400 µM of each forward and reverse primers (specific primers for the insert of interest) and 
single transformant colony cells as template. Thermocycling conditions of the colony PCR 
are shown in Table 5-4. The PCR products were directly loaded on 1% agarose gels [1% 
(w/v) agarose powder dissolved in 1x Tris-acetate- EDTA (TAE) buffer (40 mM Tris, 20 
mM acetic acid, and 1 mM EDTA)]. After applying a voltage of 7-10 V per cm for 30-60 
minutes, the products of gel electrophoresis were analysed on a UV transilluminator 
(Alpha Innotech) using AlphaImager® HP software (Fisher Scientific). A HyperLadderTM 
1kb, Bioline DNA marker was used. 
 
Table 5-4: Thermocycling conditions in colony PCR 
 
 
Positive transformant colonies were inoculated into 5 ml LB medium containing 
appropriate antibiotics and grown overnight at 37 °C. After cell harvesting, the plasmid 
DNA was extracted using GenElute Plasmid DNA Miniprep Kit (Sigma-Aldrich) and 
validated for the presence of the correct insert by DNA sequencing performed by GATC 
Biotech.  
Step Temperature Time
PCR1
1. Initial Denaturation 98 °C 20 seconds
2. Denaturation 98 °C 1 second
3. Annealing 50-60 °C 5 seconds
4. Extension 72 °C 60 seconds/kbp
5. Final extension 72 °C 5 minutes
6. Hold 4 °C hold
PCR2
1. Initial Denaturation 98 °C 20 seconds
2. Denaturation 98 °C 1 second
3. Annealing 60-65 °C 5 seconds
4. Extension 72 °C 8 minutes
5. Final extension 72 °C 10 minutes
6. Hold 4 °C hold
repeated 35 times
repeated 18 times
Step Temperature Time
1. Initial Denaturation 98 °C 5 minutes
2. Denaturation 96 °C 30 seconds
3. Annealing 60 °C 30 seconds
4. Extension 72 °C 2 minutes
5. Final extension 72 °C 4 minutes
6. Hold 4 °C hold
repeated 35 times
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5.2.3 Site-directed mutagenesis 
Point mutations and short amino acid motifs (i.e. TEV cleavage site) were introduced 
through site-directed mutagenesis using a loop-in protocol (Makarova et al., 2000). A 
single 5' phosphorylated primer was designed for each mutation so that it contained 
mutation of interest at the center of the primer and each half-site flanking the mismatch has 
a melting temperature of 58 °C with the melting temperature of the full primer close to 68 
°C. The PCR mutagenesis reaction was performed in a reaction volume of 50 µL that 
included 2.5 units PfuUltra High Fidelity DNA polymerase enzyme in 1x PfuUltra HF 
DNA polymerase reaction buffer (Agilent Technologies), 1 unit Taq DNA Ligase in 1x 
Taq DNA Ligase buffer (New England Biolabs), 200 nM dNTP mixture (Bioline), 500 nM 
of a single 5' phosphorylated primer, and 100 ng of template plasmid DNA. Thermocycling 
conditions are shown in Table 5-5. Since only one primer containing the desired mutation 
is used, PCR results in amplification of a single-stranded plasmid, ligated by Taq DNA 
ligase in the same reaction. After purification of the reaction products and DpnI digestion, 
performed as previously described, the sample was then transformed into E. coli XL10-
Gold competent cells and the sequences of the cloned plasmids were confirmed at the end 
of the construction by nucleotide sequencing by GATC Biotech. 
 
Table 5-5: Thermocycling conditions in site-directed mutagenesis 
 
5.2.4 Protein overexpression in E. coli 
All protein constructs described in this thesis were overexpressed in E. coli strains 
Rosetta™ 2 (DE3) cells from pET vectors under a T7 promoter. The expression vectors 
were transformed into cells, and overnight cultures of the transformants were set up in LB 
medium with appropriate antibiotics. In large-scale expressions, 500 ml of LB medium 
containing appropriate antibiotics was inoculated with 5 ml of overnight cultures and 
grown at 37 °C and 200 rpm until OD600 of 0.6-0.8. Next, expression was induced by 
addition of 0.5 mM of isopropyl β-D-1- thiogalactopyranoside (IPTG). Cells were grown 
Step Temperature Time
1. Initial Denaturation 95 °C 1 minute
2. Denaturation 95 °C 30 seconds
3. Annealing 55 °C 30 seconds
4. Extension 65 °C 60 seconds/kbp
5. Hold 4 °C hold
repeated 30 times
Chapter 5: Materials and methods 
 131 
at 16 °C and 200 rpm for 18 hours and then harvested by centrifugation at 5000 rpm for 15 
minutes at 4 °C. The obtained pellet was then washed once with 25 ml LB and centrifuged 
at 3000 g for 45 minutes at 4 °C. After the final harvest, the pellet was flash-frozen in 
liquid nitrogen and stored at -80 °C until further use or immediately used for purification 
(see section 5.2.5).  
 
The selenomethionine (SeMet) derivative of Hsmar1 was expressed in methionine- 
prototrophic strain Rosetta™ 2 (DE3) from plasmid Hsmar1_fl_pETM-22. 5 ml of the 
overnight culture was washed twice with M9 medium containing 1x M9 salts (Table 5-6), 
2 mM MgSO4, 0.1 mM CaCl2, 0.4% (w/v) glucose, 1 µg/ml thiamine, and 1x trace 
elements solution (Table 5-6). 50 ml of M9 medium was then inoculated with the washed 
culture (5 ml) and grown overnight at 37 °C. The overnight culture was then added to 1 
litre of fresh M9 medium and grown to OD600 of 0.6. Next, essential amino acids were 
added at the following concentrations: 100 mg/l of lysine, phenylalanine, and threonine 
and 50 mg/l of isoleucine, leucine, valine, and selenomethionine. The cultures were then 
incubated for 20 minutes at 4 °C without shaking, followed by induction of expression 
with 0.5 mM IPTG. After expression for 18 hours at 16 °C, the cultures were harvested and 
frozen as described for the other proteins. 
 
Table 5-6: Composition of 10x M9 salts and 100x trace elements. 
 
5.2.5 Protein purification 
All protein constructs described in this study were overexpressed as fusions with an N-
terminal 6xHis affinity tag and purified through a three step affinity purification scheme, 
including 1) first purification by nickel affinity chromatography, 2) tag cleavage and 
Components Amount per litre
10x M9 salts 
Na2HPO4!7 H2O 70 g
KH2PO4 30 g
NaCl 5 g
NH4Cl 10 g
100x trace elements
EDTA 5 g
FeSO4!7 H2O 0.85 g
ZnSO4!7 H2O 0.173 g
CuCl2!2 H2O 0.013 g
CoCl2!6 H2O 0.010 g
H3BO3 0.010 g
MnCl2!6 H2O 0.0016 g
(NH4)6Mo7O24!4 H2O 0.010 g
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removal by second nickel affinity chromatography, and 3) size exclusion chromatography 
(SEC) on a gel filtration column. All purification steps were performed using the 
ÄKTApurifier Protein Purification System (GE Healthcare) at 4 °C.  
 
The harvested expression pellets were resuspended in 40 ml Lysis buffer (Table 5-7). The 
resuspended cells were then lysed by sonication using a Branson Sonifier 250 set to 60% 
duty cycle and 55% output control, in 6 cycles of 45 seconds sonication and 60 seconds 
rest on ice. Next, the lysed cells were ultracentrifuged at 18000 rpm for 40 minutes at 4 °C. 
The supernatant, corresponding to the soluble fraction of E. coli proteins, was loaded onto 
a 5 ml HisTrap HP column (GE Healthcare), previously equilibrated in Loading buffer 
(Table 5-7) for the first nickel affinity purification. After immobilization on the column, 
elution of the 6xHis-tagged protein was achieved using gradually increasing imidazole 
concentrations (applying a gradient from 5% to 50% Elution buffer, Table 5-7).  
 
In order to remove the 6xHis- (in case of protein expressed from vector 
TEV_GST_SB_fl_C176S-I212S_pETM33) or TRX-6xHis tags (for all other protein 
constructs), 10 µg of 6xHis tagged TEV protease or 10 µg of 6xHis tagged 3C protease per 
mg of protein, respectively, were added and the sample was then dialysed against Gel 
filtration buffer (Table 5-7) overnight at 4 °C in order to remove imidazole and allow for 
protease cleavage.  
 
Table 5-7: Composition of purification buffers. 
 
 
A second nickel affinity purification step was performed to remove the 6xHis tag and the 
uncleaved fusion protein from the solution. The cleaved protein was further purified by 
SEC using a Superdex 200 16/60 column (GE Healthcare). When applicable, the fractions 
Buffer Composition
Purification of all Hsmar1 constructs 
Lysis buffer 1x PBS, 1 M NaCl, 10 mM imidazole, 0.2 mM TCEP, 1 tablet of cOmplete Protease Inhibitor Cocktail (Roche), 
25 mM PMSF, 25 µg/ml RNaseA (Roche), 50 µg/ml DNaseI (Roche), pH 7.5 
Loading buffer 1x PBS, 1 M NaCl, 10 mM imidazole, 0.2 mM TCEP,  pH 7.5 
Elution buffer 1x PBS, 1 M NaCl, 1 M imidazole, 0.2 mM TCEP,  pH 7.5
Gel filtration buffer 1x PBS, 1 M NaCl, 0.2 mM TCEP,  pH 7.5
Purification of all SB constructs and of A1 and B1 proteins
Lysis buffer 1x PBS, 1 M NaCl, 20 mM imidazole, 0.2 mM TCEP, 1 tablet of cOmplete Protease Inhibitor Cocktail (Roche),  
25 mM PMSF, 25 µg/ml RNaseA (Roche), 50 µg/ml DNaseI (Roche), pH 7.5 
Loading buffer 1x PBS, 1 M NaCl, 20 mM imidazole, 0.2 mM TCEP,  pH 7.5 
Elution buffer 1x PBS, 1 M NaCl, 1 M imidazole, 0.2 mM TCEP,  pH 7.5
Gel filtration buffer 1x PBS, 1 M NaCl, 0.2 mM TCEP,  pH 7.5
1xPBS – 1x phosphate buffered saline (0.2 g KCl, 0.2 g KH2PO4, 1.15 g Na2HPO4, and 8 g NaCl per litre, prepared by EMBL Media Kitchen Facility); 
TCEP - tris(2-carboxyethyl)phosphine; PMSF – phenylmethanesulphonylfluoride; 
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of interests were dialysed step-wise against appropriate buffers, with each dialysis step 
carried out for at least 4 hours at 4 °C. The dialysed proteins were concentrated to desired 
concentrations using Vivaspin® Turbo 15 or/and Turbo 2 concentrators (molecular weight 
cut-off of 10 kDa, Sartorius stedim biotech) and kept at 4 °C or frozen in liquid nitrogen 
and stored at -80 °C until further use. 
5.2.6 Sodium dodecyl-sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Protein samples were routinely analysed by electrophoresis on 12% Sodium dodecyl-
sulphate polyacrylamide (SDS-PA) gels. Protein samples were mixed with 4x SDS loading 
buffer [200 mM Tris-Cl, pH 6.8, 24% glycerol, 8% SDS, 0.02% bromophenol blue, and 
0.5 M dithiothreitol (DTT)], heated to 95° C and loaded on SDS-PA gels [12% resolving 
gel: 0.375 M Tris-Cl, pH 8.8, 0.1% SDS, 12% Acrylamide: Bisacrylamide (37.5:1), 0.1% 
(w/v) ammonium persulfate (APS), 0.16% tetramethylethylenediamine (TEMED); 4% 
stacking gel: 0.125 M Tris-Cl, pH 8.8, 0.1% SDS, 4% Acrylamide: Bisacrylamide (37.5:1), 
0.1% APS, 0.16% TEMED]. Gels were run for 45 min at 175 V in 1x Laemmli buffer 
(prepared by the EMBL Media Kitchen Facility). When applicable, precast NuPAGE 4-
12% Bis-Tris Gels (Invitrogen) were used for electrophoresis according to the 
manufacturer’s instructions. Protein marker used was Mark12TM (Life Technologies). After 
the run, gels were stained with Coomassie staining solution containing 0.075% (w/v) G250 
Coomassie Brilliant Blue (Thermo Scientific) and 0.1% (v/v) HCl. The products of gel 
electrophoresis were analysed under white light on a transilluminator (Alpha Innotech) 
using AlphaImager® HP software (Fisher Scientific). 
 
The molecular weight and theoretical extinction coefficient of the purified proteins was 
estimated using the ProtParam bioinformatic tool provided by ExPASy 
(http://www.expasy.org). Protein samples were quantified based on their UV absorption at 
280 nm wavelength measured using a Nanodrop spectrophotometer (Thermo Fisher 
Scientific). 
5.2.7 Mass spectrometry 
The efficiency of selenomethionine incorporation in the Hsmar1 derivative (see section 
2.2.4) and the identity of SB degradation products (see section 3.2.2) were investigated by 
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mass spectrometry performed by the EMBL Proteomics Core Facility. In brief, the purified 
Hsmar1 sample was concentrated to >1 mg/ml and submitted to the Core Facility, whereas 
the SB degradation products identification was performed from PA gels. Mass 
determination was performed on a Q-Tof2 iMass Spectrometer (Micromass/Waters). In the 
case of the Hsmar1 derivative, the raw data were deconvoluted using MaxEnt1 software 
(Micromass/Waters) and the number of methionine sites occupied by selenomethionine 
was estimated based on the single peak with assigned mass. 
5.3 Biochemical methods 
5.3.1 Annealing of DNA substrates 
All DNA substrates used in this work were annealed by mixing desired amounts of the 
oligonucleotides (resuspended in TE buffer, unless otherwise indicated), followed by 
incubation at 98 °C for 5 minutes and slow cooling (2-3 hours) in a switched-off heating 
block until the temperature reached the room temperature. 
5.3.2 Radioactive labelling of DNA substrates 
All oligonucleotides used in labelling reactions were unphosphorylated at the 5’-end. The 
labelling reaction contained 1x T4 Polynucleotide Kinase Reaction Buffer, 10 units of T4 
Polynucleotide Kinase (both from NEB), 20 µM oligonucleotide, and 92.5 MBq (2.5 
mCi)/ml of [γ-32P]-ATP (PerkinElmer) in 10 µl reaction mix. The reactions were incubated 
at 37 °C for 1 hour, after which 40 µl of TE buffer was added. The kinase was then heat-
inactivated by incubation at 80 °C for 30 minutes. In order to remove all unincorporated [γ-
32P]-ATP, the samples were applied to Micro Bio-Spin® Chromatography Columns (Bio-
Rad) and purified according to the manufacturer’s instructions. The Oligo Length 
Standards 10/60 and 20/100 Ladder markers (IDT) were labelled as above. To 40 µl of the 
marker, 60 µl of distilled water and 100 µl of 2x Formamide loading buffer [1x TBE (100 
mM Tris base, 100 mM boric acid, 2 mM EDTA) 90% formamide, 0.005% xylene cyanol, 
and 0.005% bromophenol blue] were added. 
5.3.3 Hsmar1 in vitro cleavage assay 
Hsmar1 in vitro cleavage assay was based on reaction conditions described in (Claeys 
Bouuaert et al., 2010). The Hsmar1 wild type and V119G mutant proteins were 
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overexpressed in E. coli and purified as described in sections 5.2.4 and 5.2.5. The DNA 
substrates used (Table 5-8) were 5’ labelled with 32P either on the NTS or on the TS.  
 
The Hsmar1 wild type protein or V119G mutant (in 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 500 mM NaCl, 1 mM MgCl2 and 0.2 mM TCEP, 
pH 7.5) were mixed with 5’ 32P- labelled DNA substrates (80 nM) (sequences provided in 
Table 5-8) at a 1:2 molar ratio in Activity buffer (20 mM HEPES, 150 mM NaCl, 20 µg/ml 
bovine serum albumin (BSA), 1 mM MgCl2 or CaCl2 and 0.2 mM TCEP, pH 7.5) in the 
final volume of 10 µl. The control samples contained no protein. 
 
Table 5-8: Oligonucleotides used in Hsmar1 in vitro cleavage assay. 
 
 
Reactions were incubated at 37 °C for 18 h and terminated by Proteinase K (NEB) 
treatment according to the manufacturer’s instructions. DNA was purified by ethanol 
precipitation: the sample was mixed with 1/10 sample volume of 3 M sodium acetate (pH 
5.2), 3 sample volumes of absolute ethanol, and 20 µg of glycogen (Thermo Scientific), 
mixed, and stored at –20 °C overnight. Next, the DNA was resuspended in 10 µl of 
distilled water, 1x Formamide loading buffer (1x TBE, 90% formamide, 0.005% xylene 
cyanol, and 0.005% bromophenol blue) was added, and the sample was analysed by PAGE 
on 12% urea-TBE sequencing gels. The gel [12% Acrylamide: Bisacrylamide (19:1) 
(BioRad), 8.3 M Urea, 1x TBE buffer, 0.17% (w/v) APS, 0.05% (v/v) TEMED] was 
Oligonucleotide Sequence
IR-NTS ACGGCCAGTGAATTCTATTAGGTTGGTGCAAAAGTAATTGCGGTTTTTGC
IR-TS GCAAAAACCGCAATTACTTTTGCACCAACCTAATAGAATTCACTGGCCGT
N1-NTS_1 ACGGCCAGTGAATTCTATTA
N1-NTS_2 GGTTGGTGCAAAAGTAATTGCGGTTTTTGC
N1-TS GCAAAAACCGCAATTACTTTTGCACCAACCTAATAGAATTCACTGGCCGT
N2-NTS_1 ACGGCCAGTGAATTCTATTAGGTTGGTGCAAAAGTAATTGCGGTTTTTGC
N2-TS_1 GCAAAAACCGCAATTACTTTTGCACCAACCTAA
N2-TS_2 TAGAATTCACTGGCCGT
IR-NTS_(-2) ACGGCCAGTGAATTCCATTAGGTTGGTGCAAAAGTAATTGCGGTTTTTGC
IR-TS_(-2) GCAAAAACCGCAATTACTTTTGCACCAACCTAATGGAATTCACTGGCCGT
IR-NTS_(-1) ACGGCCAGTGAATTCTCTTAGGTTGGTGCAAAAGTAATTGCGGTTTTTGC
IR-TS_(-1) GCAAAAACCGCAATTACTTTTGCACCAACCTAAGAGAATTCACTGGCCGT
IR-NTS_(1) ACGGCCAGTGAATTCTACTAGGTTGGTGCAAAAGTAATTGCGGTTTTTGC
IR-TS_(1) GCAAAAACCGCAATTACTTTTGCACCAACCTAGTAGAATTCACTGGCCGT
IR-NTS_(3) ACGGCCAGTGAATTCTATTCGGTTGGTGCAAAAGTAATTGCGGTTTTTGC
IR-TS_(3) GCAAAAACCGCAATTACTTTTGCACCAACCGAATAGAATTCACTGGCCGT
IR-NTS_(4) ACGGCCAGTGAATTCTATTATGTTGGTGCAAAAGTAATTGCGGTTTTTGC
IR-TS_(4) GCAAAAACCGCAATTACTTTTGCACCAACATAATAGAATTCACTGGCCGT
* Mutations are shown in red
In vitro cleavage assays with Hsmar1 wild type and mutated IR*
In vitro cleavage assays with Hsmar1 wild type and V199G
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prepared in a Model SA Sequencing Gel Electrophoresis Apparatus (Biometra). The gel 
was pre-run in 1x TBE buffer at 40 W for 30 minutes before loading and then run for 2 h 
hours at 20 W. After the run was finished, the gel was removed from the glass plates and a 
BAS-SR 2040 Phosphor Screen (FujiFilm) was exposed for 1 hour in a HypercassetteTM 
(Amersham Life Science). The screen was imaged in a Typhoon FLA 7000 
Phosphoimager (GE Healthcare Life Sciences). 
5.3.4 SB in vitro cleavage assay 
SB in vitro cleavage assays (using SB or hsSB proteins; assays in Figure 2-22, Figure 2-23, 
Figure 2-24 and Figure 3-6) were performed according to (Voigt et al., 2016) with some 
modifications. SB proteins were overexpressed in E. coli and purified as described in 
sections 5.2.4 and 5.2.5. The DNA substrates used (Table 5-9) were 5’ 32P-labelled either 
on the NTS or on the TS. SB derivatives (in 20 mM HEPES, 1 M NaCl, 1 mM MgCl2 and 
1 mM DTT, pH 8.0) were mixed with 5’ 32P- labelled Lo, Li, linked Lo-Li DNA or Lo-
TATA DNA substrate (20 nM) (sequences shown in Table 5-9) at a 50:1 molar ratio in 
activity buffer (20 mM HEPES, 100 mM NaCl, 20 µg/ml bovine serum albumin (BSA), 10 
mM MgCl2 and 1 mM DTT, pH 8.0). Reactions were incubated at 25 °C for 18 h, 
processed and analysed on the 12% urea-TBE sequencing gel as previously described in 
section 5.3.3. For assays shown in Figure 2-23, unlabelled Li DNA was added to the 
reactions containing the Lo DNA (20 nM) at 1:2, 1: 1 and 2:1 final molar ratios (Li:Lo). 
 
Table 5-9: Oligonucleotides used in SB in vitro cleavage assay. 
 
Oligonucleotide Sequence
Lo-NTS GAGCTGTGAACTCTACAGTTGAAGTCGGAAGTTTACATACACTTAAG 
Lo-TS CCACGGGACATGTTTATGCTTAAGTGTATGTAAACTTCCGACTTCAACTGTAGAGTTCACAGCTC
Li-NTS GAGCTGTGAACTCGCTATCCAGTGGGTCAGAAGTTTACATACACTAAGTCAT
Li-TS ATGACTTAGTGTATGTAAACTTCTGACCCACTGGATAGCGAGTTCACAGCTC
linked Lo-Li-NTS_1 GAGCTGTGAACTCTACAGTTGAAGTCGGAAGTTTACATACACTTAAG 
linked Lo-Li-NTS_2 GAGCTGTGAACTCGCTATCCAGTGGGTCAGAAGTTTACATACACTAAGTCAT
ATGACTTAGTGTATGTAAACTTCTGACCCACTGGATAGCGAGTTCACAGCTCCCACGGGACATGT
TTATGCTTAAGTGTATGTAAACTTCCGACTTCAACTGTAGAGTTCACAGCTC
Lo-TATA-NTS GAGCTGTGAACTATACAGTTGAAGTCGGAAGTTTACATACACTTAAG 
Lo-TATA-TS CCACGGGACATGTTTATGCTTAAGTGTATGTAAACTTCCGACTTCAACTGTATAGTTCACAGCTC
In vitro cleavage assays with SB or hsSB
linked Lo-Li-TS
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5.3.5 SB in vitro integration assay 
SB integration assays were performed using either 5’ 32P-labelled (assays in Figure 2-25 
and Figure 2-28) or fluorescently labelled 5’ 6-FAM (Fluorescein)-labelled (purchased 
with modification from IDT) (assays in Figure 3-6) DNA substrates. SB proteins were 
overexpressed in E. coli and purified as described in sections 5.2.4 and 5.2.5. The DNA 
substrates used (Table 5-10) were labelled on the TS. 
In radioactive-based assays, SB or hsSB or GST-hsSB (1 µM in 20 mM HEPES, 500 mM 
NaCl and 0.2 mM TCEP, pH 8.0) and 60 nM 5’ 32P-labelled 2nt DNA or 3nt DNA 
(sequences and position of labelling shown in Table 5-10) were preincubated at 25 °C for 1 
h in activity buffer (20 mM HEPES, 100 mM NaCl, 20 µg/ml BSA, 10 mM MgCl2 and 1 
mM DTT, pH 8.0) in a 6 µl reaction volume. 0.6 µg of target plasmid DNA pETMCN-YC 
was then added to a final reaction volume of 10 µl. A 4000 bp DNA (NoLimits 4000bp, 
Thermo Scientific) was also 5’ 32P-labelled (as described in section 5.3.1) and used as 
marker. 
 
Table 5-10: Oligonucleotides used in SB in vitro integration assay. 
 
 
Reactions were then incubated at 37 °C for 2 h (unless otherwise indicated) and terminated 
by Proteinase K (NEB) treatment according to the manufacturer’s instructions. DNA was 
purified by ethanol precipitation: the sample was mixed with 1/10 sample volume of 3 M 
sodium acetate (pH 5.2) and 3 sample volumes of absolute ethanol, mixed, and stored at -
20 °C overnight. Next, the DNA was resuspended in 10 µl of distilled water, 1x GelPilot 
Loading Dye (QIAGEN) was added, and the sample was analysed by gel electrophoresis 
on 1% agarose gel [1% (w/v) agarose powder dissolved in 1x Tris-acetate- EDTA (TAE) 
buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA)] in 1x TAE buffer. The voltage 
of 120 V was applied for 120 minutes. The gel was dried 1 h at 60 °C on a gel drying 
system (AlphaMetrix). A BAS-SR 2040 Phosphor Screen (FujiFilm) was then exposed for 
Oligonucleotide Sequence
2nt-NTS GTTGAAGTCGGAAGTTTACATACACTTAAG 
2nt-TS (6-FAM-)CCACGGGACATGTTTATGCTTAAGTGTATGTAAACTTCCGACTTCAACTG
3nt-NTS TTGAAGTCGGAAGTTTACATACACTTAAG  
3nt-TS (6-FAM-)CCACGGGACATGTTTATGCTTAAGTGTATGTAAACTTCCGACTTCAACTG
6-FAM- 5' Fluorescein
In vitro integration assays with SB or hsSBor GST-hsSB
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1 hour in a HypercassetteTM (Amersham Life Science). The screen was imaged in a 
Typhoon FLA 7000 Phosphoimager (GE Healthcare Life Sciences). 
 
When applicable, reaction samples were also run on a 1% alkaline (denaturing) agarose gel 
[1% (w/v) agarose powder dissolved in 30 mM NaCl, 2 mM EDTA, pH 7.5]. Prior to 
loading, the gel was immersed for 1 hour into alkaline electrophoresis buffer (30 mM 
NaOH, 2 mM EDTA) and 5 volumes of sample and ladder were diluted with one volume 
of 6X alkaline electrophoresis loading buffer (180 mM NaOH, 6 mM EDTA, 18% Ficoll 
400, 0.05% bromcresol green). Samples and ladder were heated at 70 °C for 5 minutes and 
then loaded onto the gel. The voltage of 30 V was applied for 17 hours. After 
electrophoresis, the gel was immersed for 30 minutes in 7% trichloroacetic acid (TCA) and 
then was dried and imaged as previously described. 
 
In fluorescence-based assays, indicated amount of SB or hsSB (in 20 mM HEPES, 500 
mM NaCl and 0.2 mM TCEP, pH 8.0) and 1.5 µM 5’-6 FAM-labelled 2 nt DNA were 
preincubated at 25 °C for 1 h in activity buffer (20 mM HEPES, 100 mM NaCl, 20 µg/ml 
BSA, 10 mM MgCl2 and 1 mM DTT, pH 8.0) in a 6 µl reaction volume. 5 µg of target 
plasmid DNA was then added to a final reaction volume of 10 µl. Reactions were then 
incubated at 37 °C for 2 h and processed by Proteinase K as previously described. DNA 
was purified by ethanol precipitation and resuspended in with GelPilot Loading Dye 
(QIAGEN). The sample was analysed by gel electrophoresis on 1% agarose gel (gel was 
not dried after run) and visualized by fluorescence using a Typhoon FLA 9500 
fluorescence scanner (GE Healthcare).  
5.3.6 Analytical size exclusion chromatography (SEC) 
The oligomeric state of Hsmar1 wild type and W118P proteins and the Mos1-SB chimera 
was determined by analytical size exclusion chromatography (SEC) on a Superdex 200 
3.2/30 column (GE Healthcare) using a ÄKTAmicro liquid chromatography system (GE 
Healthcare) according to the manufacturer’s instructions. Hsmar1 wild type and W118P 
proteins were analysed in 20 mM HEPES, 200 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, 
pH 7.5; the Mos1-SB chimera in 20 mM HEPES, 350 mM NaCl, 1 mM CaCl2 and 0.2 mM 
TCEP, pH 7.5.  
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Formation of nucleoprotein complexes, upon mixing of Hsmar1 and SB derivates with a 
variety of DNA substrates (Table 5-11), was assessed by SEC on Superdex 200 3.2/30 gel 
filtration column (GE Healthcare) using ÄKTAettan and ÄKTAmicro liquid 
chromatography systems (GE Healthcare). 
 
Hsmar1 protein-Nicked NTS DNA complexes (in Figure 2-14) were formed by mixing the 
Hsmar1 wild type (concentration: 90 µM) with Nicked NTS DNA (sequences provided in 
Table 5-11) at a 1:1.5 molar ratio in Gel filtration buffer (Table 5-7). The sample was then 
dialysed in two steps against dialysis buffer A (20 mM HEPES, 500 mM NaCl, 1 mM 
CaCl2 and 0.2 mM TCEP, pH 7.5) and then dialysis buffer B (20 mM HEPES, 200 mM 
NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5). Sample was diluted 4-fold in dialysis 
buffer B before being loaded into the analytic gel filtration column. 
 
Table 5-11: Oligonucleotides used for reconstitution of nucleoprotein complexes of Hsmar1 and SB protein 
derivatives analysed by analytical SEC. 
 
 
Oligonucleotide Sequence
Nicked NTS-TS AAAAACCGCAATTACTTTTGCACCAACCTAATAGGA
Nicked NTS-NTS_1 TCCTATTA
Nicked NTS-NTS_2 GGTTGGTGCAAAAGTAATTGCGGTTTTT
Lo′-NTS GTGAACTCTATACAGTTGAAGTCGGAAGTTTACATACACTTAAGG
Lo′-TS CCTTAAGTGTATGTAAACTTCCGACTTCAACTGTATAGAGTTCAC
Ro′-NTS CCTTAAGTGTATGTAAACTTCCGACTTCAACTGTATAGAGTTCAC
Ro′-TS GTGAACTCTATACAGTTGAAGTCGGAAGTTTACATACACTTAAGG
Li′-NTS GTGAACTCCGTCCAGTGGGTCAGAAGTTTACATACACTAAGTG
Li′-TS CACTTAGTGTATGTAAACTTCTGACCCACTGGACGGAGTTCAC
Ri′-NTS GTGAACTCCGCCCAGTGGGTCAGAAGTTAACATACACTCAATG
Ri′-TS CATTGAGTGTATGTTAACTTCTGACCCACTGGGCGGAGTTCAC
Cleaved Lo-NTS TTGAAGTCGGAAGTTTACATACACTTAAG
Cleaved Lo-TS CTTAAGTGTATGTAAACTTCCGACTTCAACTG
Nicked Lo-NTS_1 CTATACA
Nicked Lo-NTS_2 GTTGAAGTCGGAAGTTTACATACACTTAAG
Nicked Lo-TS CTTAAGTGTATGTAAACTTCCGACTTCAACTGTATAGG
Gapped Lo1-NTS_1 GCCTATA
Gapped Lo1-NTS_2 TTGAAGTCGGAAGTTTACATACACTTAAG
Gapped Lo1-TS CTTAAGTGTATGTAAACTTCCGACTTCAACTGTATAGG
Gapped Lo2-NTS_1 TGAACTCTA
Gapped Lo2-NTS_2 TTGAAGTCGGAAGTTTACATACACTTAAGG
Gapped Lo2-TS CTTAAGTGTATGTAAACTTCCGACTTCAACTGTATAGAGTTCAC
Gapped Lo3-NTS_1 GTGAACTCTA
Gapped Lo3-NTS_2 TTGAAGTCGGAAGTTTACATACACTTAAGG
Gapped Lo3-TS CCTTAAGTGTATGTAAACTTCCGACTTCAACTGTATAGAGTTCACC
Gapped Lo-Li-NTS_1 GTGAACTCTA
Gapped Lo-Li-NTS_2 TTGAAGTCAGAAGTTTACATACACTAAGTG
Gapped Lo-Li-TS CACTTAGTGTATGTAAACTTCTGACTTCAACTGTATAGAGTTCACC
Lo-DBD-NTS TTGAAGTCGGAAGTTTACATACACG
Lo-DBD-TS GTGTATGTAAACTTCCGACTTCAAC
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SB protein-DNA mixtures analysed in Figure 2-17 and Figure 2-18 were formed by mixing 
SB or hsSB proteins (concentration: 23 µM) with different DNA substrates (sequences 
provided in Table 5-11) in Gel filtration buffer (Table 5-7), at specific molar ratios and 
dialyzed step-wise against complex buffers, as indicated in Table 5-12.  
GST-hsSB protein-DNA complexes (Figure 2-28) were formed by mixing GST-hsSB 
fusion protein (concentration: 23 µM) with the Gapped Lo-Li DNA substrate  (sequence 
provided in Table 5-11) in Gel filtration buffer (Table 5-7), at a 1:1.7 molar ratio and 
dialyzed step-wise against complex buffers, as indicated in Table 5-12. 
The SB DBD protein (concentration: 26.86 µM) was incubated with the Lo DBD DNA 
substrate (sequence provided in Table 5-11) in Gel filtration buffer (Table 5-7), at a 1:1.5 
molar ratio and dialyzed step-wise against complex buffers (in order, to buffers A, then B, 
and when applicable, C), as indicated in Table 5-12, to form SB DBD nucleoprotein 
complexes (Figure 2-21). 
 
Table 5-12: Composition and reconstitution of SB protein derivative-DNA complexes analysed by analytical 
SEC. 
 
 
Protein DNA Protein:DNA 
molar ratio 
Dialysis buffer
A) 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
B) 20 mM HEPES, 350 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.6
A) 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
B) 20 mM HEPES, 350 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
A) 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
B) 20 mM HEPES, 350 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
A) 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
B) 20 mM HEPES, 350 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
40 mM HEPES, 500 mM NaCl, 1 mM MgCl2 and 0.2 mM TCEP, pH 7.5
20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 8.0
A) 20 mM HEPES, 500 mM NaCl, 10 mM CaCl2 and 0.2 mM TCEP, pH 8.0
B) 20 mM HEPES, 300 mM NaCl, 10 mM CaCl2 and 0.2 mM TCEP, pH 8.0
A) 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
B) 20 mM HEPES, 300 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
A) 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
B) 20 mM HEPES, 350 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
C) 20 mM AMPD, 250 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 9
A) 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
B) 20 mM HEPES, 350 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
C) 20 mM AMPD, 250 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 9
A) 20 mM HEPES, 500 mM NaCl and 0.2 mM TCEP, pH 7.5
B) 20 mM HEPES, 250 mM NaCl and 0.2 mM TCEP, pH 7.5
A) 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
B) 20 mM HEPES, 350 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5
C) 20 mM AMPD, 250 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 9
AMPD: 2-Amino-2-methyl-1,3-propanediol
SB DBD Lo-DBD 1:1.7
GST-hsSB Gapped Lo-Li 1:1.7
1:1.5
1:1.1
1:1.7
1:1.7
1:1.7
1:1.7
hsSB Gapped Lo-Li 1:1.7
1:1.7
1:1.5
1:2
Li′
Ro′
Lo′
hsSB
SB
SB
Gapped Lo3
Gapped Lo2
Gapped Lo1
Nicked Lo
Cleaved Lo
Ri′
SB
SB
SB
SB
SB
SB
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Together with the protein-DNA mixtures, samples of protein and DNA oligonucleotides 
were analysed by analytical SEC in same complex buffer and at the same concentrations 
used for complex formation. In each case, 30 µl of each sample was filtered using 
Centrifugal Filter Units (Millipore) and loaded onto the gel filtration column prewashed 
with the appropriate buffer. The eluting samples were detected by UV absorbance at 280 
nm (protein) and 260 nm (nucleic acid). The performance of the column and of the 
chromatography system was tested using Gel Filtration Calibration LMW standards 
(Sigma). 
5.3.7 Site-directed protein-DNA disulfide crosslinking 
Specific cysteine-substituted protein mutants were overexpressed in E. coli and purified as 
described in sections 5.2.4 and 5.2.5. DNA oligomers (Table 5-13) were synthetized and 
purified by PAGE (purchased from FUTUREsynthesis, Poznań, Poland). Backbone 
modification to a phosphoramidate with a cystamine functionalization (Figure 5-1) at the 
non-bridging position was present at specific sites of the oligonucleotides (as indicated by 
red asterisks in Table 5-13). DNA was dissolved in TE buffer supplemented with 50 mM 
KCl and annealed at 1 mM final concentration.  
 
Prior to the disulfide crosslinking experiments, the cysteine-substituted mutants were 
tested for their ability to bind the LE DNA substrate by analytical SEC. SB protein mutants 
(concentration: 12.64 µM) were mixed with LE DNA (sequence provided in Table 5-13) at 
a 1:2 molar ratio in Gel filtration buffer (Table 5-7). The mixtures were then dialysed in 
two steps against first dialysis buffer (20 mM HEPES, 500 mM NaCl, 10 mM CaCl2 and 
0.2 mM TCEP, pH 8) and second dialysis buffer (20 mM HEPES, 400 mM NaCl, 10 mM 
CaCl2 and 0.2 mM TCEP, pH 8), and then run on a on a Superdex 200 3.2/30 column (GE 
Healthcare) as described in section 5.3.6. 
 
All crosslinking reactions were performed at a concentration of 6.8 µM protein and 10.2 
µM DNA. Complexes were formed by mixing protein and DNA in Gel filtration buffer 
(Table 5-7), followed by a first dialysis step (against buffer containing 20 mM HEPES, 500 
mM NaCl and 0.5 mM DTT, pH 7.5) and then a second dialysis step alternatively in 
dialysis buffer A (20 mM HEPES and 350 mM NaCl, pH 7.5), B (20 mM HEPES, 350 
mM NaCl and 0.2 mM DTT, pH 7.5) or C (20 mM HEPES, 350 mM NaCl and 0.5 mM 
DTT, pH 7.5) (as indicated in Figure 2-21 C; for complexes shown in Figure 2-21 B and D, 
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the second dialysis step was performed with buffer B only). Samples of the mutant proteins 
alone were subjected to the same dialysis procedure. The crosslinking reaction was carried 
out at 25 °C for 24 h in a 15 µl reaction volume. 4x SDS loading buffer (with or without 
300 mM DTT, as indicated in Figure 2-21) was added to the reactions that were then 
analysed by SDS-PAGE on precast NuPAGE 4-12% Bis-Tris Gels (Invitrogen) (as 
described in section 5.2.6). Apart from Coomassie staining, when applicable, gels were 
also stained with 1x SYBR® Gold Nucleic Acid Gel Stain (Life technologies) and 
visualized in the UV transilluminator (Alpha Innotech) using AlphaImager® HP software 
(Fisher Scientific).  
 
Table 5-13: Oligonucleotides used for SB protein-DNA crosslinking experiments. 
 
 
 
Figure 5-1: Structure of P-cystamine. 
5.3.8 Dissucimidyl suberate (DSS)-mediated crosslinking of the SB 
protein  
All samples (protein alone or nucleoprotein complexes) contained 23.76 µM SB protein 
and were dialyzed first against buffer containing 20 mM HEPES, 500 mM NaCl, 1 mM 
CaCl2 and 0.2 mM TCEP, pH 7.5 and then against a second dialysis buffer (20 mM 
HEPES, 350 mM NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5). Nucleoprotein 
Oligonucleotide Sequence
LE-NTS TTGAAGTCGGAAGTTTACATACACTTAGG
LE-TS CCTAAGTGTATGTAAACTTCCGACTTCAACTG
LE1-NTS TTGAAGTCGGAAGTTTACATACACTTAGG
LE1-TS CCTAAGTGTATGTAAACTTCCGACTTCA*ACTG
LE2-NTS TTGAAGTCGGAAGTTTACATACACTTAGG
LE2-TS CCTAAGTGTATGTAAACTTCCGACTTC*AACTG
LE3-NTS TTGAAGTCGGAAGTTTACATACACTTAGG
LE3-TS CCTAAGTGTA*TGTAAACTTCCGACTTCAACTG
LE4-NTS TTGAAGTCGGAAGTTTACATACACTTAGG
LE4-TS CCTAAGTGTATGTAAAC*TTCCGACTTCAACTG
Red asterisks (*) mark the site of the P-cystamine modification on the backbone phosphate.
Structure of P-cystamine
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complexes were formed by mixing SB protein and Gapped Lo-Li DNA (sequence in Table 
5-11) in Gel filtration buffer (Table 5-7) and they were subjected to a third dialysis step 
against buffer containing 20 mM 2-amino-2-methyl-1,3-propanediol (AMPD), 250 mM 
NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 9.0. All samples were incubated at 25 °C for 6 
h in a 10 µl reaction volume. Then DSS [Thermo Fisher Scientific; dissolved in 
dimethylformamide (DMF)] at a final concentration of 2.5 µM was added to the samples 
for crosslinking. DMF only was added to control samples. All samples were incubated at 
25 °C for 30 minutes. Crosslinking reactions were then stopped by adding 1 M TrisHCl pH 
7.5 and by incubation at 25 °C for 15 minutes. Finally, samples were analysed by SDS-
PAGE (as described in section 5.2.6) after addition of 4x SDS loading buffer (containing 
100 mM DTT).  
5.3.9 Site-specific cysteine-based crosslinking of the SB protein 
Specific protein mutants (SBR14C-C176S-I212S, SBD17C-C176S-I212S and SBC176S-I212S) were 
overexpressed in E. coli and purified as described in sections 5.2.4 and 5.2.5. All samples 
(protein alone or nucleoprotein complexes) contained 22 µM SB derivatives and were 
dialyzed first against buffer containing 20 mM HEPES, 500 mM NaCl, 1 mM CaCl2 and 
0.2 mM TCEP, pH 7.5 and then against a second dialysis buffer (20 mM HEPES, 350 mM 
NaCl, 1 mM CaCl2 and 0.2 mM TCEP, pH 7.5). The protein alone samples were subjected 
to a third dialysis step against buffer containing 20 mM HEPES, 350 mM NaCl, 1 mM 
CaCl2, pH 7.5.  Nucleoprotein complexes were formed by mixing SBD17C- C176S-I212S protein 
and Gapped Lo3 DNA (sequence in Table 5-11) at 1:1.5 ratios in Gel filtration buffer 
(Table 5-7) and, after the above-mentioned two-step dialysis, they were subjected to a third 
dialysis step against buffer containing 20 mM AMPD, 250 mM NaCl, 1 mM CaCl2 and 0.2 
mM TCEP, pH 9.0. All samples were incubated at 25 °C for 48 h in a 10 µl reaction 
volume. Finally, samples were analysed by SDS-PAGE (as described in section 5.2.6) after 
addition of 4x SDS loading buffer (containing 300 mM DTT or no DTT, as indicated in 
Figure 2-27).  
5.3.10 Limited proteolysis of SB proteins 
Trypsin (Roche) was resuspended in 1% acetic acid in appropriate concentrations to obtain 
working aliquots that were snapped freeze in liquid nitrogen, and stored at -80 °C. Stock 
solution of protease were thawed and transferred to ice quickly before use. After 
Biophysical methods 
   144
purification (see section 5.2.5), SB and hsSB proteins were dialysed against buffer 
containing 1x PBS and 300 mM NaCl, pH 7.5. Appropriate amounts of trypsin were mixed 
with 45 µg SB or hsSB protein to molar ratios of 1:100 or 1:1000 in a final reaction 
volume of 90 µl. All samples were incubated at 25 °C. After the desired incubation time, 
reactions were stopped by adding 4x SDS loading buffer and by incubating them at 70 °C 
for 10 minutes, followed by boiling at 98 °C for 5 minutes. Samples were then analysed by 
SDS-PAGE on precast NuPAGE 4-12% Bis-Tris Gels (Invitrogen) (as described in section 
5.2.6). 
5.3.11 Analysis of SB proteins’ stability  
Following purification (section 5.2.5), SB and hsSB proteins were dialysed against buffer 
containing 1x PBS and 300 mM NaCl, pH 7.5. 10 µg SB or hsSB protein were incubated at 
37 °C in a final volume of 20 µl. After the desired incubation time, reactions were stopped 
by adding 4x SDS loading buffer (containing 300 mM DTT or no DTT, as indicated in 
Figure 3-4) and by boiling at 98 °C for 5 minutes. Samples were then analysed by SDS-
PAGE on precast NuPAGE 4-12% Bis-Tris Gels (Invitrogen) (as described in section 
5.2.6). 
5.4 Biophysical methods 
5.4.1 In vitro fluorescence-based oligomerization assay 
A1, B1, A1-SB, B1-SB, A1-Hsmar1 and B1-Hsmar1 proteins were overexpressed in E. 
coli and purified as described in sections 5.2.4 and 5.2.5. Proteins [1 µM in 1x PBS, 1 M 
NaCl, 5% (v/v) glycerol, 1 mM MgCl2 and 0.2 mM TCEP, pH 7.5] were measured directly 
or upon mixing with DNA (Cleaved Lo for SB and Cleaved IR for Hsmar1, see sequences 
in Table 5-14) at a 1:4 molar ratio in 40 mM HEPES, 200 mM NaCl, 5 mM MgCl2 and 0.2 
mM TCEP, pH 7.5. Samples were incubated for the indicated incubation times at 4 ̊C and 
50 µl aliquots of each sample were measured in a 96- well plate reader (BioTeK Synergy4 
from BioTeK Germany, Bad Friedrichshall, Germany) at 22 ̊C at excitation wavelength 
535 nm. Emission was recorded at 600 nm. To evaluate statistical significance of the 
measurements, two-tailed two-sample t-test was performed. 
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Table 5-14: Oligonucleotides used for in vitro fluorescence-based oligomerization assay. 
 
5.4.2 Circular dichroism spectroscopy 
SB and hsSB proteins were overexpressed in E. coli and purified as described in sections 
5.2.4 and 5.2.5. After purification, protein samples were dialyzed against buffer containing 
1x PBS and 300 mM NaCl, pH 7.5. Circular dichroism spectra of the protein samples (200 
µl at a concentration of 7.6 µM) were recorded on a Jasco J-715 spectropolarimeter using 
fused silica cuvettes (1 mm palmlenght) that are maintained at temperatures between 10-
25° C (± 0.1 °C) using a Jasco PTC-348W peltier temperature control system. Thermal 
stability was assessed by monitoring the ellipticity at 206 nm while heating the sample at a 
rate of 1 °C/min. Data were analysed using the JASCO software program. 
5.5 Small Angle X-ray Scattering  
5.5.1 Principles of Small Angle X-ray Scattering  
Small Angle X-ray Scattering (SAXS) has been employed in this work to obtain low-
resolution structural information on the Hsmar1 transposase. Therefore, a brief 
introduction to the basic principles of SAXS is provided in this section [composed based 
on (D. Svergun et al., 2003)]. SAXS is an experimental technique that provides structural 
analysis and physical information for a variety of 1–100 nm and beyond particle systems. 
In biological applications, SAXS is used to determine the structure of biological 
macromolecules in terms of average particle size and shape.  
 
In comparison to other structural biology methods, as nuclear magnetic resonance (NMR) 
and X-ray crystallography, SAXS provides some technical advantages and thus, represents 
a powerful complementary tool for these techniques. For example, application of solution 
NMR is limited to protein size, whereas SAXS can be used for studying small molecules as 
well as for large multi-molecular assemblies. Structure determination by X-ray 
crystallography may take several weeks or even years and requires generation of well-
diffracting macromolecular crystals, whereas SAXS measurements take days and the 
Oligonucleotide Sequence
Cleaved Lo-NTS TTGAAGTCGGAAGTTTACATACACTTAAG
Cleaved Lo-TS CTTAAGTGTATGTAAACTTCCGACTTCAACTG
Cleaved IR-NTS GGTTGGTGCAAAAGTAATTGCGGTTTTT
Cleaved IR-TS AAAAACCGCAATTACTTTTGCACCAACCTAA
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macromolecule can be analysed in solution. The SAXS method is accurate, mostly non-
destructive and usually requires minimum amounts of sample. However, with SAXS it is 
not possible to obtain structural information of macromolecules at atomic resolution. 
 
Conceptually, SAXS experiments are simple: a solution of macromolecules is exposed to a 
highly collimated X-ray beam (with wavelength λ typically around 0.15 nm) that scatters 
elastically between 0 and 5 degrees (“small angles”). Biological SAXS is often performed 
at synchrotron radiation sources because biological molecules normally scatter weakly and 
the measured solutions are dilute. The scattered intensity I(q) is recorded on a detector and 
plotted as a function of momentum transfer q (q= 4πsinθ/λ, where 2θ is the angle between 
the incident and scattered radiation). The random positions and orientations of particles in 
solution result in an isotropic intensity distribution that, for monodisperse non-interacting 
particles, is proportional to the scattering from a single particle averaged over all 
orientations.  
From the intensity of the macromolecule-containing solution the scattering from only the 
solvent is subtracted to obtain a final scattering curve. Generally, in a SAXS experiment, 
several solutions with varying concentrations of the macromolecule are measured to check 
that concentration effects do not affect the scattering curve. The SAXS curve contains 
information about the gross structural features -shape, quaternary and tertiary structure- of 
the macromolecule. At low resolution (2-3 nm resolution) the curves are rapidly decaying 
functions of q essentially determined by the particle shape and differ between proteins with 
different folds and molecular masses. At medium resolution (2 to 0.5 nm) the differences 
are already less pronounced and above 0.5 nm resolution all curves are very similar. 
 
Data analysis of the extrapolated scattering curve begins with the inspection of the start of 
the scattering curve in the region around q=0. If the region follows the Guinier 
approximation, the sample is not aggregated. The lowest resolution portion of the SAXS 
data curve is dictated by a single size parameter, the radius of gyration Rg, which is the 
square root of the average distance of each scatterer from the particle center. For ideal 
monodisperse systems, the so-called Guinier plot [Log(I(q)) versus q2] should be a linear 
function, whose slope yields the radius of gyration Rg and intercept gives the forward-
scattered intensity at zero angle, I(0). Whereas the radius of gyration Rg characterizes the 
particle size, the parameter I(0) is useful to determine the molecular mass. Furthermore, by 
computing the Fourier transform of the scattering curve into real space, it is possible to 
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derive a pair-distribution function P(r), which provides information on the distances 
between electrons in the scattering sample and permits to calculate the maximum linear 
dimension (Dmax) of the macromolecule. Moreover, the Porod plot [q4 I(q) versus q] 
provides other useful information such as an estimation of the particle volume (Porod 
volume). 
 
From the SAXS curve is also possible to obtain an ab initio low-resolution model of the 
macromolecule. However, reconstruction of a three-dimensional model of an object from 
its one-dimensional scattering pattern is a challenging task. In fact, SAXS data does not 
imply a single solution and thus, reconstruction of the 3D structure might result in large 
number of different models. One of the available approaches is to use an ensemble of 
dummy residues  (each amino acid is represented as one entity) and simulated annealing to 
build a locally “chain-compatible” dummy residue model inside a sphere of diameter 
Dmax, as implemented in the program GASBOR (D. I. Svergun et al., 2001). Furthermore, 
the X-ray scattering data can be used to fit separate domains (X-ray or NMR structures) 
into the SAXS envelope to generate models of macromolecular complexes. 
5.5.2 Experimental procedures 
SAXS data were collected at 293 K at 0.992 Å on beamline BM-29 at the European 
Synchrotron Radiation Facility (ESRF, Grenoble, France). The sample to detector distance 
was 2.87 m, and scattering data were collected within the momentum transfer  (q) range 
0.001–0.50 Å. Data were collected in multiple 1 s frames, inspected and averaged in 
PRIMUS (Konarev et al., 2003) normalized to the incident beam intensity and the 
scattering of the buffer subtracted. To check for concentration-dependent effects, scattering 
data were collected from Hsmar1 samples (Hsmar1 wild type and Hsmar1 W188P 
proteins) (40µl in 20 mM HEPES, 500 mM NaCl, 0.2 mM TCEP, pH 7.5) at 1.0 mg/ml, 
2.0 mg/ml, 3.0 mg/ml and 4.0 mg/ml. The averaged curved shown in Figure 2-12 
correspond to 1.0 mg/mL solution. SAXS data were calibrated against bovine serum 
albumin (BSA) at 4.3 mg/ml. Radius of gyration Rg and forward-scattered intensity at zero 
angle I(0) were determined by Guinier analysis. The SAXS data were transformed using 
GNOM (Petoukhov et al., 2007) into a distribution of paired distances, P(r), from which 
the maximum dimension (Dmax) of the transposase and the Porod volume (Porod, 1982) 
were obtained. An estimate of the molecular mass (Mw) of the transposase was obtained 
from the Porod volume. Low resolution protein structure models were reconstructed ab 
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initio from the SAXS data by a chain-like ensemble of dummy residues using GASBOR 
(D. I. Svergun et al., 2001). No symmetry was imposed for the calculations. Theoretical 
scattering curves for the Mos1 PEC and apo models were calculated from their 
crystallographic atomic coordinates using CRYSOL (D.I.  Svergun et al., 1995). 
5.6 X-ray crystallography methods 
5.6.1 Principles of biomolecular X-ray crystallography 
X-ray crystallography has been employed in this work as a technique for macromolecular 
structure determination. Therefore, a brief introduction to the basic principles of 
biomolecular X-ray crystallography is provided in this section [composed based on (Rupp, 
2010)]. X-ray crystallography is a powerful method that allows obtaining accurate and 
precise molecular structures of macromolecules (even of large molecular assemblies) at the 
atomic resolution level. About 90% of the structures deposited in Protein Data Bank (PDB) 
have been determined by X-ray crystallography.  
 
In order to apply X-ray crystallography, well-ordered crystals of the macromolecules of 
interest need to be produced in the first place. Crystals are periodic assemblies of 
macromolecules, held together by weak inter-molecular interactions. In order to form 
crystals, the protein solution must be brought into a supersaturated, thermodynamically 
metastable state, in which crystal nucleation and growth can occur while the solution 
equilibrates. Supersaturation is achieved through the addition of crystallizing (or 
precipitating) agents such as salts or poly-alcohols, and by the manipulation of various 
parameters that include temperature, ionic strength and pH. This state should be reached 
slowly enough to allow the growth of single, well-ordered crystals. The most common 
technique used for crystal growth is the vapour diffusion method, where a drop containing 
the protein, buffer and precipitant is allowed to equilibrate with a larger reservoir 
containing similar buffers and precipitants in higher concentrations. Searching for 
successful crystallization conditions requires sampling of a vast combination of 
parameters. Moreover, several crystallization methods, in combination with post-
crystallization treatments, may be applied to obtain well-ordered crystals that diffract to 
atomic resolution. 
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Once crystals are obtained, a single-crystal diffraction experiment is carried out. Briefly, a 
single crystal mounted on a goniostat is exposed to a finely collimated, intense X-ray beam 
in the 5-20 keV energy range (circa 2.3 to 0.6 Å wavelength). Individual diffraction images 
are recorded on an area detector during small rotation increments of the crystal and 
combined into a diffraction data set. Since crystals are highly sensitive to radiation damage 
by the intense ionizing X-ray radiation, cooling of crystals to cryogenic temperatures (100 
K) is general practice. The diffraction images consist of spots, also known as reflections, 
which are created by scattered X-rays in specific directions of constructive interference. 
For each reflection, its position hkl (describing the direction of diffraction) and its intensity 
Ihkl can be observed directly from the diffraction pattern. The diffraction images are not 
direct pictures of the molecule, rather transforms of the molecular shape into diffraction 
space (called reciprocal space). Each reflection position in the diffraction image (or the so-
called reciprocal lattice) corresponds to a specific real lattice plane in the crystal and 
contains information about the entire molecular structure. 
 
The basic mathematical tool of back-transformation from reciprocal diffraction space into 
direct molecular space is the Fourier transform (FT). FT allows deconvolution of any 
function into the sum of a series of sine functions with their individual amplitudes, 
frequencies and phase shifts. Each diffracted X-ray beam that results in a reflection spot in 
the diffraction experiment corresponds to one term in the Fourier sum that describes the 
image (precisely the electron density) of the macromolecule of interest. This means that if 
the amplitude, frequency, and the phase of each individual collected reflection (which 
together constitute the structure factor function) is available, the electron density 
distribution of the diffracting object can be reconstituted by performing an inverse FT. 
 
However, the parameters available for all reflections in the diffraction pattern comprise 
their frequency, the angle of diffraction (θ; described by position hkl) and the amplitude 
(described by intensity Ihkl), whereas the phase information is missing from the obtained 
diffraction pattern. For this reason, in order to complete the Fourier summation, phase 
information has to be estimated separately. For this, the phases can be derived 
experimentally (experimental phasing) or from a structurally-related macromolecular 
model (molecular replacement). 
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The molecular replacement (MR) method is a phasing technique that can be applied when 
a structurally similar search model (sequence identity of approximately 30%) to a molecule 
in the target crystal structure is available. Thus, the phase values from the structure factors 
of the model are used as initial phase estimates for the new macromolecular structure. MR 
requires a rotational and translational search to determine the proper orientation and 
location of the search model in the unknown crystal structure. The overlap between search 
model and target structure is generally assessed by comparing the observed and calculated 
structure factor amplitudes or Patterson functions (density functions calculated as the FT of 
the squared structure function amplitudes without phases) of the data and the search model. 
 
Experimental phasing by isomorphous replacement involves collecting at least two 
diffraction datasets: one on a crystal of the native protein of interest and one on its heavy 
atom derivative. The heavy atom derivative crystals can be produced by soaking of already 
formed crystals in heavy atom-containing crystallization solutions, or by heavy atom 
derivatization of the macromolecule, for example by replacing methionines with 
selenomethionines in a protein. Heavy atoms contain large number of electrons and 
therefore scatter X-rays strongly, resulting in increased reflection intensities at specific 
positions. The differences between the spot intensities in the diffraction patterns of native 
and derivative datasets can be used to determine the heavy atom substructure. Therefore, 
the phases for the heavy atoms can be calculated, which provide the initial phase estimate 
for the entire protein structure. Depending on the number of different derivative crystals 
used, the method is referred to as single isomorphous replacement (SIR) or multiple 
isomorphous replacement (MIR).  
 
Experimental phasing can be also applied by measuring the so-called anomalous scattering 
(or anomalous dispersion) that corresponds to a phase shift of scattered photons by heavy 
atoms. This phase shift can be used to locate the heavy atom positions with Patterson 
methods, and then to determine the phases of all reflections. Commonly used is the multi-
wavelength anomalous dispersion (MAD) phasing that uses multiple datasets collected on 
the same crystal at wavelengths corresponding to the absorption peak, inflection point, and 
remote positions on the heavy atom’s absorption spectrum. If crystals are particularly 
sensitive to radiation damage, only one dataset at the absorption peak is collected and thus 
single-wavelength anomalous diffraction (SAD) phasing is performed. 
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Once the phases are estimated by any of the phasing methods described, an initial electron 
density map can be calculated from the structure factors. Based on the map, a model of the 
macromolecule is built either automatically or manually. The obtained initial phases are 
only approximate, and thus need to be further refined in an iterative process that includes 
manual model building and real space and reciprocal space refinement. During model 
building and refinement, atomic coordinates are optimized to maximize the agreement 
between measured and calculated structure factors. The fit of the model to the experimental 
data is constantly monitored by specific statistical indicators (R-factors). The final model is 
also validated in terms of protein chemistry and geometry, and if satisfactory, it is 
deposited in the PDB for public use. 
5.6.2  Preparation of protein-DNA complexes for crystallization 
For crystallization experiments, Hsmar1 protein-Nicked NTS DNA complexes were 
prepared as for SEC experiment (section 5.3.6) with at least 95%-pure protein, as 
determined by SDS-PAGE analysis, and PAGE purified oligonucleotides (IDT). Moreover, 
prior to its use, the required amount of Nicked NTS DNA was lyophilized using a vacuum 
concentrator (Vacufuge plus, Eppendorf) and Hsmar1 wild type protein (in Gel filtration 
buffer) was added to lyophilized DNA at a 1:1.5 molar ratio. The mixture was then 
subjected to dialysis as described in section 5.3.6.  
 
SB DBD protein-Lo DBD DNA complexes were prepared as for SEC experiment (section 
5.3.6). The dialysed protein-DNA mixture was then concentrated to a protein concentration 
of 3.6 mg/ml using Vivaspin® Turbo 2 concentrators (molecular weight cut-off of 3 kDa, 
Sartorius stedim biotech). The concentration of the protein was estimated assuming that the 
protein amount remained the same before and after complex formation and concentration. 
5.6.3 Crystallization of protein-DNA complexes and post-
crystallization treatments 
In order to form crystals of macromolecular complexes, the macromolecular solution has 
to be brought to a supersaturated state. For this, the vapour diffusion method was used, in 
which the supersaturation of the macromolecule is accomplished by increasing the 
concentration of the macromolecule and the precipitant simultaneously. In detail, a 0.1- 2 
µl drop of the macromolecule solution is mixed with a 0.1-2 µl drop of the precipitant 
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solution and the mixture is placed in a sealed environment with a larger (0.5-1 ml) 
reservoir of the precipitant solution.  
 
The initial crystallization screens were prepared by the EMBL Crystallization Facility and 
included commercially available crystallization screens The Classics Suite (QIAGEN) and 
PEGs II (QIAGEN), as well as the JCSG+ screen (Page et al., 2003) prepared in-house. 
The screens were prepared in 96-well MRC sitting drop Crystallization PlatesTM 
(Molecular Dimensions) using a Mosquito Crystallization Robot (TTP Labtech). To a 0.1 
µl drop of the reservoir precipitant solution, 0.1 µl of the protein-DNA complex solution 
was added and the plates were sealed. The screens were handled and stored for crystal 
growth at 20 °C. 
 
Crystals likely containing SB DBD-Lo DBD DNA were obtained in 18% (w/v) PEG4000 
and 0.1 M sodium acetate, pH 4.6. However, the presence of protein in the crystals could 
not be unambiguously assed and crystal optimization attempts resulted in thin clusters of 
needles, incompatible with data collection. 
For Hsmar1 protein-DNA crystals, the initial condition that yielded small crystals [20% 
(w/v) PEG3350 and 0.2 M sodium thiocyanate, pH 6.9] was further optimized to yield 
larger crystals. For this, fine screening of varying PEG3350 concentrations against varying 
pH was manually set up in 24-well crystallization plates (Hampton Research), as shown in 
Figure 5-2. After 500 µl of specified solution was placed in the reservoir, a 1-2 µl drop of 
the mother liquor was set on the glass cover slip and 1-2 µl of Hsmar1 protein-DNA 
complex solution was added depending on the desired ratios. The cover slips were placed 
over the reservoir and sealed, allowing for vapour diffusion to occur. The plates were set 
up and stored at 20 °C. This setup allowed for fine-tuning of parameters such as precipitant 
amount, pH, protein-DNA complex concentration, and precipitant-to-complex ratio in 
large drops that supported growth of large crystals. Additionally, sitting drop 24-well 
plates were also set up but yielded no crystals. 
Crystals obtained after optimization were washed several times in drops containing the 
crystallogenic condition and were finally dissolved in water, and analysed by SDS-PAGE 
using precast NuPAGE 4-12% Bis-Tris Gels (Invitrogen) stained with PierceTM Silver 
Stain Kit (Thermo-Fischer) according to the manufacturer’s instructions. 
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In addition, crystallization experiments were carried out at the High Throughput 
Crystallization Laboratory of the EMBL Grenoble Outstation (in collaboration with J.A. 
Márquez Laboratory) using the sitting-drop vapour-diffusion method and CrystalDirect 
plates (MiTeGen, Ithaca, USA). Crystallization experiments were set up with 500 nl 
sample and 500 nl crystallization solution on the inner surface of the films within a 
CrystalDirect plate using a Cartesian PixSys robot (Cartesian Technologies). The plates 
were sealed on their upper side with CrystalClear film (Hampton Research) and the 
experiments were incubated at 20 °C in a RockImager system (Formulatrix Inc.). 
 
 
 
 
Figure 5-2: Optimization screen of crystallization parameters (precipitant concentration and pH) in 24-well 
crystallization plates. All wells contained 0.1 M HEPES buffer at the indicated pH, PEG 3350 at the 
indicated concentrations and 0.2 or 0.25 M sodium thiocyanate. 
 
In order to further improve the diffraction power of the Hsmar1 protein-DNA crystals, the 
streak seeding method was used. In brief, the biggest crystals obtained from SCREEN 2 
and 3 (growing in 20-25% (w/v) PEG 3350, 0.2-0.25 M sodium thiocyanate and 100 mM 
HEPES, pH 7.5) were crushed into micro crystals with a probe and transferred to a Seed 
Bead tube (Hampton Reseach) and treated according to the manufacturer’s instruction to 
obtain a seed stock. Different dilutions of this seed stock were used for the streak seeding 
experiments, in which a seeding probe was used to deposit the seeds in a recipient drop 
containing the sample and reagent, pre-equilibrated for two hours (Figure 5-3). Streak 
seeding was carried out by running the tip of the probe in a straight line across the middle 
SCREEN 1 SCREEN 3
% (w/v) PEG3350
10 15 17 19 19.5 20 20.5 21 23 25 27 30
HEPES pH 1 2 3 4 5 6 HEPES pH 1 2 3 4 5 6
6.0 A 6.0 A
6.5 B 6.5 B
6.8 C 6.8 C
6.9 D 6.9 D
SCREEN 2 SCREEN 4
% (w/v) PEG3350 % (w/v) PEG3350
10 15 17 19 19.5 20 20.5 21 23 25 27 30
HEPES pH 1 2 3 4 5 6 HEPES pH 1 2 3 4 5 6
7.0 A 7.0 A
7.2 B 7.2 B
7.5 C 7.5 C
8.0 D 8.0 D
% (w/v) PEG3350
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of the drop. This procedure was repeated sequentially in more drops to obtain dilutions of 
the original seed stock. 
 
 
 
Figure 5-3: Seeding screen in 24-well crystallization plates. All wells contained 0.1 M HEPES buffer, pH 
7.5, PEG 3350 at the indicated concentrations and 0.2 or 0.25 M sodium thiocyanate. 
As post-crystallization treatments, dehydration protocols and annealing have been 
employed (Heras et al., 2005). Crystal dehydration was performed by equilibrating the 
protein crystals over a reservoir with a higher percentage of precipitant (up to 25% PEG 
3350). The hanging drop containing the crystals was allowed to dehydrate for 24 h. The 
annealing method was applied by transiently returning the flash-cooled crystal to ambient 
temperature. However, application of both dehydration and annealing protocols failed to 
improve the crystal diffraction quality. 
5.6.4 Heavy atom derivative crystals 
Heavy atom derivatization of Hsmar1 crystals was performed by crystal soaking. The 
platinum and cadmium derivative crystals were prepared by transferring the crystals to a 2 
µl drop of the reservoir solution supplemented with 1 mM K2PtCl4, K2Pt(CN)4 or CdI2 
(Heavy Atom ScreensTM, Hampton Research) for 5-30 minutes, and then transferring the 
crystal back to a fresh drop of reservoir solution (back-soaking). The crystal were 
immediately fished and frozen in liquid nitrogen as described in section 5.6.5.  
Additionally, SeMet derivative crystals were obtained with purified SeMet-containing 
Hsmar1, following the same complex formation and crystallization protocols as for native 
complex crystallization (see sections 5.2.4 and 5.6.3). 
5.6.5 Data collection 
Crystals obtained from 24-well plates were fished using 0.05 – 0.4 mm CryoLoops 
(Hampton Research) and transferred immediately into liquid nitrogen-containing 
MicroTubes (Hampton Research). Alternatively, crystals were first flash-cooled to liquid 
SEEDING SEEDING
SCREEN 1 0.2 M NaSCN SCREEN 2 0.25 M NaSCN
PEG3350% 1 2 3 4 5 6 PEG3350% 1 2 3 4 5 6
19% A 19% A
17% B 17% B
15% C 15% C
13% D 13% D
---dilutions--->---dilutions--->
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nitrogen temperatures by placing them in 100 K nitrogen gas cold stream and then 
transferred to liquid nitrogen-containing MicroTubes for storage. Crystals were transferred 
into solutions containing cryoprotecting agents [the optimal one being a solution of 2,3-
butanediol at 20% (w/v)] before being frozen in liquid nitrogen. The crystals were 
transferred to the X-ray source in Cryogenic Dewar Flasks (TED PELLA) under cryogenic 
conditions. 
 
X-ray diffraction data from native and derivative Hsmar1 protein-Nicked NTS DNA 
crystals were collected by the rotation method on tuneable beamlines ID-23 and ID-29 at 
the European Synchrotron Radiation Facility (ESRF) in Grenoble, France and on beamline 
P13 Petra-III in Hamburg, Germany. The samples were mounted onto the goniometer by 
an automatic sample changer and rotated as the data were collected. The best native dataset 
(1774 images) was collected on beamline P13 Petra-III at 12.7 keV using 0.15° oscillation 
and 0.037 sec exposure. 
  
The best SeMet derivative datasets were collected at multiple wavelengths (peak and 
inflection point of the anomalous signal as well as at the high energy remote) on beamline 
P13 Petra-III using 0.10° oscillation and 0.097 sec exposure. The platinum and cadmium 
derivative crystals did not show any diffraction. At PetraIII P13 beamline, data collection 
was also performed on native crystals close to the absorption edge of calcium (6 keV) 
using 0.10° oscillation and 0.097 sec exposure. 
5.6.6 Data processing 
All datasets were initially processed in XDS, part of the XDS Program Package (Kabsch, 
2010), to select the datasets with highest resolution and the best statistics. In addition, due 
to high diffraction anisotropy, available datasets, alone or in combination, are being 
currently processed by the STARANISO server (Tickle et al., 2017 ). Together, the 
information from the data statistics table gave an indication for which datasets should be 
chosen for further data processing, and these datasets were internally scaled in XSCALE 
from the XDS Program Package, producing a final table of data statistics that are reported 
in the results sections (Figure 2-16). The reflection file was then converted to .mtz format 
using XDSCONV from the XDS Program Package, and the resulting reflection file was 
used for first structure solution attempts. 
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The initial attempts to solve the crystal structure of the crystallized complex used the 
molecular replacement method. For this, various homologous transposases structures and 
structure-derived models were used as search models in Phaser-MR (McCoy et al., 2007), 
part of the Phenix suite. However, no correct solutions could be unambiguously identified. 
5.7 Structural modelling 
 
The N-terminal SB DNA binding domain, containing the dimer interface between two 
HTH domains, was modelled based on the Mos1 DBD [3HOT, (Richardson et al., 2009)] 
using I-TASSER (Yang et al., 2015). The full length Hsmar1 transposase apo dimer was 
modelled using the crystal structure of the Hsmar1 catalytic domain dimer and homology 
models of HTH1 and HTH2 [generated based on Mos1 by threading in Phyre2 (Karaca et 
al., 2011; Kelley et al., 2015)]. An ensemble of the Hsmar1 domains has been iteratively 
constructed and minimized against the low-resolution SAXS data [calculating the 
corresponding theoretical scattering curves with CRYSOL (D.I.  Svergun et al., 1995)].  
Flexible parts have been manually built in Coot (Emsley et al., 2004). The Hsmar1 PEC 
model was generated based on the Mos1 PEC [PDB: 3HOT, (Richardson et al., 2009)] 
using I-TASSER (Yang et al., 2015).  Finally, all the assembled models were refined in 
HADDOCK (van Zundert et al., 2016). The obtained models were visualized using the 
PyMOL Molecular Graphics System (Version 1.5.0.4, Schrödinger, LLC). 
5.8 Cell biology methods 
5.8.1 Cell culture 
HeLa cells [American Type Culture Collection (ATCC); provided by Protein Expression 
and Purification Core Facility, EMBL Heidelberg] were maintained in Dulbecco's 
Modified Eagle Medium [DMEM low Glucose medium (Gibco)] supplemented with 10% 
(v/v) fetal bovine serum (FBS; Sigma) and 2 mM L-glutamine (Life Technologies). 
Chinese hamster ovary (CHO) cells (Invitrogen; R758-07) were maintained in Ham’s F12 
K (Kaighn’s) medium (Gibco) containing 10% (v/v) FBS. Mouse ESCs (mESCs) [AB2.2 
ES cell line (Mus musculus), ATCC, courtesy of S. Henkel, Neveu Laboratory, EMBL 
Heidelberg] were maintained without feeders in “serum plus LIF” medium composed of 
DMEM (high glucose, no glutamine, with sodium bicarbonate, Invitrogen) supplemented 
with 15% (v/v) ES-qualified fetal calf serum (EmbryoMax, Millipore), 10 ng/ml murine 
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Leukemia inhibitory factor (LIF; Protein Expression and Purification Core Facility, EMBL 
Heidelberg, Germany), 1× non-essential amino acids, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.1 mM β-mercaptoethanol 
(all Invitrogen) on culture dishes (Nunc) coated with 0.1% (v/v) gelatine (Sigma) solution.  
 
The medium of all cell lines was changed daily and cells were passaged every other day 
with 0.05% Trypsin-EDTA (Invitrogen) at passaging ratios of 1/6–1/8. All cell lines were 
maintained at 37 °C in a humidified 5% CO2 atmosphere in a HeracellTM 150i (Thermo 
Fisher Scientific).  
5.8.2 In vivo transposition assay using SB coding plasmids 
Transposition efficiency of SB and hsSB proteins was quantified in HeLa cells using a 
modified form of the protocol described by Ivics and colleagues (Ivics et al., 1997). One 
day prior to transfection, cells were plated in a 6-well plate (Sigma) in 2 ml of complete 
media at a density of 3 × 105 cells per well. Transfection was performed using JetPei® 
DNA Transfection Reagent (Polyplus-transfection) at 60-80% of cell confluency following 
the manufacturer’s instructions. 0.5 µg of SB_PGK-neo plasmid (containing the neomycin 
resistance gene flanked by the SB transposon ends) and 0.5 µg (unless otherwise indicated) 
of the SB_fl_pCMV(CAT)T7 (Mates et al., 2009) or the SB-C176S-
I212S_pCMV(CAT)T7  plasmid (encoding SB or hsSB protein, respectively) were mixed 
prior to transfection. All the transfection reactions were filled up to the same total DNA 
amount using a filler plasmid (pUC19). The recommended amount of DNA/JetPei® 
mixture was added in a drop-wise manner to the cells. 
 
After a recovery period of 24 h, transfected cells were trypsinized in a total volume of 1 ml 
(in one well of a 6-well plate) and 10 or 100 µl aliquots of the cell suspension were re-
plated (1:100 and 1:10, respectively) onto 10 cm dishes (Sigma). The medium was 
exchanged for selection medium containing 1 mg/ml G-418 (Geneticin, Life Technologies) 
24 h later. Cells were selected for two weeks by replacing the selection medium twice a 
week. After selection, surviving colonies were fixed with 5% formaldehyde (Sigma), 
stained with Methylene blue (Sigma), imaged and counted using ImageJ software. In the 
assay in Figure 3-13, the final number of neomycin-resistant colonies shown in the graph 
has been corrected for the dilution used. Three independent experiments were performed 
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for each condition. To evaluate statistical significance, two-tailed one-sample t-test was 
performed. 
5.8.3 Rapamycin-based in vivo transposition assay  
Transposition activity of FRB- and FKBP- transposases (SB and Hsmar1) fusion proteins 
was quantified in HeLa cells using a modified version of the protocol described in (Ivics et 
al., 1997) and in the previous section. One day prior to transfection with JetPei®, cells were 
plated in a 6-well plate at a density of 3 x 105 cells per well. 0.5 µg of donor plasmid 
SB_PGK-neo was co-trasfected with FRB_SB_fl_EWS and/or FKBP_SB_fl_EWS 
plasmids (0.5 µg each). 0.5 µg of donor plasmid pHsmar1-neo was co-trasfected with 
FRB_Hsmar1_fl_EWS and/or FKBP_Hsmar1_fl_EWS plasmids (0.03 µg each).  
 
One hour after transfection, different concentrations of rapamycin (Sigma-Aldrich; 
provided by D. Yushchenko, EMBL Heidelberg) were added to the cells to induce 
dimerization. After a recovery period of 24 h, cells were trypsinized and a 1:100 dilution of 
the cell suspension was plated onto 10 cm Petri dishes. Selection, staining and 
quantification of the surviving colonies were performed as previously described in section 
5.8.2. Three independent experiments were performed for each condition. The number of 
neomycin resistant colonies for all conditions was normalized to the untreated sample (no 
rapamycin; corresponding to 100% transposition rates). To evaluate statistical significance, 
two-tailed one-sample t-test was performed. 
5.8.4 In vivo transposition assays by hsSB protein delivery in HeLa 
cells, CHO cells and mESCs 
hsSB protein was prepared for electroporation as follows: purified hsSB was dialysed in 
two steps in buffer containing 20 mM HEPES, 300 mM NaCl, 1 mM MgCl2 and 0.2 mM 
TCEP, pH 7.5 and concentrated to 20 mg/ml using Vivaspin 2 concentrators (Sartorius). 
Protein samples were filtered using 0.22 µm centrifugal filters (Millipore) prior to 
electroporation into cells. The activity of hsSB was quantified by drug selection or FACS 
using modified protocols from Ivics and colleagues (Ivics et al., 1997). HeLa cells, CHO 
cells and mESCs were plated one day prior to transfection in a 6-well plate at a density of 3 
× 105 cells per well. Transfection was performed with 1 µg of the SB_PGK-neo plasmid or 
the SB_T2/Venus plasmid (containing a neomycin resistance gene and a Venus gene, 
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respectively, flanked by the SB transposon ends). The NT (non-transfected) control 
samples were treated with transfection reagent, but no transposon plasmids. HeLa cells 
were transfected using JetPei® (Polyplus) transfection reagent. CHO and mESCs were 
transfected using FuGENE® (Invitrogen), according to the manufacturer’s instructions, to 
improve transfection efficiency. After a recovery period of 4.5 h, cells were trypsinized, 
washed with PBS and resuspended in R buffer (provided with the Neon® system) at a cell 
density of 3–3.5 × 107 cells per ml. For each condition, 10 µl of the cell suspension was 
transfected with indicated amounts of hsSB using a Neon® transfection system (10 µl kit, 
Thermo Fisher Scientific) following settings listed in Table 5-15. Following 
electroporation, cells were plated onto 6-well plates containing medium and incubated at 
37 °C in a 5% CO2 atmosphere. 
 
Table 5-15: Settings used for electroporation of different cell lines by the Neon® transfection system. 
 
 
HeLa cells and CHO cells transfected with the SB_PGK-neo transposon donor plasmid 
were trypsinized after a recovery period of 24 h in a total volume of 1 ml, and 100 µl of the 
cell suspension was plated onto 10 cm dishes containing medium. Selection, staining and 
quantification of the surviving colonies were performed as previously described in section 
5.8.2. HeLa cells, CHO cells and mESCs transfected with the SB_T2/Venus plasmid were 
sorted by flow cytometry 2 days after electroporation to obtain a pure population of Venus-
expressing cells, which had acquired the SB_T2/Venus plasmid. Twenty-one days after 
electroporation, the percentage of Venus-positive cells (in whose genome the Venus 
cassette was stably integrated by hsSB) was quantified by flow cytometry to determine the 
transposition efficiency (as described in the following section).  
5.8.5 Fluorescence-activated cell sorting (FACS) 
Two days post-transfection, HeLa cells, CHO cells and mESCs were dissociated to a 
single-cell suspension with 0.05% Trypsin-EDTA (Invitrogen), resuspended in D-PBS 
containing 2% BSA and 2.5 mM EDTA, strained through a 40 µm cell strainer (BD 
Biosciences) and sorted on a BD FACSMelodyTM or a BD FACSAria FusionTM flow 
cytometer (BD Bioscience) in the EMBL Flow Cytometry Core Facility. Only Venus+ cells 
Cell lines Voltage (V) Time (ms) Pulse number
HeLa 1005 35 2
CHO 1650 10 3
mESCs 1200 20 2
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were collected for further culturing. After 21 days, the cells were measured for Venus 
expression and stained with propidium iodide (PI, at a final concentration of 1 µg/ml) or 
4',6-diamidino-2-phenylindole (DAPI, at a final concentration of 0.1 µg/ml) to determine 
the ratio between living and dead cells. Flow cytometry measurements were performed on 
a BD LSRFortessa, BD Accuri or Beckman Coulter Cyan flow cytometer. When 
necessary, GFP/PI fluorescent spillover was compensated with the according controls. The 
results were analysed using FlowJo software or the FCS Express 4 Flow Cytometry 
software (De Novo Software). 
5.8.6 Western blot analysis of HeLa cell lysate 
Hela cells were treated for in vivo transposition using the protocols described above [using 
SB proteins (section 5.8.4) or SB proteins-encoding plasmids (section 5.8.2)]. At the 
indicated time points after electroporation, cells were harvested, washed twice with PBS 
and sonicated (using a VialTweeter sonifier, Hielscher Ultrasound Technology, set to 65% 
duty cycle and 50% output control, in 1 minute) in RIPA buffer (50 mM TrisHCl pH 7.4, 
150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% SDS) for lysis. Total protein extracts (20 
µg) were separated by gel electrophoresis [using precast NuPAGE 4-12% Bis-Tris Gels 
(Invitrogen)] and transferred to a nitrocellulose membrane (Whatman® Protran®) using a 
semi-dry transfer system (Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell, Bio-
Rad). Membranes were probed with Sleeping Beauty transposase antibody, polyclonal goat 
IgG (R&D Systems). The internal loading control was glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and was detected with an anti-GAPDH antibody (GAPDH 
Monoclonal Antibody, Cusabio). The intensities of the bands were measured using the 
Image Lab Software (Bio-Rad). 
5.8.7 Cell surface immunostaining 
To test the maintenance of pluripotency after transfection, mESCs were tested for surface 
expression of the self-renewal marker Oct4. Cells were fixed for 10 min with 4% 
Paraformaldehyde (PFA) in PBS and quenched with 150 mM glycine in PBS for 5 min at 
25 °C. Cells were blocked for 30 min in PBS buffer containing 5% BSA and incubated 
overnight at 4 °C with anti-Oct4 antibody (Oct-3/4, Santa Cruz). Cells were washed and 
incubated with an anti-mouse secondary antibody [F(ab')2-goat anti-mouse IgG (H+L) 
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secondary antibody, Pacific blue conjugate from Invitrogen], for 2 h at at 25 °C. Cells were 
then analysed on a LSRFortessa flow cytometer (BD BioScience) (see section 5.8.5).  
5.8.8 Sequence analysis of SB insertions in the HeLa cell genome 
Genomic DNA from neomycin-resistant homogenous HeLa clones was purified using the 
GenEluteTM Mammalian Genomic DNA Miniprep Kit (Sigma) according to the 
manufacturer’s instructions. Neomycin transgene insertions were PCR amplified using 
specific primers for the left (Left_end) and right (Right_end) transposon ends and a 
random primer (Random_primer) (Table 5-16). The thermocycling conditions are shown in 
Table 5-3. All primers contained a specific barcode (underlined in the primer sequences) 
used for sequencing. Sequence analysis of the resulting PCR products was performed in 
the EMBL Genomics Core Facility (T. Rausch and V. Benes, EMBL Heidelberg).  
 
Table 5-16: Primers used for amplification of SB insertions in the HeLa cell genome. 
 
 
Table 5-17: Thermocycling conditions for amplification of SB insertions in the HeLa cell genome.  
Primer Sequence*
Left_end CTGGAGTTCAGACGTGTGCTCTTCCGATCTAGTAGATGTCCTAACTGACTTGC
Right_end CTGGAGTTCAGACGTGTGCTCTTCCGATCTTCCTAACTGACCTAAGACAGG
Random_primer CTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNCTCAG
* Nucleotides belonging to the barcodes are underlined
Step Temperature Time
1. Initial Denaturation 95 °C 3 minutes
2. Denaturation 94 °C 20 seconds
3. Annealing 63 °C 45 seconds
4. Extension 72 °C 3 minutes
5. Denaturation 94 °C 20 seconds
6. Annealing 63 °C 45 seconds
7. Extension 72 °C 3 minutes
8. Denaturation 94 °C 20 seconds
9. Annealing 63 °C 45 seconds repeated 12 times
10. Extension 72 °C 3 minutes
11. Denaturation 94 °C 20 seconds
12. Annealing 44 °C 1 minute
13. Extension 72 °C 3 minutes
14. Final Extension 72 °C 7 minutes
15. Hold 4 °C hold
repeated 9 times
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